{"config":{"indexing":"full","lang":["en"],"min_search_length":3,"prebuild_index":false,"separator":"[\\s\\-]+"},"docs":[{"location":"","text":"Welcome to MkDocs For full documentation visit mkdocs.org . Commands mkdocs new [dir-name] - Create a new project. mkdocs serve - Start the live-reloading docs server. mkdocs build - Build the documentation site. mkdocs -h - Print help message and exit. Project layout mkdocs.yml # The configuration file. docs/ index.md # The documentation homepage. ... # Other markdown pages, images and other files.","title":"Home"},{"location":"#welcome-to-mkdocs","text":"For full documentation visit mkdocs.org .","title":"Welcome to MkDocs"},{"location":"#commands","text":"mkdocs new [dir-name] - Create a new project. mkdocs serve - Start the live-reloading docs server. mkdocs build - Build the documentation site. mkdocs -h - Print help message and exit.","title":"Commands"},{"location":"#project-layout","text":"mkdocs.yml # The configuration file. docs/ index.md # The documentation homepage. ... # Other markdown pages, images and other files.","title":"Project layout"},{"location":"approach/","text":"* \uadfc\uace8\uaca9\uacc4 \uc99d\uc0c1 \ud658\uc790\uc758 \uc811\uadfc \ubc29\ubc95 \ub098\uc774/\uc131\ubcc4, \uc720\ubcd1\ub960, \uc784\uc0c1 \ubcd1\ub825, \uc804\uc2e0 \uc99d\uc0c1 \ub098\uc774/\uc131\ubcc4, \uc720\ubcd1\ub960, \uc784\uc0c1 \ubcd1\ub825, \uc804\uc2e0 \uc99d\uc0c1 \uad00\uc808 vs \ube44\uad00\uc808 \uad00\uc808 vs \ube44\uad00\uc808 \uae09\uc131 vs \ub9cc\uc131 \uae09\uc131 vs \ub9cc\uc131 \uc5fc\uc99d vs \ube44\uc5fc\uc99d \uc5fc\uc99d vs \ube44\uc5fc\uc99d \uce68\ubc94 \uac1c\uc218 \uce68\ubc94 \uac1c\uc218 \uce68\ubc94 \ubd80\uc704 \uce68\ubc94 \ubd80\uc704 Viewer does not support full SVG 1.1 1. \uad00\uc808 vs \ube44\uad00\uc808 \uad00\uc808\uc131 \ube44\uad00\uc808\uc131 \ud65c\ub9c9, \ud65c\uc561, \uad00\uc808\uc5f0\uace8, \uad00\uc808\ub0b4 \uc778\ub300, \uad00\uc808 \ud53c\ub9c9, \uad00\uc808 \uc8fc\uc704 \ubf08 \uad00\uc808 \uc8fc\ubcc0 \uc778\ub300, \ud798\uc904, \uc724\ud65c\ub0ad, \uadfc\uc721, \uadfc\ub9c9, \ubf08, \uc2e0\uacbd, \ud53c\ubd80 \uae4a\uc740 \uacf3\uc5d0\uc11c \ub290\ub07c\ub294 \ubbf8\ub9cc\uc131 \ud1b5\uc99d \uad00\uc808\uacfc \ub5a8\uc5b4\uc9c4 \ubd80\uc704\uc758 \uad6d\uc18c\uc801 \ud1b5\uc99d \ub2a5\ub3d9, \uc218\ub3d9 \uc6b4\ub3d9 \uc2dc \uc6c0\uc9c1\uc784\uc758 \uc81c\ud55c \ub2a5\ub3d9 \uc6b4\ub3d9\uc2dc \ud1b5\uc99d, \uc218\ub3d9 \uc6b4\ub3d9\uc5d0\ub294 \ud1b5\uc99d\uc774 \uc5c6\uc74c. \ud2b9\uc815\ud55c \uc6c0\uc9c1\uc784\uc774\ub098 \uc790\uc138\uc5d0 \uc758\ud574 \uc720\ubc1c\ub418\uae30\ub3c4 \ud568. \uad00\uc808 \ubd80\uc885 (\ud65c\ub9c9 \uc99d\uc2dd, \uc0bc\ucd9c, \uace8\ud615\uc131) \uac70\uc758 \uc5c6\uc74c \uad00\uc808 \ub9c8\ucc30\uc74c, \ubd88\uc548\uc815\uc131, \ubcc0\ud615 \uac70\uc758 \uc5c6\uc74c 1-1. \uc5f0\ubd80 \uc870\uc9c1 \ub958\ub9c8\ud2f0\uc998 : \uad00\uc808 \uc8fc\uc704 \uad6c\uc870\ub97c \uce68\ubc94\ud558\ub294 \uc9c8\ud658\uc744 \ucd1d\uce6d - Tendinitis - Enthesitis - Bursitis - Structural disorder - Neurovascular entrapment disorders - Complex regional pain syndrome (CRPS) - Myofascial pain syndrome - Generalized pain disorders 2. \uae09\uc131 vs \ub9cc\uc131 2-1. \uae09\uc131 (\ubc1c\ubcd1 6\uc8fc \uc774\ub0b4) second to minutes : internal derangement, fracture, or trauma Over hours to 2 days : usually inflammation or infection-related \uc5fc\uc99d\uc131 \ube44\uc5fc\uc99d\uc131 Septic arthritis Trauma or internal derangement Crystal arthritis Non-inflammatory joint disease Reactive arthritis Bone disease Existing inflammatory polyarthritis Metastatic disease Existing systemic disease-related Soft tissue lesions \uad00\uc808\uc561 \ubd84\uc11d - \uc798 \ubaa8\ub974\uba74 \uc2dc\ud589\ud558\uc790! | | \uc815\uc0c1 | \ube44\uc5fc\uc99d\uad00\uc808\uc5fc | \uc5fc\uc99d\uad00\uc808\uc5fc | \ud654\ub18d\uad00\uc808\uc5fc | \ucd9c\ud608\uad00\uc808\uc5fc | | ------ | ---------------- | -------------------------------------------------- | ------------------------------------------------------------ | ---------------- | ------------------------------------------------------------ | | \uc0c9 | \ubb34\uc0c9/\ud22c\uba85\ud55c \ud669\uc0c9 | \ud669\uc0c9 | \ud669\uc0c9/\ubc31\uc0c9 | \ubc31\uc0c9/\ub2e4\uc591 | \ubd89\uc740\uc0c9 | | \ud22c\uba85\ub3c4 | \ud22c\uba85 | \ud22c\uba85 | \ud22c\uba85/\ud0c1\ud568 | \ud0c1\ud568 | \ud0c1\ud568 | | \uc810\ub3c4 | \ub9e4\uc6b0 \ub192\uc74c | \ub192\uc74c | \ub0ae\uc74c | \ub9e4\uc6b0 \ub0ae\uc74c/\ub2e4\uc591 | | | \ubc31\ud608\uad6c | < 150 | < 2000 | 2000~50000 | >50000 | | | PMN | < 25% | < 25% | >70% | >90% | | | \ubc30\uc591 | \uc74c\uc131 | \uc74c\uc131 | \uc74c\uc131 | \uc591\uc131 | \uc74c\uc131 | | \uc9c4\ub2e8 | | OA Traumatic arthritis Early RA AVN | RA Acute crystalopathy Viral arthritis PsA ReA | Septic arthritis | Trauma Coagulopathy Tumor Charcot arthropathy | \ube44\uc5fc\uc99d\uad00\uc808\uc5fc\uacfc \uc5fc\uc99d\uad00\uc808\uc5fc\uc758 \uad6c\ubd84 : WBC 2000~3000\uc774 \uae30\uc900 3. \uc5fc\uc99d\uc131 vs \ube44\uc5fc\uc99d\uc131 \uc5fc\uc99d\uc131 \ube44\uc5fc\uc99d\uc131 \uacbd\uc9c1 1\uc2dc\uac04 \uc774\uc0c1, \uc870\uc870\uac15\uc9c1 1\uc2dc\uac04 \ubbf8\ub9cc, \ub0ae \ud65c\ub3d9 \uc2dc, \uac04\ud5d0\uc801 \ud65c\ub3d9\uc2dc \ud638\uc804 \uc545\ud654 \uc5fc\uc99d\uc758 \uc9d5\ud6c4 \ubc1c\uc801, \uc5f4\uac10, \uc555\ud1b5, \ubd80\uc885 \ub4f1\uc744 \ub3d9\ubc18 \ubd80\uc885\uc774\ub098 \uc5f4\uac10\uc744 \ub3d9\ubc18\ud558\uc9c0 \uc54a\uc740 \ud1b5\uc99d \uc804\uc2e0 \uc99d\uc0c1 \ud53c\ub85c, \ubc1c\uc5f4, \ubc1c\uc9c4, \uccb4\uc911 \uac10\uc18c \uc5c6\uc74c \uac80\uc0ac\uc2e4 \uc18c\uacac ESR/CRP \uc0c1\uc2b9, \ud608\uc18c\ud310 \uc99d\uac00, \ub9cc\uc131 \uc9c8\ud658\uc5d0 \uc758\ud55c \ube48\ud608, \uc800\uc54c\ubd80\ubbfc\ud608\uc99d \ub4f1 \uc815\uc0c1 \uc6d0\uc778 \uac10\uc5fc, \uacb0\uc815\uad00\uc808\uc5fc, \uba74\uc5ed\uc131, \ubc18\uc751\uc131 \uc678\uc0c1, \ubc18\ubcf5\uc801\uc778 \uc0ac\uc6a9, \ud1f4\ud589\uc131, \uc885\uc591, \ud1b5\uc99d \uc804\ub2ec \uc774\uc0c1 4. \uad00\uc808 \uce68\ubc94 \uac1c\uc218 4-1. Chronic mono - & oligoarticular (1-3) \uac10\uc5fc\uc131 \uad00\uc808\uc5fc \uc5fc\uc99d\uc131 \uad00\uc808\uc5fc \ube44\uc5fc\uc99d\uc131 \uad00\uc808\uc5fc \uc885\uc591 4-2. Chronic polyarticular (>4) \uc5fc\uc99d\uc131 \uad00\uc808\uc5fc \ube44\uc5fc\uc99d\uc131 \uad00\uc808\uc5fc \uacb0\uccb4\uc870\uc9c1\uc9c8\ud658 \uad00\ub828 5. \uad00\uc808 \uce68\ubc94 \ubd80\uc704\uc640 \ud328\ud134 5-1. \uad00\uc808 \uce68\ubc94 \ubd80\uc704 \ub300\uce6d\uc801 \ube44\ub300\uce6d\uc801 RA, JIA (systemic/polyarticular types) Ankylosing spondylitis AOSD Reactive arthritis, PsA (oligoarticular type), Enteropathic arthritis, Undifferentiated SpA Systemic lupus erythematosus Behcet's ds. Mixed Connective Tissue Disease JIA (Pauciarticular types) Polymyalgia Rheumatica Palindromic rheumatism Rheumatic fever (Adult onset) Jaccoud arthritis 5-2. \uad00\uc808 \uce68\ubc94 \ud328\ud134 \ub300\uce6d\uc131 \uce68\ubc94\uad00\uc808 \uc218 \ub300/\uc18c\uad00\uc808 \ubd84\ud3ec \uc0c1/\ud558\uc9c0 \uc9c4\ub2e8 \ub300\uce6d\uc801 \ub2e4\uad00\uc808 \ub300/\uc18c\uad00\uc808 \ub9d0\ucd08\uad00\uc808 \uc0c1/\ud558\uc9c0 \ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc \ube44\ub300\uce6d\uc801 \uc18c\uc218\uad00\uc808 \ub300\uad00\uc808 \ucc99\ucd94/\ub9d0\ucd08\uad00\uc808 \ud558\uc9c0 \uac15\uc9c1\uc131 \ucc99\ucd94\uc5fc \ube44\ub300\uce6d\uc801 \uc18c\uc218 or \ub2e4\uad00\uc808 \ub300/\uc18c\uad00\uc808 \ub9d0\ucd08\uad00\uc808 \uc0c1/\ud558\uc9c0 \uac74\uc120\uad00\uc808\uc5fc \ube44\ub300\uce6d\uc801 \uc18c\uc218 or \ub2e4\uad00\uc808 \ub300\uad00\uc808/\uc190\ubc1c\uac00\ub77d\uc5fc \ub9d0\ucd08\uad00\uc808 \ud558\uc9c0 \ubc18\uc751\uad00\uc808\uc5fc \ube44\ub300\uce6d\uc801 \ub2e8 or \uc18c\uc218\uad00\uc808 \ub300/\uc18c\uad00\uc808 \ub9d0\ucd08\uad00\uc808 \uc0c1/\ud558\uc9c0 \ud1b5\ud48d 6. \uc784\uc0c1 \ubcd1\ub825\uacfc \uc804\uc2e0 \uc99d\uc0c1 6-1. \ub098\uc774 & \uc131\ubcc4 \uc5f0\ub839 \uc5ec\uc131 \ub0a8\ub140\uacf5\ud1b5 \ub0a8\uc131 \uc18c\uc544 0-16 \uc678\uc0c1, \ubc14\uc774\ub7ec\uc2a4, JIA \uccad\uc18c\ub144 17~35 \ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc, \uc804\uc2e0\ud64d\ubc18\ub8e8\ud478\uc2a4 \uac74\uc120\uad00\uc808\uc5fc \ubc18\uc751\uad00\uc808\uc5fc \uac15\uce59\ucc99\ucd94\uc5fc \uc911\ub144 35~65 \ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc \uace8\uad00\uc808\uc5fc \ud1b5\ud48d \ub178\ub144 >65 \uace8\uad00\uc808\uc5fc \ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc \ub958\ub9c8\ud2f0\uc2a4\ub2e4\ubc1c\uadfc\ud1b5 \uacb0\uc815\uad00\uc808\uc5fc(\ud1b5\ud48d, \uac00\uc131\ud1b5\ud48d) 6-2. \ubcd1\ub825 \uccad\ucde8 \uc120\ud589/\uc720\ubc1c\uc778\uc790 \uc678\uc0c1 (\uace8\uad34\uc0ac, \ubc18\uc6d4\ud310 \uc190\uc0c1) \uc57d\ubb3c \ubcf5\uc6a9 \uac10\uc5fc\ub825 (\ub958\ub9c8\ud2f0\uc2a4\uc5f4, \ubc18\uc751\uad00\uc808\uc5fc, \ubc14\uc774\ub7ec\uc2a4\uc131 \uac04\uc5fc) \ub3d9\ubc18\uc9c8\ud658 \ub2f9\ub1e8\ubcd1 (CTS, \ub2f9\ub1e8\ubcd1\uc131 \uc190\uc894\uc808\uc99d, trigger finger) \uc2e0\ubd80\uc804 (\ud1b5\ud48d) \uac74\uc120 (\uac74\uc120 \uad00\uc808\uc5fc) \uace8\uc218\uc885 (\uc694\ud1b5) \uc554 (\uadfc\uc721\uc5fc, \ubd80\uc885\uc591 \uc99d\ud6c4\uad70) \uace8\ub2e4\uacf5\uc99d (\uace8\uc808) \uc8fc\uc694 \uc720\ubc1c \uc57d\uc81c \uc99d\uc0c1 \uc720\ubc1c \uc57d\uc81c \uad00\uc808\ud1b5 \uadfc\uc721\ud1b5 \ud1b5\ud48d \uace8\uad34\uc0ac \ud608\uad00\uc5fc \uc8fc\uc694 \uc804\uc2e0 \uc99d\uc0c1 Symptom Possible Dx. Neurologic Mouth Eyes Respiratory GI Skin Genitourinary Trauma Non-specific symptomes Hematologic Obstetric history","title":"Dx. Tests & Meds"},{"location":"approach/#_1","text":"\ub098\uc774/\uc131\ubcc4, \uc720\ubcd1\ub960, \uc784\uc0c1 \ubcd1\ub825, \uc804\uc2e0 \uc99d\uc0c1 \ub098\uc774/\uc131\ubcc4, \uc720\ubcd1\ub960, \uc784\uc0c1 \ubcd1\ub825, \uc804\uc2e0 \uc99d\uc0c1","title":"* \uadfc\uace8\uaca9\uacc4 \uc99d\uc0c1 \ud658\uc790\uc758 \uc811\uadfc \ubc29\ubc95"},{"location":"approach/#1-vs","text":"\uad00\uc808\uc131 \ube44\uad00\uc808\uc131 \ud65c\ub9c9, \ud65c\uc561, \uad00\uc808\uc5f0\uace8, \uad00\uc808\ub0b4 \uc778\ub300, \uad00\uc808 \ud53c\ub9c9, \uad00\uc808 \uc8fc\uc704 \ubf08 \uad00\uc808 \uc8fc\ubcc0 \uc778\ub300, \ud798\uc904, \uc724\ud65c\ub0ad, \uadfc\uc721, \uadfc\ub9c9, \ubf08, \uc2e0\uacbd, \ud53c\ubd80 \uae4a\uc740 \uacf3\uc5d0\uc11c \ub290\ub07c\ub294 \ubbf8\ub9cc\uc131 \ud1b5\uc99d \uad00\uc808\uacfc \ub5a8\uc5b4\uc9c4 \ubd80\uc704\uc758 \uad6d\uc18c\uc801 \ud1b5\uc99d \ub2a5\ub3d9, \uc218\ub3d9 \uc6b4\ub3d9 \uc2dc \uc6c0\uc9c1\uc784\uc758 \uc81c\ud55c \ub2a5\ub3d9 \uc6b4\ub3d9\uc2dc \ud1b5\uc99d, \uc218\ub3d9 \uc6b4\ub3d9\uc5d0\ub294 \ud1b5\uc99d\uc774 \uc5c6\uc74c. \ud2b9\uc815\ud55c \uc6c0\uc9c1\uc784\uc774\ub098 \uc790\uc138\uc5d0 \uc758\ud574 \uc720\ubc1c\ub418\uae30\ub3c4 \ud568. \uad00\uc808 \ubd80\uc885 (\ud65c\ub9c9 \uc99d\uc2dd, \uc0bc\ucd9c, \uace8\ud615\uc131) \uac70\uc758 \uc5c6\uc74c \uad00\uc808 \ub9c8\ucc30\uc74c, \ubd88\uc548\uc815\uc131, \ubcc0\ud615 \uac70\uc758 \uc5c6\uc74c","title":"1. \uad00\uc808 vs \ube44\uad00\uc808"},{"location":"approach/#1-1","text":": \uad00\uc808 \uc8fc\uc704 \uad6c\uc870\ub97c \uce68\ubc94\ud558\ub294 \uc9c8\ud658\uc744 \ucd1d\uce6d - Tendinitis - Enthesitis - Bursitis - Structural disorder - Neurovascular entrapment disorders - Complex regional pain syndrome (CRPS) - Myofascial pain syndrome - Generalized pain disorders","title":"1-1. \uc5f0\ubd80 \uc870\uc9c1 \ub958\ub9c8\ud2f0\uc998"},{"location":"approach/#2-vs","text":"","title":"2. \uae09\uc131 vs \ub9cc\uc131"},{"location":"approach/#2-1-6","text":"second to minutes : internal derangement, fracture, or trauma Over hours to 2 days : usually inflammation or infection-related \uc5fc\uc99d\uc131 \ube44\uc5fc\uc99d\uc131 Septic arthritis Trauma or internal derangement Crystal arthritis Non-inflammatory joint disease Reactive arthritis Bone disease Existing inflammatory polyarthritis Metastatic disease Existing systemic disease-related Soft tissue lesions","title":"2-1. \uae09\uc131 (\ubc1c\ubcd1 6\uc8fc \uc774\ub0b4)"},{"location":"approach/#-","text":"| | \uc815\uc0c1 | \ube44\uc5fc\uc99d\uad00\uc808\uc5fc | \uc5fc\uc99d\uad00\uc808\uc5fc | \ud654\ub18d\uad00\uc808\uc5fc | \ucd9c\ud608\uad00\uc808\uc5fc | | ------ | ---------------- | -------------------------------------------------- | ------------------------------------------------------------ | ---------------- | ------------------------------------------------------------ | | \uc0c9 | \ubb34\uc0c9/\ud22c\uba85\ud55c \ud669\uc0c9 | \ud669\uc0c9 | \ud669\uc0c9/\ubc31\uc0c9 | \ubc31\uc0c9/\ub2e4\uc591 | \ubd89\uc740\uc0c9 | | \ud22c\uba85\ub3c4 | \ud22c\uba85 | \ud22c\uba85 | \ud22c\uba85/\ud0c1\ud568 | \ud0c1\ud568 | \ud0c1\ud568 | | \uc810\ub3c4 | \ub9e4\uc6b0 \ub192\uc74c | \ub192\uc74c | \ub0ae\uc74c | \ub9e4\uc6b0 \ub0ae\uc74c/\ub2e4\uc591 | | | \ubc31\ud608\uad6c | < 150 | < 2000 | 2000~50000 | >50000 | | | PMN | < 25% | < 25% | >70% | >90% | | | \ubc30\uc591 | \uc74c\uc131 | \uc74c\uc131 | \uc74c\uc131 | \uc591\uc131 | \uc74c\uc131 | | \uc9c4\ub2e8 | | OA Traumatic arthritis Early RA AVN | RA Acute crystalopathy Viral arthritis PsA ReA | Septic arthritis | Trauma Coagulopathy Tumor Charcot arthropathy | \ube44\uc5fc\uc99d\uad00\uc808\uc5fc\uacfc \uc5fc\uc99d\uad00\uc808\uc5fc\uc758 \uad6c\ubd84 : WBC 2000~3000\uc774 \uae30\uc900","title":"\uad00\uc808\uc561 \ubd84\uc11d - \uc798 \ubaa8\ub974\uba74 \uc2dc\ud589\ud558\uc790!"},{"location":"approach/#3-vs","text":"\uc5fc\uc99d\uc131 \ube44\uc5fc\uc99d\uc131 \uacbd\uc9c1 1\uc2dc\uac04 \uc774\uc0c1, \uc870\uc870\uac15\uc9c1 1\uc2dc\uac04 \ubbf8\ub9cc, \ub0ae \ud65c\ub3d9 \uc2dc, \uac04\ud5d0\uc801 \ud65c\ub3d9\uc2dc \ud638\uc804 \uc545\ud654 \uc5fc\uc99d\uc758 \uc9d5\ud6c4 \ubc1c\uc801, \uc5f4\uac10, \uc555\ud1b5, \ubd80\uc885 \ub4f1\uc744 \ub3d9\ubc18 \ubd80\uc885\uc774\ub098 \uc5f4\uac10\uc744 \ub3d9\ubc18\ud558\uc9c0 \uc54a\uc740 \ud1b5\uc99d \uc804\uc2e0 \uc99d\uc0c1 \ud53c\ub85c, \ubc1c\uc5f4, \ubc1c\uc9c4, \uccb4\uc911 \uac10\uc18c \uc5c6\uc74c \uac80\uc0ac\uc2e4 \uc18c\uacac ESR/CRP \uc0c1\uc2b9, \ud608\uc18c\ud310 \uc99d\uac00, \ub9cc\uc131 \uc9c8\ud658\uc5d0 \uc758\ud55c \ube48\ud608, \uc800\uc54c\ubd80\ubbfc\ud608\uc99d \ub4f1 \uc815\uc0c1 \uc6d0\uc778 \uac10\uc5fc, \uacb0\uc815\uad00\uc808\uc5fc, \uba74\uc5ed\uc131, \ubc18\uc751\uc131 \uc678\uc0c1, \ubc18\ubcf5\uc801\uc778 \uc0ac\uc6a9, \ud1f4\ud589\uc131, \uc885\uc591, \ud1b5\uc99d \uc804\ub2ec \uc774\uc0c1","title":"3. \uc5fc\uc99d\uc131 vs \ube44\uc5fc\uc99d\uc131"},{"location":"approach/#4","text":"","title":"4. \uad00\uc808 \uce68\ubc94 \uac1c\uc218"},{"location":"approach/#4-1-chronic-mono-oligoarticular-1-3","text":"","title":"4-1. Chronic mono - &amp; oligoarticular (1-3)"},{"location":"approach/#_2","text":"","title":"\uac10\uc5fc\uc131 \uad00\uc808\uc5fc"},{"location":"approach/#_3","text":"","title":"\uc5fc\uc99d\uc131 \uad00\uc808\uc5fc"},{"location":"approach/#_4","text":"","title":"\ube44\uc5fc\uc99d\uc131 \uad00\uc808\uc5fc"},{"location":"approach/#_5","text":"","title":"\uc885\uc591"},{"location":"approach/#4-2-chronic-polyarticular-4","text":"","title":"4-2. Chronic polyarticular (&gt;4)"},{"location":"approach/#_6","text":"","title":"\uc5fc\uc99d\uc131 \uad00\uc808\uc5fc"},{"location":"approach/#_7","text":"","title":"\ube44\uc5fc\uc99d\uc131 \uad00\uc808\uc5fc"},{"location":"approach/#_8","text":"","title":"\uacb0\uccb4\uc870\uc9c1\uc9c8\ud658 \uad00\ub828"},{"location":"approach/#5","text":"","title":"5. \uad00\uc808 \uce68\ubc94 \ubd80\uc704\uc640 \ud328\ud134"},{"location":"approach/#5-1","text":"\ub300\uce6d\uc801 \ube44\ub300\uce6d\uc801 RA, JIA (systemic/polyarticular types) Ankylosing spondylitis AOSD Reactive arthritis, PsA (oligoarticular type), Enteropathic arthritis, Undifferentiated SpA Systemic lupus erythematosus Behcet's ds. Mixed Connective Tissue Disease JIA (Pauciarticular types) Polymyalgia Rheumatica Palindromic rheumatism Rheumatic fever (Adult onset) Jaccoud arthritis","title":"5-1. \uad00\uc808 \uce68\ubc94 \ubd80\uc704"},{"location":"approach/#5-2","text":"\ub300\uce6d\uc131 \uce68\ubc94\uad00\uc808 \uc218 \ub300/\uc18c\uad00\uc808 \ubd84\ud3ec \uc0c1/\ud558\uc9c0 \uc9c4\ub2e8 \ub300\uce6d\uc801 \ub2e4\uad00\uc808 \ub300/\uc18c\uad00\uc808 \ub9d0\ucd08\uad00\uc808 \uc0c1/\ud558\uc9c0 \ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc \ube44\ub300\uce6d\uc801 \uc18c\uc218\uad00\uc808 \ub300\uad00\uc808 \ucc99\ucd94/\ub9d0\ucd08\uad00\uc808 \ud558\uc9c0 \uac15\uc9c1\uc131 \ucc99\ucd94\uc5fc \ube44\ub300\uce6d\uc801 \uc18c\uc218 or \ub2e4\uad00\uc808 \ub300/\uc18c\uad00\uc808 \ub9d0\ucd08\uad00\uc808 \uc0c1/\ud558\uc9c0 \uac74\uc120\uad00\uc808\uc5fc \ube44\ub300\uce6d\uc801 \uc18c\uc218 or \ub2e4\uad00\uc808 \ub300\uad00\uc808/\uc190\ubc1c\uac00\ub77d\uc5fc \ub9d0\ucd08\uad00\uc808 \ud558\uc9c0 \ubc18\uc751\uad00\uc808\uc5fc \ube44\ub300\uce6d\uc801 \ub2e8 or \uc18c\uc218\uad00\uc808 \ub300/\uc18c\uad00\uc808 \ub9d0\ucd08\uad00\uc808 \uc0c1/\ud558\uc9c0 \ud1b5\ud48d","title":"5-2. \uad00\uc808 \uce68\ubc94 \ud328\ud134"},{"location":"approach/#6","text":"","title":"6. \uc784\uc0c1 \ubcd1\ub825\uacfc \uc804\uc2e0 \uc99d\uc0c1"},{"location":"approach/#6-1","text":"\uc5f0\ub839 \uc5ec\uc131 \ub0a8\ub140\uacf5\ud1b5 \ub0a8\uc131 \uc18c\uc544 0-16 \uc678\uc0c1, \ubc14\uc774\ub7ec\uc2a4, JIA \uccad\uc18c\ub144 17~35 \ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc, \uc804\uc2e0\ud64d\ubc18\ub8e8\ud478\uc2a4 \uac74\uc120\uad00\uc808\uc5fc \ubc18\uc751\uad00\uc808\uc5fc \uac15\uce59\ucc99\ucd94\uc5fc \uc911\ub144 35~65 \ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc \uace8\uad00\uc808\uc5fc \ud1b5\ud48d \ub178\ub144 >65 \uace8\uad00\uc808\uc5fc \ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc \ub958\ub9c8\ud2f0\uc2a4\ub2e4\ubc1c\uadfc\ud1b5 \uacb0\uc815\uad00\uc808\uc5fc(\ud1b5\ud48d, \uac00\uc131\ud1b5\ud48d)","title":"6-1. \ub098\uc774 &amp; \uc131\ubcc4"},{"location":"approach/#6-2","text":"\uc120\ud589/\uc720\ubc1c\uc778\uc790 \uc678\uc0c1 (\uace8\uad34\uc0ac, \ubc18\uc6d4\ud310 \uc190\uc0c1) \uc57d\ubb3c \ubcf5\uc6a9 \uac10\uc5fc\ub825 (\ub958\ub9c8\ud2f0\uc2a4\uc5f4, \ubc18\uc751\uad00\uc808\uc5fc, \ubc14\uc774\ub7ec\uc2a4\uc131 \uac04\uc5fc) \ub3d9\ubc18\uc9c8\ud658 \ub2f9\ub1e8\ubcd1 (CTS, \ub2f9\ub1e8\ubcd1\uc131 \uc190\uc894\uc808\uc99d, trigger finger) \uc2e0\ubd80\uc804 (\ud1b5\ud48d) \uac74\uc120 (\uac74\uc120 \uad00\uc808\uc5fc) \uace8\uc218\uc885 (\uc694\ud1b5) \uc554 (\uadfc\uc721\uc5fc, \ubd80\uc885\uc591 \uc99d\ud6c4\uad70) \uace8\ub2e4\uacf5\uc99d (\uace8\uc808)","title":"6-2. \ubcd1\ub825 \uccad\ucde8"},{"location":"approach/#_9","text":"\uc99d\uc0c1 \uc720\ubc1c \uc57d\uc81c \uad00\uc808\ud1b5 \uadfc\uc721\ud1b5 \ud1b5\ud48d \uace8\uad34\uc0ac \ud608\uad00\uc5fc","title":"\uc8fc\uc694 \uc720\ubc1c \uc57d\uc81c"},{"location":"approach/#_10","text":"Symptom Possible Dx. Neurologic Mouth Eyes Respiratory GI Skin Genitourinary Trauma Non-specific symptomes Hematologic Obstetric history","title":"\uc8fc\uc694 \uc804\uc2e0 \uc99d\uc0c1"},{"location":"index2/","text":"Welcome to MkDocs For full documentation visit mkdocs.org . Commands mkdocs new [dir-name] - Create a new project. mkdocs serve - Start the live-reloading docs server. mkdocs build - Build the documentation site. mkdocs -h - Print help message and exit. Project layout mkdocs.yml # The configuration file. docs/ index.md # The documentation homepage. ... # Other markdown pages, images and other files.","title":"Introduction"},{"location":"index2/#welcome-to-mkdocs","text":"For full documentation visit mkdocs.org .","title":"Welcome to MkDocs"},{"location":"index2/#commands","text":"mkdocs new [dir-name] - Create a new project. mkdocs serve - Start the live-reloading docs server. mkdocs build - Build the documentation site. mkdocs -h - Print help message and exit.","title":"Commands"},{"location":"index2/#project-layout","text":"mkdocs.yml # The configuration file. docs/ index.md # The documentation homepage. ... # Other markdown pages, images and other files.","title":"Project layout"},{"location":"SSc/ssc/","text":"\uc9c8\ubcd1\uc758 \ucd08\uae30\uc5d0\ub294 \ub69c\ub837\ud55c \uc5fc\uc99d\uc18c\uacac\uacfc \ud608\uad00\uc190\uc0c1\uc5d0 \ub530\ub978 \ud608\uad00\ubcd1\uc99d\uc744 \ubcf4\uc774\uace0, \uc810\ucc28 \uc790\uac00\uba74\uc5ed\uc758 \ud65c\uc131\ud654\uc5d0 \ub530\ub978 \ud53c\ubd80\uc640 \uc804\uc2e0 \uc7a5\uae30 (lung, GI tract, heart, kidney)\uc758 \uc12c\uc720\ud654\uac00 \uc9c4\ud589\ud558\ub294 \uc9c8\ud658 1. Historical Perspective (1847) Gintrac : Sclerodermie \uc6a9\uc5b4 \uc0ac\uc6a9. (\ud604\uc7ac \uae30\uc900\uc73c\ub85c \ubcfc \ub54c \uac00\uc7a5 SSc\uc5d0 \uac00\uc7a5 \ud569\ub2f9\ud55c \uccab case) (1860) Maurice Raynaud : RP \ubc1c\ud45c (Sclerodermie and cold-induced \"asphyxie locale\") (1897) Osler : Scleroderma\uac00 systemic ds.\ub77c\ub294 \uac83\uc744 \uc778\uc2dd (1924) Matsui : \ubd80\uac80\uc5d0 \uadfc\uac70\ud558\uc5ec Scleroderma\uc758 internal organ involvement \uac15\uc870 (1945) Goetz : Progressive systemic sclerosis \uc6a9\uc5b4 \uc81c\uc548 (1964) Winterbauer : CRST \uc0ac\ub840 \uc81c\uc2dc\ub97c \ud1b5\ud574 SSc\uc758 subtype concept \ub3c4\uc785 \u2192 \uc774\ud6c4 esophageal dysmotility\uae4c\uc9c0 \ud3ec\ud568\ud558\uc5ec CREST symdrome\uc774\ub77c\ub294 \uc6a9\uc5b4 \ub3c4\uc785 (1969) SSc\uc758 \ubd80\uac80 case \ube44\uad50 : \uc8fc\ub85c skin, GI, PD, CV, Muscle \ub4f1\uc5d0 involve\ud568. (1970s) ACE inhibitor\uac00 SRC\ub97c \ud638\uc804\uc2dc\ud0ac \uc218 \uc788\ub2e4\ub294 \uac83\uc774 \ubc1d\ud600\uc9d0. (1979) Skin involvement\uc758 \ud3c9\uac00 \ubc29\ubc95 \uc81c\uc2dc : mRSS (2001) Leroy, Medsger : RP+Abnormal NPC+\uc790\uac00\ud56d\uccb4 \uc591\uc131 \uc18c\uacac\uc774 SSc \uc870\uae30 \uc9c4\ub2e8\uc5d0 \uc720\uc6a9\ud560 \uac83\uc774\ub77c\uace0 \uc81c\uc548 (2013) ACR/EULAR classification criteria 2. \ubd84\ub958 Localized scleroderma : \uc12c\uc720\ud654\uac00 \ud53c\ubd80\uc640 \ud53c\ud558\uc870\uc9c1\uc5d0\ub9cc \uad6d\ud55c\ub41c \ud615\ud0dc Morphea (\ubc18\uc0c1 \uad6d\ud55c \ud53c\ubd80\uacbd\ud654\uc99d) Linear (\uc120 \ud53c\ubd80\uacbd\ud654\uc99d) - en coup de sabre Systemic sclerosis : \uc12c\uc720\ud654\uac00 \ud53c\ubd80 \ubc0f \uc804\uc2e0\uc7a5\uae30\ub97c \uce68\ubc94\ud568 limited cutaneous SSc : \ud53c\ubd80 \uce68\ubc94\uc774 \ud314\uafc8\uce58\uc640 \ubb34\ub98e\uc758 \uc6d0\uc704\ubd80\uae4c\uc9c0\ub9cc \uc77c\uc5b4\ub0a8 diffuse cutaneous SSc : \uadf8 \ubcf4\ub2e4 \ub354 \ubab8\ud1b5 \ubd80\uc704\uae4c\uc9c0 \ud655\uc7a5. Systemic sclerosis sine scleroderma : \ud53c\ubd80 \uce68\ubc94(-), \uc790\uac00\ud56d\uccb4 (+), \ub0b4\ubd80\uc7a5\uae30 \uce68\ubc94 (+) SSc overlap syndrome : polyarthritis, myositis, sicca complex, hypothyroidism, PBC, MCTD ** RP + Abnormal NFC\ub9cc \uc788\ub294 \uacbd\uc6b0\uc5d0\ub294 UCTD\ub85c \uc77c\ub2e8 \uc0dd\uac01\ud558\ub294\ub370, \uc774 \ud658\uc790\uad70\uc758 \uc57d 20% \uc815\ub3c4\uac00 2~4\ub144 \ud6c4\uc5d0 SSc\uac00 \ubc1c\ubcd1\ud55c\ub2e4. 3. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790 \uc8fc\ub85c 40\ub300 (35~50\uc138), M:F = 1:9. 25\uc138 \uc774\uc804 \ubc1c\ubcd1\uc740 \ub4dc\ubb3c\ub2e4. \ubc1c\ubcd1\ub960 : \ubc31\ub9cc\uba85 \ub2f9 13.9~21\uba85, \uc720\ubcd1\ub960 : \ubc31\ub9cc\uba85 \ub2f9 276\uba85. Diffuse < limited \ucd08\uae30\uc5d0 RP, Abnormal NFC, Antoantibodies\uac00 \uc788\uc744 \ub54c \ub354 \uc798 \uc9c4\ud589\ud558\ub294 \uacbd\ud5a5. ** \ubc1c\uc0dd\ub960 \ubc0f \uc720\ubcd1\ub960\uc740 \uc778\uc885/\ubbfc\uc871\uc5d0 \ub530\ub77c \ub2e4\ub974\ub2e4. \uc0c1\ub300\uc801\uc73c\ub85c \uc544\uc2dc\uc544\uc640 \uc720\ub7fd\uc740 \ub0ae\uc740 \ud3b8\uc774\uace0, Choctaw \uc544\uba54\ub9ac\uce74 \uc6d0\uc8fc\ubbfc\uc774 \uac00\uc7a5 \ub192\uc740 \uc720\ubcd1\ub960\uc744 \ubcf4\uc774\uba70 African-American\uc774 White\ubcf4\ub2e4 \ubc1c\ubcd1\ub960\ub3c4 \ub192\uace0 \uc784\uc0c1 \uc591\uc0c1\ub3c4 \ub354 \uc2ec\ud558\ub2e4. 4. \ubcd1\uc778\uae30\uc804 \ucf5c\ub77c\uac90\uc758 \uce68\ucc29 + \ud608\uad00\uc758 \uc774\uc0c1 + \uc5fc\uc99d \uc138\ud3ec\uc758 \uce68\uc724 Diffuse microangiopathy + inflammation and autoimmunity + viscelral and vascular fibrosis \uc720\uc804\uc801 \uc694\uc778 : HLA-DPB1 * 0901, HLA-DPB1 * 1301 \ud658\uacbd\uc801 \uc694\uc778 : \ube44\ub2d0 \ud074\ub85c\ub77c\uc774\ub4dc, \uaddc\uc9c4, \uc720\uae30\uc6a9\uc81c, \uac00\uacf5 \uc720\ucc44\uaf43 \uc624\uc77c, L-tryptopan, CMV, Parvo B19, bleomycin, pentazocine, cocaine (smoking\uc740 \uad00\ub828\uc774 \uc5c6\ub2e4) \ud608\uad00\uae30\ub2a5\uc7a5\uc560 : vasculopathy d/t anti-endothelial antibody \uba74\uc5ed\uae30\ub2a5\uc7a5\uc560 \uc12c\uc720\ud654 : \uc12c\uc720\ubaa8\uc138\ud3ec/\uadfc\uc12c\uc720\ubaa8\uc138\ud3ec\uac00 \uacfc\ub3c4\ud558\uac8c \ud615\uc131 -> collagen\uacfc \uac19\uc740 extracellular matrix\uac00 \uacfc\ub3c4\ud558\uac8c \uce68\ucc29. 5. \uc784\uc0c1\uc99d\uc0c1 \uc8fc\uc99d\uc0c1 Skin thickening & organ involvement : diffuse type\uc774 \ub354 \ube60\ub974\uac8c \uc9c4\ud589\ud558\uace0 \ub0b4\ubd80 \uc7a5\uae30 \uce68\ubc94\ub3c4 \ub354 \uc2ec\ud558\ub2e4. \uc5fc\uc99d/\ubd80\uc885\uae30 -> \uc9c4\ud589\uc131 \ud53c\ubd80 \uc12c\uc720\ud654 -> \ud53c\ubd80 \uc704\ucd95/\uad6c\ucd95 sclerodactyly, digital pit, mauskopt, salt and pepper, telangiectasia, calcinosis cutis \ud53c\ubd80\uce68\ubc94\uc740 mRSS\ub85c \ud3c9\uac00\ud568. Raynaud\u2019s phenomenon : \uac00\uc7a5 \uba3c\uc800 \ub098\ud0c0\ub098\ub294 \uc99d\uc0c1. \ucd94\uc704\ub098 stress\uac00 \uc788\uc744 \ub54c pallor -> cyanosis -> rubor + \uc99d\uc0c1\uc774 \uc788\ub294 \uac83. \uc77c\ucc28\uc131 : \uc800\uc628\uc5d0 \ub300\ud55c \uacfc\ud55c \uc0dd\ub9ac\uc801 \ubc18\uc751. \ud608\uad00 \uad6c\uc870 \ubcc0\ud654\ub294 \uc5c6\uc73c\ubbc0\ub85c \uc870\uc9c1 \uc190\uc0c1\uc73c\ub85c \uc9c4\ud589\ud558\uc9c0 \uc54a\uc74c. \uc774\ucc28\uc131 : \ud608\uad00 \uad6c\uc870 \ubcc0\ud654\uc5d0 \ub530\ub978 \ud5c8\ud608\uacfc \uc870\uc9c1 \uc190\uc0c1 -> pitting, ulcer, necrosis, autoamputation \uc774\uc678 \uc99d\uc0c1 Lung : ILD -> HRCT + PFT + KL-6 / PAH -> 2DE + RHC + NT-proBNP / Lung cancer Heart : pericardial effusion, pericarditis, constrictive pericarditis, conduction \uc7a5\uc560, MI \ub4f1 GI tract : GERD/Barrett\u2019s esophagus, Esophageal adenocarcinoma, Gastroparesis, GAVE, Malabsorbtion, Bacterial overgrowth, pneumatosis cystoides intestinalis, pseudo-obstruction Liver : PBC Kidney : SRC, crescentic GN, MGN (d/t D-penicillamine use) MS : CTS, Multiple arthritis, Tendon friction rub, acrolysis etc. : erectile dysfunction, dyspareunia 6. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8 6-1. \ud608\uc561\uac80\uc0ac Routine lab + ANA Anticentromere Ab., Anti-topoisomerase I Ab, Anti-RNA pol.III Ab. 6-2. \uc190\ud1b1\uc8fc\ub984 \ubaa8\uc138\ud608\uad00\uacbd \uac80\uc0ac (NFC) \ub300\uac1c \ud53c\ubd80 \uacbd\ud654 \ubc1c\uc0dd \uc218\uc8fc~\uc218\ub144 \uc804\ubd80\ud130 RP \ubc1c\uc0dd. Giant capillary, hemorrhage, loop & neovascularization 6-3. \ubd84\ub958\uae30\uc900 2013 ACR/EULAR SSc classification criteria (9\uc810 \uc774\uc0c1) MCP\ub97c \ud3ec\ud568\ud558\uc5ec proximal\ub85c skin thickening\uc774 \uc9c4\ud589\ud558\uba74 9\uc810\uc73c\ub85c SSc \ubd84\ub958\uac00 \uac00\ub2a5\ud558\ub2e4. Skin thickening\uc774 MCP\uc758 distal\uc5d0\ub9cc \uad6d\ud55c\ub41c\ub2e4\uba74 \ub098\uba38\uc9c0 \uae30\uc900\uc744 \uc801\uc6a9\ud55c\ub2e4. \uc721\uc548\uc0c1 Finger skin thickening\uc774\ub098 tip ulcer, telangiectasia, RP\uac00 \uc788\ub294\uac00? Abnormal NFC\uac00 \ubcf4\uc774\ub294\uac00? PAH\ub098 ILD\uac00 \uc788\ub294\uac00? \uc790\uac00\ud56d\uccb4\uac00 \ub098\uc624\ub294\uac00? ** \uc784\uc0c1\uc801\uc73c\ub85c\ub294 CREST \uc911 3\uac00\uc9c0 \uc774\uc0c1\uc744 \ub9cc\uc871\ud558\uba74 SSc\ub85c \ud310\ub2e8\ud558\uae30\ub3c4 \ud55c\ub2e4. ** SSc sine scleroderma \ucc98\ub7fc skin lesion\uc774 \uc5c6\ub294 internal organ involvement\ub3c4 \uc788\uc73c\ubbc0\ub85c \ub9cc\uc57d \uc790\uac00\ud56d\uccb4\uac00 \uc591\uc131\uc77c \uacbd\uc6b0\uc5d4 \uc99d\uc0c1\uc774 \uc544\uc8fc \uc800\uba85\ud558\uc9c0 \uc54a\ub354\ub77c\ub3c4 (e.g. RP + NFC (+)\ub9cc \uc788\ub294 \uacbd\uc6b0) \uce58\ub8cc \uc2dc\uc791\uc744 \uad8c\uc720\ud558\uae30\ub3c4 \ud55c\ub2e4. 6-4. \uac10\ubcc4\uc9c4\ub2e8 NSF, eosinophilic fasciitis, scleredema, scleremyxedema 7. \uce58\ub8cc\uc6d0\uce59 \uc694\uc57d \uc7a5\uae30 \uce68\ubc94\uc5d0 \ub530\ub978 \ub300\uc99d\uc801\uc778 \uce58\ub8cc\ub97c \ud55c\ub2e4. \uba74\uc5ed\uc5b5\uc81c\uc81c : CYC, MMF RP : \ubcf4\uc628, \uae08\uc5f0, nifedipine, Losartan, sildenafil, iloprost IV, low dose aspirin, bosentan PAH : bosentan, riociguat, epoprostenol SRC : ACE I GI tract : PPI, cyclic broad-spectrum antibiotics Skin/MS : MTX, NSAIDs 8. \uacbd\uacfc\uc640 \uc608\ud6c4 \uc0ac\ub9dd\ub960\uc740 subtype, \ub0b4\ubd80 \uc7a5\uae30 \uce68\ubc94 \uc815\ub3c4, \ub3d9\ubc18 \uc9c8\ud658\uc5d0 \uc758\ud574 \uc601\ud5a5 \uc744 \ubc1b\ub294\ub2e4. dcSSc\uac00 lcSSc\ubcf4\ub2e4 \uc608\ud6c4\uac00 \ub354 \ub098\uc058\ub2e4. (\uc0ac\ub9dd\uae4c\uc9c0 median 7.1\ub144 : 15.0\ub144) PAH\uac00 \ud604\uc7ac\ub85c\uc11c\ub294 \uac00\uc7a5 \uc0ac\ub9dd \uc704\ud5d8\uc774 \ub192\ub2e4. (Esp. HFpEF c PAH) - \ud3c9\uade0 4\ub144 \ubd88\ub7c9 \uc608\ud6c4 \uc778\uc790 : Male, \uace0\ub839, extensive skin/organ involvement (esp. PAH, SRC), tendon friction rub, Anti-topoisomerase I ab.","title":"Systemic Sclerosis"},{"location":"SSc/ssc/#1-historical-perspective","text":"(1847) Gintrac : Sclerodermie \uc6a9\uc5b4 \uc0ac\uc6a9. (\ud604\uc7ac \uae30\uc900\uc73c\ub85c \ubcfc \ub54c \uac00\uc7a5 SSc\uc5d0 \uac00\uc7a5 \ud569\ub2f9\ud55c \uccab case) (1860) Maurice Raynaud : RP \ubc1c\ud45c (Sclerodermie and cold-induced \"asphyxie locale\") (1897) Osler : Scleroderma\uac00 systemic ds.\ub77c\ub294 \uac83\uc744 \uc778\uc2dd (1924) Matsui : \ubd80\uac80\uc5d0 \uadfc\uac70\ud558\uc5ec Scleroderma\uc758 internal organ involvement \uac15\uc870 (1945) Goetz : Progressive systemic sclerosis \uc6a9\uc5b4 \uc81c\uc548 (1964) Winterbauer : CRST \uc0ac\ub840 \uc81c\uc2dc\ub97c \ud1b5\ud574 SSc\uc758 subtype concept \ub3c4\uc785 \u2192 \uc774\ud6c4 esophageal dysmotility\uae4c\uc9c0 \ud3ec\ud568\ud558\uc5ec CREST symdrome\uc774\ub77c\ub294 \uc6a9\uc5b4 \ub3c4\uc785 (1969) SSc\uc758 \ubd80\uac80 case \ube44\uad50 : \uc8fc\ub85c skin, GI, PD, CV, Muscle \ub4f1\uc5d0 involve\ud568. (1970s) ACE inhibitor\uac00 SRC\ub97c \ud638\uc804\uc2dc\ud0ac \uc218 \uc788\ub2e4\ub294 \uac83\uc774 \ubc1d\ud600\uc9d0. (1979) Skin involvement\uc758 \ud3c9\uac00 \ubc29\ubc95 \uc81c\uc2dc : mRSS (2001) Leroy, Medsger : RP+Abnormal NPC+\uc790\uac00\ud56d\uccb4 \uc591\uc131 \uc18c\uacac\uc774 SSc \uc870\uae30 \uc9c4\ub2e8\uc5d0 \uc720\uc6a9\ud560 \uac83\uc774\ub77c\uace0 \uc81c\uc548 (2013) ACR/EULAR classification criteria","title":"1. Historical Perspective"},{"location":"SSc/ssc/#2","text":"Localized scleroderma : \uc12c\uc720\ud654\uac00 \ud53c\ubd80\uc640 \ud53c\ud558\uc870\uc9c1\uc5d0\ub9cc \uad6d\ud55c\ub41c \ud615\ud0dc Morphea (\ubc18\uc0c1 \uad6d\ud55c \ud53c\ubd80\uacbd\ud654\uc99d) Linear (\uc120 \ud53c\ubd80\uacbd\ud654\uc99d) - en coup de sabre Systemic sclerosis : \uc12c\uc720\ud654\uac00 \ud53c\ubd80 \ubc0f \uc804\uc2e0\uc7a5\uae30\ub97c \uce68\ubc94\ud568 limited cutaneous SSc : \ud53c\ubd80 \uce68\ubc94\uc774 \ud314\uafc8\uce58\uc640 \ubb34\ub98e\uc758 \uc6d0\uc704\ubd80\uae4c\uc9c0\ub9cc \uc77c\uc5b4\ub0a8 diffuse cutaneous SSc : \uadf8 \ubcf4\ub2e4 \ub354 \ubab8\ud1b5 \ubd80\uc704\uae4c\uc9c0 \ud655\uc7a5. Systemic sclerosis sine scleroderma : \ud53c\ubd80 \uce68\ubc94(-), \uc790\uac00\ud56d\uccb4 (+), \ub0b4\ubd80\uc7a5\uae30 \uce68\ubc94 (+) SSc overlap syndrome : polyarthritis, myositis, sicca complex, hypothyroidism, PBC, MCTD ** RP + Abnormal NFC\ub9cc \uc788\ub294 \uacbd\uc6b0\uc5d0\ub294 UCTD\ub85c \uc77c\ub2e8 \uc0dd\uac01\ud558\ub294\ub370, \uc774 \ud658\uc790\uad70\uc758 \uc57d 20% \uc815\ub3c4\uac00 2~4\ub144 \ud6c4\uc5d0 SSc\uac00 \ubc1c\ubcd1\ud55c\ub2e4.","title":"2. \ubd84\ub958"},{"location":"SSc/ssc/#3","text":"\uc8fc\ub85c 40\ub300 (35~50\uc138), M:F = 1:9. 25\uc138 \uc774\uc804 \ubc1c\ubcd1\uc740 \ub4dc\ubb3c\ub2e4. \ubc1c\ubcd1\ub960 : \ubc31\ub9cc\uba85 \ub2f9 13.9~21\uba85, \uc720\ubcd1\ub960 : \ubc31\ub9cc\uba85 \ub2f9 276\uba85. Diffuse < limited \ucd08\uae30\uc5d0 RP, Abnormal NFC, Antoantibodies\uac00 \uc788\uc744 \ub54c \ub354 \uc798 \uc9c4\ud589\ud558\ub294 \uacbd\ud5a5. ** \ubc1c\uc0dd\ub960 \ubc0f \uc720\ubcd1\ub960\uc740 \uc778\uc885/\ubbfc\uc871\uc5d0 \ub530\ub77c \ub2e4\ub974\ub2e4. \uc0c1\ub300\uc801\uc73c\ub85c \uc544\uc2dc\uc544\uc640 \uc720\ub7fd\uc740 \ub0ae\uc740 \ud3b8\uc774\uace0, Choctaw \uc544\uba54\ub9ac\uce74 \uc6d0\uc8fc\ubbfc\uc774 \uac00\uc7a5 \ub192\uc740 \uc720\ubcd1\ub960\uc744 \ubcf4\uc774\uba70 African-American\uc774 White\ubcf4\ub2e4 \ubc1c\ubcd1\ub960\ub3c4 \ub192\uace0 \uc784\uc0c1 \uc591\uc0c1\ub3c4 \ub354 \uc2ec\ud558\ub2e4.","title":"3. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790"},{"location":"SSc/ssc/#4","text":"\ucf5c\ub77c\uac90\uc758 \uce68\ucc29 + \ud608\uad00\uc758 \uc774\uc0c1 + \uc5fc\uc99d \uc138\ud3ec\uc758 \uce68\uc724 Diffuse microangiopathy + inflammation and autoimmunity + viscelral and vascular fibrosis \uc720\uc804\uc801 \uc694\uc778 : HLA-DPB1 * 0901, HLA-DPB1 * 1301 \ud658\uacbd\uc801 \uc694\uc778 : \ube44\ub2d0 \ud074\ub85c\ub77c\uc774\ub4dc, \uaddc\uc9c4, \uc720\uae30\uc6a9\uc81c, \uac00\uacf5 \uc720\ucc44\uaf43 \uc624\uc77c, L-tryptopan, CMV, Parvo B19, bleomycin, pentazocine, cocaine (smoking\uc740 \uad00\ub828\uc774 \uc5c6\ub2e4) \ud608\uad00\uae30\ub2a5\uc7a5\uc560 : vasculopathy d/t anti-endothelial antibody \uba74\uc5ed\uae30\ub2a5\uc7a5\uc560 \uc12c\uc720\ud654 : \uc12c\uc720\ubaa8\uc138\ud3ec/\uadfc\uc12c\uc720\ubaa8\uc138\ud3ec\uac00 \uacfc\ub3c4\ud558\uac8c \ud615\uc131 -> collagen\uacfc \uac19\uc740 extracellular matrix\uac00 \uacfc\ub3c4\ud558\uac8c \uce68\ucc29.","title":"4. \ubcd1\uc778\uae30\uc804"},{"location":"SSc/ssc/#5","text":"\uc8fc\uc99d\uc0c1 Skin thickening & organ involvement : diffuse type\uc774 \ub354 \ube60\ub974\uac8c \uc9c4\ud589\ud558\uace0 \ub0b4\ubd80 \uc7a5\uae30 \uce68\ubc94\ub3c4 \ub354 \uc2ec\ud558\ub2e4. \uc5fc\uc99d/\ubd80\uc885\uae30 -> \uc9c4\ud589\uc131 \ud53c\ubd80 \uc12c\uc720\ud654 -> \ud53c\ubd80 \uc704\ucd95/\uad6c\ucd95 sclerodactyly, digital pit, mauskopt, salt and pepper, telangiectasia, calcinosis cutis \ud53c\ubd80\uce68\ubc94\uc740 mRSS\ub85c \ud3c9\uac00\ud568. Raynaud\u2019s phenomenon : \uac00\uc7a5 \uba3c\uc800 \ub098\ud0c0\ub098\ub294 \uc99d\uc0c1. \ucd94\uc704\ub098 stress\uac00 \uc788\uc744 \ub54c pallor -> cyanosis -> rubor + \uc99d\uc0c1\uc774 \uc788\ub294 \uac83. \uc77c\ucc28\uc131 : \uc800\uc628\uc5d0 \ub300\ud55c \uacfc\ud55c \uc0dd\ub9ac\uc801 \ubc18\uc751. \ud608\uad00 \uad6c\uc870 \ubcc0\ud654\ub294 \uc5c6\uc73c\ubbc0\ub85c \uc870\uc9c1 \uc190\uc0c1\uc73c\ub85c \uc9c4\ud589\ud558\uc9c0 \uc54a\uc74c. \uc774\ucc28\uc131 : \ud608\uad00 \uad6c\uc870 \ubcc0\ud654\uc5d0 \ub530\ub978 \ud5c8\ud608\uacfc \uc870\uc9c1 \uc190\uc0c1 -> pitting, ulcer, necrosis, autoamputation \uc774\uc678 \uc99d\uc0c1 Lung : ILD -> HRCT + PFT + KL-6 / PAH -> 2DE + RHC + NT-proBNP / Lung cancer Heart : pericardial effusion, pericarditis, constrictive pericarditis, conduction \uc7a5\uc560, MI \ub4f1 GI tract : GERD/Barrett\u2019s esophagus, Esophageal adenocarcinoma, Gastroparesis, GAVE, Malabsorbtion, Bacterial overgrowth, pneumatosis cystoides intestinalis, pseudo-obstruction Liver : PBC Kidney : SRC, crescentic GN, MGN (d/t D-penicillamine use) MS : CTS, Multiple arthritis, Tendon friction rub, acrolysis etc. : erectile dysfunction, dyspareunia","title":"5. \uc784\uc0c1\uc99d\uc0c1"},{"location":"SSc/ssc/#6","text":"","title":"6. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8"},{"location":"SSc/ssc/#6-1","text":"Routine lab + ANA Anticentromere Ab., Anti-topoisomerase I Ab, Anti-RNA pol.III Ab.","title":"6-1. \ud608\uc561\uac80\uc0ac"},{"location":"SSc/ssc/#6-2-nfc","text":"\ub300\uac1c \ud53c\ubd80 \uacbd\ud654 \ubc1c\uc0dd \uc218\uc8fc~\uc218\ub144 \uc804\ubd80\ud130 RP \ubc1c\uc0dd. Giant capillary, hemorrhage, loop & neovascularization","title":"6-2. \uc190\ud1b1\uc8fc\ub984 \ubaa8\uc138\ud608\uad00\uacbd \uac80\uc0ac (NFC)"},{"location":"SSc/ssc/#6-3","text":"2013 ACR/EULAR SSc classification criteria (9\uc810 \uc774\uc0c1) MCP\ub97c \ud3ec\ud568\ud558\uc5ec proximal\ub85c skin thickening\uc774 \uc9c4\ud589\ud558\uba74 9\uc810\uc73c\ub85c SSc \ubd84\ub958\uac00 \uac00\ub2a5\ud558\ub2e4. Skin thickening\uc774 MCP\uc758 distal\uc5d0\ub9cc \uad6d\ud55c\ub41c\ub2e4\uba74 \ub098\uba38\uc9c0 \uae30\uc900\uc744 \uc801\uc6a9\ud55c\ub2e4. \uc721\uc548\uc0c1 Finger skin thickening\uc774\ub098 tip ulcer, telangiectasia, RP\uac00 \uc788\ub294\uac00? Abnormal NFC\uac00 \ubcf4\uc774\ub294\uac00? PAH\ub098 ILD\uac00 \uc788\ub294\uac00? \uc790\uac00\ud56d\uccb4\uac00 \ub098\uc624\ub294\uac00? ** \uc784\uc0c1\uc801\uc73c\ub85c\ub294 CREST \uc911 3\uac00\uc9c0 \uc774\uc0c1\uc744 \ub9cc\uc871\ud558\uba74 SSc\ub85c \ud310\ub2e8\ud558\uae30\ub3c4 \ud55c\ub2e4. ** SSc sine scleroderma \ucc98\ub7fc skin lesion\uc774 \uc5c6\ub294 internal organ involvement\ub3c4 \uc788\uc73c\ubbc0\ub85c \ub9cc\uc57d \uc790\uac00\ud56d\uccb4\uac00 \uc591\uc131\uc77c \uacbd\uc6b0\uc5d4 \uc99d\uc0c1\uc774 \uc544\uc8fc \uc800\uba85\ud558\uc9c0 \uc54a\ub354\ub77c\ub3c4 (e.g. RP + NFC (+)\ub9cc \uc788\ub294 \uacbd\uc6b0) \uce58\ub8cc \uc2dc\uc791\uc744 \uad8c\uc720\ud558\uae30\ub3c4 \ud55c\ub2e4.","title":"6-3. \ubd84\ub958\uae30\uc900"},{"location":"SSc/ssc/#6-4","text":"NSF, eosinophilic fasciitis, scleredema, scleremyxedema","title":"6-4. \uac10\ubcc4\uc9c4\ub2e8"},{"location":"SSc/ssc/#7","text":"\uc694\uc57d \uc7a5\uae30 \uce68\ubc94\uc5d0 \ub530\ub978 \ub300\uc99d\uc801\uc778 \uce58\ub8cc\ub97c \ud55c\ub2e4. \uba74\uc5ed\uc5b5\uc81c\uc81c : CYC, MMF RP : \ubcf4\uc628, \uae08\uc5f0, nifedipine, Losartan, sildenafil, iloprost IV, low dose aspirin, bosentan PAH : bosentan, riociguat, epoprostenol SRC : ACE I GI tract : PPI, cyclic broad-spectrum antibiotics Skin/MS : MTX, NSAIDs","title":"7. \uce58\ub8cc\uc6d0\uce59"},{"location":"SSc/ssc/#8","text":"\uc0ac\ub9dd\ub960\uc740 subtype, \ub0b4\ubd80 \uc7a5\uae30 \uce68\ubc94 \uc815\ub3c4, \ub3d9\ubc18 \uc9c8\ud658\uc5d0 \uc758\ud574 \uc601\ud5a5 \uc744 \ubc1b\ub294\ub2e4. dcSSc\uac00 lcSSc\ubcf4\ub2e4 \uc608\ud6c4\uac00 \ub354 \ub098\uc058\ub2e4. (\uc0ac\ub9dd\uae4c\uc9c0 median 7.1\ub144 : 15.0\ub144) PAH\uac00 \ud604\uc7ac\ub85c\uc11c\ub294 \uac00\uc7a5 \uc0ac\ub9dd \uc704\ud5d8\uc774 \ub192\ub2e4. (Esp. HFpEF c PAH) - \ud3c9\uade0 4\ub144 \ubd88\ub7c9 \uc608\ud6c4 \uc778\uc790 : Male, \uace0\ub839, extensive skin/organ involvement (esp. PAH, SRC), tendon friction rub, Anti-topoisomerase I ab.","title":"8. \uacbd\uacfc\uc640 \uc608\ud6c4"},{"location":"crystalopathy/gout/","text":"1. The burden of Gout Gout is the most common inflammatory arthritis It is more common in men than in women Prevalence ranges from <1% to 4% Prevalence increases with age Prevalence of CV, renal, and metabolic comorbidities is high in patients with gout and is substantially higher than in patients without gout (Zhu Y, et al. Am J med. 2012;125:679-687.e1) 2. New clinical staging system Asymptomatic disease Stage A Stage B Symptomatic disease Stage C Stage D 3. \uc774\ubbf8 \uc54c\uace0 \uc788\ub294 \uc0ac\uc2e4 \ubb34\uc99d\uc0c1 \uace0\uc694\uc0b0\ud608\uc99d : \uce58\ub8cc\ud558\uc9c0 \uc54a\ub294\ub2e4. \uae09\uc131\uae30\uc5d0\ub294 \ud608\uc911 \uc694\uc0b0 \ub18d\ub3c4\uac00 \uc815\uc0c1\uc77c \uc218 \uc788\ub2e4. \uae09\uc131\uae30\uc5d0 \ud608\uc911 \uc694\uc0b0 \ub18d\ub3c4\ub97c \ubcc0\ud654\uc2dc\ud0a4\uba74 \uc548\ub41c\ub2e4?? \ud608\uc911\uc694\uc0b0\ub18d\ub3c4 \ubaa9\ud45c : <6mg/dl (or <5mg/dl) \ud1b5\ud48d\ud658\uc790\uc5d0\uc11c ULT\uc758 \uc801\uc751\uc99d : Tophi, frequent attack > 2/yr, CKD Stage 2 \uc774\uc0c1, \uc694\ub85c\uacb0\uc11d \uacfc\uac70\ub825 3-1. \uae09\uc131\uae30 \ud1b5\ud48d \uce58\ub8cc\uc758 \uc77c\ubc18 \uc6d0\uce59 \uac00\ub2a5\ud55c \ube60\ub978 \uc2dc\uac04 \uc774\ub0b4\uc5d0, \uc801\uc5b4\ub3c4 24\uc2dc\uac04 \uc774\ub0b4\uc5d0 \uce58\ub8cc\ub97c \uc2dc\uc791\ud55c\ub2e4. Colchine, NSAIDs, steroid \ub4f1\uc744 \uce68\ubc94\ub41c \uad00\uc808\uc758 \uc218, \uad00\uc808\uc5fc\uc758 \uc911\uc99d\ub3c4, \ub3d9\ubc18\uc9c8\ud658\uc5d0 \ub530\ub77c \ub2e8\ub3c5 \ud639\uc740 \ubcd1\uc6a9 \ud22c\uc5ec NSAIDs \uc911\uc5d0 \ub354 \uc120\ud638\ub418\ub294 \uc57d\uc81c\ub294 \uc5c6\ub2e4. Colchine NSAIDs Steroid CKD III~V X X \uc18c\ud654\uc131 \uada4\uc591 X X \uc2ec\ubd80\uc804 \ub610\ub294 \ud56d\uc751\uace0\uc81c \uc0ac\uc6a9 X \ub2f9\ub1e8 \ub610\ub294 \uac10\uc5fc X \uac04\uc9c8\ud658 X X 3-2. \uc7ac\ubc1c\uc744 \ub9c9\uae30 \uc704\ud55c \uc608\ubc29 \uce58\ub8cc Colchine 0.6mg qd or BID : 3~6\uac1c\uc6d4 \uc0ac\uc6a9 Tophi\uac00 \uc788\ub294 \uacbd\uc6b0 : 6\uac1c\uc6d4 Tophi\uac00 \uc5c6\ub294 \uacbd\uc6b0 : 3\uac1c\uc6d4 Half dose NSAIDs : 3~6\uac1c\uc6d4 \uc0ac\uc6a9 Low dose prednisolone (<10mg) : 3~6\uac1c\uc6d4 \uc0ac\uc6a9 3-3. \ub9cc\uc131 \ud1b5\ud48d\uc5d0\uc11c \uace0\uc694\uc0b0\ud608\uc99d \uc870\uc808 \uce58\ub8cc \uae30\uac04 : \ud3c9\uc0dd \uc2dd\uc774\uc694\ubc95 : \uc57d\ubb3c\uce58\ub8cc\ubcf4\ub2e4 \uc911\uc694\ud558\uc9c0\ub294 \uc54a\ub2e4. \uce58\ub8cc \ubaa9\ud45c\uac00 \ub418\ub294 \ud608\uccad \uc694\uc0b0 \ub18d\ub3c4 : 5~6mg/dl (\uacb0\uc808\uc774 \uc788\uc73c\uba74 <5mg/dl) Uric acid\uac00 \ub2e4\uc591\ud55c neurodegenerative disease\ub97c \uc608\ubc29\ud560 \uc218\ub3c4 \uc788\ub2e4\ub294 \uc5f0\uad6c\uac00 \uc788\ub2e4. SUA\ub97c <3mg/dL\ub85c \ub0ae\ucd94\ub294 \uac83\uc740 \ucd94\ucc9c\ub418\uc9c0 \uc54a\ub294\ub2e4. ULT\ub97c Acute attack \uc911\uc5d0 \uc4f0\ub098, \ub098\uc911\uc5d0 \uc4f0\ub098 \ubcc4 \ucc28\uc774\uac00 \uc5c6\ub2e4. (Joint bone spine 82(2015) 428-431) \uc694\uc0b0\ud615\uc131\uc5b5\uc81c\uc81c (Xanthine Oxidase Inhibitors, XOI) : allopurinol (100mg/d\ub85c \uc2dc\uc791), febuxostat \uc694\uc0b0\ubc30\uc124\ucd09\uc9c4\uc81c (Uricosuric agents) : Benzbromarone (O), Probenecid (X) ** Comparative recommendations between three societies for starting ULT (Pascart T et al, Rheumatology. 2018 Mar 13) ** Current recommendations for treatment of hyperuricemia in gout patients (\uc5f0\uc218\uac15\uc88c slide) 4. Urate lowering therapy 4-1. Allopurinol Starting dose should be <= 100mg/d starting low followed by gradual upward titration in patients, particularly those with mod. to severe CKD, may not be necessary Maintenance dose can exceed 300mg/d even in patients with CKD HLA-B*5801 screening in subpopulations : high risk for severe allopurinol hypersensitivity reaction mild form (2%) : \uacbd\ubbf8\ud55c \ubc1c\uc9c4, \uc911\ub2e8\uc2dc \ud638\uc804 Severe form (~0.1%) : \uc0ac\ub9dd\ub960 20~25%, \ubcf5\uc6a9 2~5\uc8fc \ud6c4 \ubc1c\uc0dd (TEN, SJS, DRESS syndrome) Risk factor : \uc2e0\uae30\ub2a5 \uc800\ud558, thiazide\uacc4 \uc774\ub1e8\uc81c \ubcd1\uc6a9, \ud398\ub2c8\uc2e4\ub9b0 \uc54c\ub7ec\uc9c0, \uc720\uc804\ud615 (HLA-B*5801: \ud55c\uad6d\uc778 \uc57d 12%) 4-2. Febuxostat The guidelines do not prefer either allopurionl or febuxostat Cost is an issue with febuxostat Updated labelling to include a black box warning in Feb. 2019 (CARES trial) CARES trial\uc758 \ubb38\uc81c\uc810? placebo comparator\uac00 \uc5c6\ub294 \uc784\uc0c1\uc5f0\uad6c\uc774\ub2e4. Dropout rate\uac00 \ub108\ubb34 \ub192\uc740 (45~57%) \uc784\uc0c1\uc5f0\uad6c\uc774\ub2e4. Febuxostat\uc5d0 \uc758\ud55c \uc0ac\ub9dd\ub960 \uc99d\uac00\uc758 \uc6d0\uc778\uc744 \uc54c \uc218 \uc5c6\ub2e4. \uc0ac\ub9dd \ud658\uc790\uc758 85% \uc774\uc0c1\uc740 febuxostat \uc0ac\uc6a9\uc744 \uc911\ub2e8\ud55c \uc774\ud6c4\uc5d0 \ubc1c\uc0dd\ud588\ub2e4. \ud1b5\ud48d\ubc1c\uc791\uc758 temporal course\uc640 severity\uc5d0 \ub300\ud55c \uc784\uc0c1\uc790\ub8cc\uac00 \uc5c6\ub2e4. \ub450 \uad70\uac04\uc5d0 NSAIDs\uc640 aspirin \uc0ac\uc6a9 \ube44\uc728\uc774 \ub2e4\ub974\ub2e4. \uc774\ub85c \uc778\ud55c \uc2ec\ud608\uad00\uacc4 \ud569\ubcd1\uc99d \ubc1c\uc0dd\uc758 \uc704\ud5d8\uc740 \uacc4\uc0b0\ub418\uc9c0 \uc54a\uc558\ub2e4. \ub300\ubd80\ubd84 \uc11c\uc591\uc778 \ud658\uc790\ub97c \ub300\uc0c1\uc73c\ub85c \uc9c4\ud589\ud55c \uc784\uc0c1\uc2dc\ud5d8 \uacb0\uacfc\ub85c \uc6b0\ub9ac\ub098\ub77c \uc2e4\uc81c \uc758\ub8cc \uc0c1\ud669\uacfc\ub294 \ub2e4\ub974\ub2e4. 4-3. Uricosuric agent : benzbromarone \ub300\uac1c XOI\uc5d0 add\ud574\uc11c \uc0ac\uc6a9\ud55c\ub2e4. \uc801\uc751\uc99d : \ud1b5\ud48d\ud658\uc790\uc774\uba74\uc11c \ub2e4\uc74c \uc0ac\ud56d\uc744 \ub9cc\uc871\ud560 \ub54c eGFR 60ml/min/1.73m2 \uc774\uc0c1 (30~60ml/min/1.73m2\uc778 \uacbd\uc6b0\uc5d0\ub294 \uc0ac\uc6a9 \uac00\ub2a5) No \uc2e0\uc7a5\uacb0\uc11d No \uc694\ub85c\uacb0\uc11d 60\uc138 \ubbf8\ub9cc \uac04\ub3c5\uc131 \ub4f1 \ubd80\uc791\uc6a9 \uc704\ud5d8 \ub54c\ubb38\uc5d0 \uc0ac\uc6a9\uc5d0 \uc81c\ud55c\uc774 \uc788\ub2e4. 4-4. Uricosuric agent : Pegloticase A pegylated uric acid-specific enzyme \uc694\uc0b0(uric acid)\uc744 \uc218\uc6a9\uc131\uc778 \uc54c\ub780\ud1a0\uc778 (allantoin)\uc73c\ub85c \uc804\ud658 2010\ub144 \uc694\uc0b0\uc800\ud558\uc790\uc5d0 \ubc18\uc751\ud558\uc9c0 \uc54a\ub294 \uc911\uc99d\uc758 \uacb0\uc808\uc131 \ud1b5\ud48d\ud658\uc790 \uc0ac\uc6a9\uc6a9\ub7c9 \ub9e4 2\uc8fc\ub9c8\ub2e4 8mg\uc529 \uc815\uc8fc \uc8fc\uc785\ubb3c \ubc18\uc751 (infusion reaction) : \uc2dc\uc791 \uc804 \ud56d\ud788\uc2a4\ud0c0\ubbfc\uc81c\uc640 \uae00\ub8e8\ucf54\ucf54\ub974\ud2f0\ucf54\uc774\ub4dc \ubcd1\uc6a9 \ucd5c\uc18c\ud55c \uce58\ub8cc \uc2dc\uc791 7\uc77c \uc804\ubd80\ud130 \uae09\uc131 \ud1b5\ud48d \uc608\ubc29 \uce58\ub8cc\ub97c \uad8c\uace0\ud568.","title":"Crystalopathy"},{"location":"crystalopathy/gout/#1-the-burden-of-gout","text":"Gout is the most common inflammatory arthritis It is more common in men than in women Prevalence ranges from <1% to 4% Prevalence increases with age Prevalence of CV, renal, and metabolic comorbidities is high in patients with gout and is substantially higher than in patients without gout (Zhu Y, et al. Am J med. 2012;125:679-687.e1)","title":"1. The burden of Gout"},{"location":"crystalopathy/gout/#2-new-clinical-staging-system","text":"Asymptomatic disease Stage A Stage B Symptomatic disease Stage C Stage D","title":"2. New clinical staging system"},{"location":"crystalopathy/gout/#3","text":"\ubb34\uc99d\uc0c1 \uace0\uc694\uc0b0\ud608\uc99d : \uce58\ub8cc\ud558\uc9c0 \uc54a\ub294\ub2e4. \uae09\uc131\uae30\uc5d0\ub294 \ud608\uc911 \uc694\uc0b0 \ub18d\ub3c4\uac00 \uc815\uc0c1\uc77c \uc218 \uc788\ub2e4. \uae09\uc131\uae30\uc5d0 \ud608\uc911 \uc694\uc0b0 \ub18d\ub3c4\ub97c \ubcc0\ud654\uc2dc\ud0a4\uba74 \uc548\ub41c\ub2e4?? \ud608\uc911\uc694\uc0b0\ub18d\ub3c4 \ubaa9\ud45c : <6mg/dl (or <5mg/dl) \ud1b5\ud48d\ud658\uc790\uc5d0\uc11c ULT\uc758 \uc801\uc751\uc99d : Tophi, frequent attack > 2/yr, CKD Stage 2 \uc774\uc0c1, \uc694\ub85c\uacb0\uc11d \uacfc\uac70\ub825","title":"3. \uc774\ubbf8 \uc54c\uace0 \uc788\ub294 \uc0ac\uc2e4"},{"location":"crystalopathy/gout/#3-1","text":"\uac00\ub2a5\ud55c \ube60\ub978 \uc2dc\uac04 \uc774\ub0b4\uc5d0, \uc801\uc5b4\ub3c4 24\uc2dc\uac04 \uc774\ub0b4\uc5d0 \uce58\ub8cc\ub97c \uc2dc\uc791\ud55c\ub2e4. Colchine, NSAIDs, steroid \ub4f1\uc744 \uce68\ubc94\ub41c \uad00\uc808\uc758 \uc218, \uad00\uc808\uc5fc\uc758 \uc911\uc99d\ub3c4, \ub3d9\ubc18\uc9c8\ud658\uc5d0 \ub530\ub77c \ub2e8\ub3c5 \ud639\uc740 \ubcd1\uc6a9 \ud22c\uc5ec NSAIDs \uc911\uc5d0 \ub354 \uc120\ud638\ub418\ub294 \uc57d\uc81c\ub294 \uc5c6\ub2e4. Colchine NSAIDs Steroid CKD III~V X X \uc18c\ud654\uc131 \uada4\uc591 X X \uc2ec\ubd80\uc804 \ub610\ub294 \ud56d\uc751\uace0\uc81c \uc0ac\uc6a9 X \ub2f9\ub1e8 \ub610\ub294 \uac10\uc5fc X \uac04\uc9c8\ud658 X X","title":"3-1. \uae09\uc131\uae30 \ud1b5\ud48d \uce58\ub8cc\uc758 \uc77c\ubc18 \uc6d0\uce59"},{"location":"crystalopathy/gout/#3-2","text":"Colchine 0.6mg qd or BID : 3~6\uac1c\uc6d4 \uc0ac\uc6a9 Tophi\uac00 \uc788\ub294 \uacbd\uc6b0 : 6\uac1c\uc6d4 Tophi\uac00 \uc5c6\ub294 \uacbd\uc6b0 : 3\uac1c\uc6d4 Half dose NSAIDs : 3~6\uac1c\uc6d4 \uc0ac\uc6a9 Low dose prednisolone (<10mg) : 3~6\uac1c\uc6d4 \uc0ac\uc6a9","title":"3-2. \uc7ac\ubc1c\uc744 \ub9c9\uae30 \uc704\ud55c \uc608\ubc29 \uce58\ub8cc"},{"location":"crystalopathy/gout/#3-3","text":"\uce58\ub8cc \uae30\uac04 : \ud3c9\uc0dd \uc2dd\uc774\uc694\ubc95 : \uc57d\ubb3c\uce58\ub8cc\ubcf4\ub2e4 \uc911\uc694\ud558\uc9c0\ub294 \uc54a\ub2e4. \uce58\ub8cc \ubaa9\ud45c\uac00 \ub418\ub294 \ud608\uccad \uc694\uc0b0 \ub18d\ub3c4 : 5~6mg/dl (\uacb0\uc808\uc774 \uc788\uc73c\uba74 <5mg/dl) Uric acid\uac00 \ub2e4\uc591\ud55c neurodegenerative disease\ub97c \uc608\ubc29\ud560 \uc218\ub3c4 \uc788\ub2e4\ub294 \uc5f0\uad6c\uac00 \uc788\ub2e4. SUA\ub97c <3mg/dL\ub85c \ub0ae\ucd94\ub294 \uac83\uc740 \ucd94\ucc9c\ub418\uc9c0 \uc54a\ub294\ub2e4. ULT\ub97c Acute attack \uc911\uc5d0 \uc4f0\ub098, \ub098\uc911\uc5d0 \uc4f0\ub098 \ubcc4 \ucc28\uc774\uac00 \uc5c6\ub2e4. (Joint bone spine 82(2015) 428-431) \uc694\uc0b0\ud615\uc131\uc5b5\uc81c\uc81c (Xanthine Oxidase Inhibitors, XOI) : allopurinol (100mg/d\ub85c \uc2dc\uc791), febuxostat \uc694\uc0b0\ubc30\uc124\ucd09\uc9c4\uc81c (Uricosuric agents) : Benzbromarone (O), Probenecid (X) ** Comparative recommendations between three societies for starting ULT (Pascart T et al, Rheumatology. 2018 Mar 13) ** Current recommendations for treatment of hyperuricemia in gout patients (\uc5f0\uc218\uac15\uc88c slide)","title":"3-3. \ub9cc\uc131 \ud1b5\ud48d\uc5d0\uc11c \uace0\uc694\uc0b0\ud608\uc99d \uc870\uc808"},{"location":"crystalopathy/gout/#4-urate-lowering-therapy","text":"","title":"4. Urate lowering therapy"},{"location":"crystalopathy/gout/#4-1-allopurinol","text":"Starting dose should be <= 100mg/d starting low followed by gradual upward titration in patients, particularly those with mod. to severe CKD, may not be necessary Maintenance dose can exceed 300mg/d even in patients with CKD HLA-B*5801 screening in subpopulations : high risk for severe allopurinol hypersensitivity reaction mild form (2%) : \uacbd\ubbf8\ud55c \ubc1c\uc9c4, \uc911\ub2e8\uc2dc \ud638\uc804 Severe form (~0.1%) : \uc0ac\ub9dd\ub960 20~25%, \ubcf5\uc6a9 2~5\uc8fc \ud6c4 \ubc1c\uc0dd (TEN, SJS, DRESS syndrome) Risk factor : \uc2e0\uae30\ub2a5 \uc800\ud558, thiazide\uacc4 \uc774\ub1e8\uc81c \ubcd1\uc6a9, \ud398\ub2c8\uc2e4\ub9b0 \uc54c\ub7ec\uc9c0, \uc720\uc804\ud615 (HLA-B*5801: \ud55c\uad6d\uc778 \uc57d 12%)","title":"4-1. Allopurinol"},{"location":"crystalopathy/gout/#4-2-febuxostat","text":"The guidelines do not prefer either allopurionl or febuxostat Cost is an issue with febuxostat Updated labelling to include a black box warning in Feb. 2019 (CARES trial) CARES trial\uc758 \ubb38\uc81c\uc810? placebo comparator\uac00 \uc5c6\ub294 \uc784\uc0c1\uc5f0\uad6c\uc774\ub2e4. Dropout rate\uac00 \ub108\ubb34 \ub192\uc740 (45~57%) \uc784\uc0c1\uc5f0\uad6c\uc774\ub2e4. Febuxostat\uc5d0 \uc758\ud55c \uc0ac\ub9dd\ub960 \uc99d\uac00\uc758 \uc6d0\uc778\uc744 \uc54c \uc218 \uc5c6\ub2e4. \uc0ac\ub9dd \ud658\uc790\uc758 85% \uc774\uc0c1\uc740 febuxostat \uc0ac\uc6a9\uc744 \uc911\ub2e8\ud55c \uc774\ud6c4\uc5d0 \ubc1c\uc0dd\ud588\ub2e4. \ud1b5\ud48d\ubc1c\uc791\uc758 temporal course\uc640 severity\uc5d0 \ub300\ud55c \uc784\uc0c1\uc790\ub8cc\uac00 \uc5c6\ub2e4. \ub450 \uad70\uac04\uc5d0 NSAIDs\uc640 aspirin \uc0ac\uc6a9 \ube44\uc728\uc774 \ub2e4\ub974\ub2e4. \uc774\ub85c \uc778\ud55c \uc2ec\ud608\uad00\uacc4 \ud569\ubcd1\uc99d \ubc1c\uc0dd\uc758 \uc704\ud5d8\uc740 \uacc4\uc0b0\ub418\uc9c0 \uc54a\uc558\ub2e4. \ub300\ubd80\ubd84 \uc11c\uc591\uc778 \ud658\uc790\ub97c \ub300\uc0c1\uc73c\ub85c \uc9c4\ud589\ud55c \uc784\uc0c1\uc2dc\ud5d8 \uacb0\uacfc\ub85c \uc6b0\ub9ac\ub098\ub77c \uc2e4\uc81c \uc758\ub8cc \uc0c1\ud669\uacfc\ub294 \ub2e4\ub974\ub2e4.","title":"4-2. Febuxostat"},{"location":"crystalopathy/gout/#4-3-uricosuric-agent-benzbromarone","text":"\ub300\uac1c XOI\uc5d0 add\ud574\uc11c \uc0ac\uc6a9\ud55c\ub2e4. \uc801\uc751\uc99d : \ud1b5\ud48d\ud658\uc790\uc774\uba74\uc11c \ub2e4\uc74c \uc0ac\ud56d\uc744 \ub9cc\uc871\ud560 \ub54c eGFR 60ml/min/1.73m2 \uc774\uc0c1 (30~60ml/min/1.73m2\uc778 \uacbd\uc6b0\uc5d0\ub294 \uc0ac\uc6a9 \uac00\ub2a5) No \uc2e0\uc7a5\uacb0\uc11d No \uc694\ub85c\uacb0\uc11d 60\uc138 \ubbf8\ub9cc \uac04\ub3c5\uc131 \ub4f1 \ubd80\uc791\uc6a9 \uc704\ud5d8 \ub54c\ubb38\uc5d0 \uc0ac\uc6a9\uc5d0 \uc81c\ud55c\uc774 \uc788\ub2e4.","title":"4-3. Uricosuric agent : benzbromarone"},{"location":"crystalopathy/gout/#4-4-uricosuric-agent-pegloticase","text":"A pegylated uric acid-specific enzyme \uc694\uc0b0(uric acid)\uc744 \uc218\uc6a9\uc131\uc778 \uc54c\ub780\ud1a0\uc778 (allantoin)\uc73c\ub85c \uc804\ud658 2010\ub144 \uc694\uc0b0\uc800\ud558\uc790\uc5d0 \ubc18\uc751\ud558\uc9c0 \uc54a\ub294 \uc911\uc99d\uc758 \uacb0\uc808\uc131 \ud1b5\ud48d\ud658\uc790 \uc0ac\uc6a9\uc6a9\ub7c9 \ub9e4 2\uc8fc\ub9c8\ub2e4 8mg\uc529 \uc815\uc8fc \uc8fc\uc785\ubb3c \ubc18\uc751 (infusion reaction) : \uc2dc\uc791 \uc804 \ud56d\ud788\uc2a4\ud0c0\ubbfc\uc81c\uc640 \uae00\ub8e8\ucf54\ucf54\ub974\ud2f0\ucf54\uc774\ub4dc \ubcd1\uc6a9 \ucd5c\uc18c\ud55c \uce58\ub8cc \uc2dc\uc791 7\uc77c \uc804\ubd80\ud130 \uae09\uc131 \ud1b5\ud48d \uc608\ubc29 \uce58\ub8cc\ub97c \uad8c\uace0\ud568.","title":"4-4. Uricosuric agent : Pegloticase"},{"location":"misc/misc/","text":"Note: This is the demo content for demonstration purpose only. The primary function of this content is to show you what this theme can do. There is a more detailed explanation in the Getting Started section. \uba54\ub2741 \uc911\uac04\uba54\ub2741 Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. \uc911\uac04\uba54\ub2742 Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. \uba54\ub274 2 Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. \uba54\ub274 3 \uc911\uac04\uba54\ub2743 Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. \uc911\uac04\uba54\ub2744 Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. \uc911\uac04\uba54\ub274 5 Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.","title":"Miscellaneous"},{"location":"misc/misc/#1","text":"","title":"\uba54\ub2741"},{"location":"misc/misc/#1_1","text":"Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.","title":"\uc911\uac04\uba54\ub2741"},{"location":"misc/misc/#2","text":"Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.","title":"\uc911\uac04\uba54\ub2742"},{"location":"misc/misc/#2_1","text":"Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.","title":"\uba54\ub274 2"},{"location":"misc/misc/#3","text":"","title":"\uba54\ub274 3"},{"location":"misc/misc/#3_1","text":"Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.","title":"\uc911\uac04\uba54\ub2743"},{"location":"misc/misc/#4","text":"Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum. Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.","title":"\uc911\uac04\uba54\ub2744"},{"location":"misc/misc/#5","text":"Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.","title":"\uc911\uac04\uba54\ub274 5"},{"location":"myopathy/iim/","text":"\uace8\uaca9\uadfc\uc744 \uce68\ubc94\ud558\uc5ec \uadfc\uc721\uc758 \uc5fc\uc99d\uacfc \uadfc\ub825\uc800\ud558\ub97c \ucd08\ub798\ud558\ub294 \uc6d0\uc778 \ubd88\uba85\uc758 \uc804\uc2e0 \uc790\uac00\uba74\uc5ed\uc9c8\ud658 ** PM (1863) -> DM (1891) -> IBM (1971) 1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790 1-1. \uc5ed\ud559 \ubc1c\ubcd1\ub960 : 100\ub9cc \uba85 \ub2f9 2.18~7.7\uba85 \uc720\ubcd1\ub960 : 10\ub9cc \uba85 \ub2f9 10~20\uba85 Bimordial (<15, 45~54), \ub0a8:\uc5ec = 1:1.5, malignancy\ub294 DM\uc5d0\uc11c \ub354 \ud638\ubc1c\ud558\uace0 \ub0a8\uc131/\uc5f0\ud558\uace4\ub780\uc774 \uc788\uc744 \ub54c \uc554 \ubc1c\ubcd1 \uc704\ud5d8\uc774 \ub192\uc74c. 1-2. \ubd84\ub958 (2003, Amato) Polymyositis Dermatomyositis Inclusion-body myositis Immune-mediated necrotizing myositis \ube44\ud2b9\uc774\uc801 \uadfc\uc5fc 2. \ubcd1\uc778\uae30\uc804 \uc720\uc804 + \ud658\uacbd + \uba74\uc5ed 3. \uc784\uc0c1\uc99d\uc0c1 3-1. \uc804\uc2e0\uc99d\uc0c1 & \uadfc\uace8\uaca9\uc99d\uc0c1 \ud53c\ub85c\uac10, \ubc1c\uc5f4, \uccb4\uc911\uac10\uc18c Symmetrical, proximal muscle weakness : subacute \uc548\uad6c\uadfc\uc721\uc740 \uac70\uc758 \uce68\ubc94\ud558\uc9c0 \uc54a\uc74c. 3-2. \uad00\uc808 \uc678 \uc99d\uc0c1 skin : heliotrope rash, scaly eruption, Gottron\u2019s papule, V sign, shawl sign, mechanic\u2019s hand (antisynthetase syndrome) calcification synovitis Lung : ILD Heart : conduction abnormality, arrythmia GI tract : dysphasia, aspiration pneumonia, GERD, PBC, Sclerosing cholangitis RP, Malignancy (ovarian ca., breast ca., melanoma, colon ca., NHL) : ESR \ub192\uace0, \ud45c\ud53c \uad34\uc0ac, \ud53c\ubd80 \ud608\uad00\uc5fc\uc744 \ubcf4\uc77c \ub54c 4. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8 4-1. \ud608\uc561\uac80\uc0ac Muscle enzyme : CK, AST, ALT, LDH, Aldolase \uc790\uac00\ud56d\uccb4 : ANA, Anti-Jo, Anti-U1RNP (MSA, MAA) 4-2. \uadfc\uc804\ub3c4 \uac80\uc0ac \uc77c\ubc18\uc801\uc73c\ub85c \ube44\ud2b9\uc774\uc801 (Insertional activity \uc99d\uac00, positive sharp waves, fibrilation potentials) 4-3. \uc870\uc9c1\uac80\uc0ac \uadfc\uc721\uc0dd\uac80 \ud53c\ubd80\uc0dd\uac80 : \ud53c\ubd80 \uc18c\uacac\uc774 \uc6b0\uc138\ud558\uc9c0\ub9cc \uc804\ud615\uc801\uc774\uc9c0 \uc54a\uc740 \uacbd\uc6b0 4-4. \uc601\uc0c1\uac80\uc0ac & \uae30\ud0c0 X-ray, MSUS, CT MRI : Bx. site \uacb0\uc815, \ub2e4\ub978 \uac80\uc0ac \uacb0\uacfc\uac00 \uc815\uc0c1\uc77c \ub54c \uc9c8\ud658 \uc545\ud654\ub97c \ud655\uc778\ud560 \ub54c, \ub2e4\ub978 \uc9c8\ud658\uacfc \uac10\ubcc4\ud560 \ub54c PFT, PET-CT, EGD/CFS, NFC 4-5. \ubd84\ub958\uae30\uc900 Bohan-Peter classification criteria (1975) ENMC classification criteria (2003) 4-6. \uac10\ubcc4\uc9c4\ub2e8 Anemia, Viral infection (EBV, HBV, HCV, HIV, TB, Syphilis, Toxocariasis), etc. 5. \uce58\ub8cc\uc6d0\uce59 5-1. \uc694\uc57d GC : 1mg/kg/d -> MTX \uc4f0\uba74\uc11c taper -> 5~10mg/d\ub85c \uc720\uc9c0. \uc99d\uc0c1 + muscle enzyme \ud638\uc804 \uc5ec\ubd80\ub85c f/u MTX : 10~15mg/week AZA, MMF, Prograf \ub4f1 Dermatomyositis : HCQ 6. \uacbd\uacfc\uc640 \uc608\ud6c4 \uce58\ub8cc \ubc1b\uc740 PM/DM\uc758 5\ub144 \uc0dd\uc874\uc728 : 95%, 10\ub144 \uc0dd\uc874\uc728 : 84% Overlap\uc77c \uacbd\uc6b0 \uacbd\ud55c \uadfc\uc5fc \uc591\uc0c1. PM\uc774 DM\ubcf4\ub2e4 \uc608\ud6c4\uac00 \uc88b\ub2e4. \uace0\ub839\uc778 \uacbd\uc6b0 \uc9c8\ubcd1\uc758 \uacbd\uacfc\uac00 \ub9e4\uc6b0 \ube60\ub974\ub2e4.","title":"Idiopathic Inflammatory Myositis"},{"location":"myopathy/iim/#1","text":"","title":"1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790"},{"location":"myopathy/iim/#1-1","text":"\ubc1c\ubcd1\ub960 : 100\ub9cc \uba85 \ub2f9 2.18~7.7\uba85 \uc720\ubcd1\ub960 : 10\ub9cc \uba85 \ub2f9 10~20\uba85 Bimordial (<15, 45~54), \ub0a8:\uc5ec = 1:1.5, malignancy\ub294 DM\uc5d0\uc11c \ub354 \ud638\ubc1c\ud558\uace0 \ub0a8\uc131/\uc5f0\ud558\uace4\ub780\uc774 \uc788\uc744 \ub54c \uc554 \ubc1c\ubcd1 \uc704\ud5d8\uc774 \ub192\uc74c.","title":"1-1. \uc5ed\ud559"},{"location":"myopathy/iim/#1-2-2003-amato","text":"Polymyositis Dermatomyositis Inclusion-body myositis Immune-mediated necrotizing myositis \ube44\ud2b9\uc774\uc801 \uadfc\uc5fc","title":"1-2. \ubd84\ub958 (2003, Amato)"},{"location":"myopathy/iim/#2","text":"\uc720\uc804 + \ud658\uacbd + \uba74\uc5ed","title":"2. \ubcd1\uc778\uae30\uc804"},{"location":"myopathy/iim/#3","text":"","title":"3. \uc784\uc0c1\uc99d\uc0c1"},{"location":"myopathy/iim/#3-1","text":"\ud53c\ub85c\uac10, \ubc1c\uc5f4, \uccb4\uc911\uac10\uc18c Symmetrical, proximal muscle weakness : subacute \uc548\uad6c\uadfc\uc721\uc740 \uac70\uc758 \uce68\ubc94\ud558\uc9c0 \uc54a\uc74c.","title":"3-1. \uc804\uc2e0\uc99d\uc0c1 &amp; \uadfc\uace8\uaca9\uc99d\uc0c1"},{"location":"myopathy/iim/#3-2","text":"skin : heliotrope rash, scaly eruption, Gottron\u2019s papule, V sign, shawl sign, mechanic\u2019s hand (antisynthetase syndrome) calcification synovitis Lung : ILD Heart : conduction abnormality, arrythmia GI tract : dysphasia, aspiration pneumonia, GERD, PBC, Sclerosing cholangitis RP, Malignancy (ovarian ca., breast ca., melanoma, colon ca., NHL) : ESR \ub192\uace0, \ud45c\ud53c \uad34\uc0ac, \ud53c\ubd80 \ud608\uad00\uc5fc\uc744 \ubcf4\uc77c \ub54c","title":"3-2. \uad00\uc808 \uc678 \uc99d\uc0c1"},{"location":"myopathy/iim/#4","text":"","title":"4. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8"},{"location":"myopathy/iim/#4-1","text":"Muscle enzyme : CK, AST, ALT, LDH, Aldolase \uc790\uac00\ud56d\uccb4 : ANA, Anti-Jo, Anti-U1RNP (MSA, MAA)","title":"4-1. \ud608\uc561\uac80\uc0ac"},{"location":"myopathy/iim/#4-2","text":"\uc77c\ubc18\uc801\uc73c\ub85c \ube44\ud2b9\uc774\uc801 (Insertional activity \uc99d\uac00, positive sharp waves, fibrilation potentials)","title":"4-2. \uadfc\uc804\ub3c4 \uac80\uc0ac"},{"location":"myopathy/iim/#4-3","text":"\uadfc\uc721\uc0dd\uac80 \ud53c\ubd80\uc0dd\uac80 : \ud53c\ubd80 \uc18c\uacac\uc774 \uc6b0\uc138\ud558\uc9c0\ub9cc \uc804\ud615\uc801\uc774\uc9c0 \uc54a\uc740 \uacbd\uc6b0","title":"4-3. \uc870\uc9c1\uac80\uc0ac"},{"location":"myopathy/iim/#4-4","text":"X-ray, MSUS, CT MRI : Bx. site \uacb0\uc815, \ub2e4\ub978 \uac80\uc0ac \uacb0\uacfc\uac00 \uc815\uc0c1\uc77c \ub54c \uc9c8\ud658 \uc545\ud654\ub97c \ud655\uc778\ud560 \ub54c, \ub2e4\ub978 \uc9c8\ud658\uacfc \uac10\ubcc4\ud560 \ub54c PFT, PET-CT, EGD/CFS, NFC","title":"4-4. \uc601\uc0c1\uac80\uc0ac &amp; \uae30\ud0c0"},{"location":"myopathy/iim/#4-5","text":"Bohan-Peter classification criteria (1975) ENMC classification criteria (2003)","title":"4-5. \ubd84\ub958\uae30\uc900"},{"location":"myopathy/iim/#4-6","text":"Anemia, Viral infection (EBV, HBV, HCV, HIV, TB, Syphilis, Toxocariasis), etc.","title":"4-6. \uac10\ubcc4\uc9c4\ub2e8"},{"location":"myopathy/iim/#5","text":"","title":"5. \uce58\ub8cc\uc6d0\uce59"},{"location":"myopathy/iim/#5-1","text":"GC : 1mg/kg/d -> MTX \uc4f0\uba74\uc11c taper -> 5~10mg/d\ub85c \uc720\uc9c0. \uc99d\uc0c1 + muscle enzyme \ud638\uc804 \uc5ec\ubd80\ub85c f/u MTX : 10~15mg/week AZA, MMF, Prograf \ub4f1 Dermatomyositis : HCQ","title":"5-1. \uc694\uc57d"},{"location":"myopathy/iim/#6","text":"\uce58\ub8cc \ubc1b\uc740 PM/DM\uc758 5\ub144 \uc0dd\uc874\uc728 : 95%, 10\ub144 \uc0dd\uc874\uc728 : 84% Overlap\uc77c \uacbd\uc6b0 \uacbd\ud55c \uadfc\uc5fc \uc591\uc0c1. PM\uc774 DM\ubcf4\ub2e4 \uc608\ud6c4\uac00 \uc88b\ub2e4. \uace0\ub839\uc778 \uacbd\uc6b0 \uc9c8\ubcd1\uc758 \uacbd\uacfc\uac00 \ub9e4\uc6b0 \ube60\ub974\ub2e4.","title":"6. \uacbd\uacfc\uc640 \uc608\ud6c4"},{"location":"other_diseases/others/","text":"Note: This is the demo content for demonstration purpose only. The primary function of this content is to show you what this theme can do. There is a more detailed explanation in the Getting Started section.","title":"Other diseases"},{"location":"pain/pain/","text":"Note: This is the demo content for demonstration purpose only. The primary function of this content is to show you what this theme can do. There is a more detailed explanation in the Getting Started section.","title":"Pain"},{"location":"ra/ra/","text":"\ub958\ub9c8\ud2f0\uc2a4\uad00\uc808\uc5fc\uc740 \ud56dCCP\ud56d\uccb4\uc640 \uac19\uc740 \uc790\uac00\ud56d\uccb4\ub97c \ub3d9\ubc18\ud558\ub294 \uc790\uac00\uba74\uc5ed\uc9c8\ud658\uc73c\ub85c \uad00\uc808\uc190\uc0c1\uc774 \uc77c\uc5b4\ub098\ub294 \ub300\ud45c\uc801\uc778 \uadfc\uace8\uaca9\uacc4 \ub9cc\uc131 \uc5fc\uc99d\uc131 \uba74\uc5ed \uc9c8\ud658\uc774\ub2e4. 1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790 1-1. \uc5ed\ud559 \uc804 \uc138\uacc4\uc801\uc73c\ub85c\ub294 0.3~1%, 10\ub9cc\uba85 \ub2f9 5~50\uba85, \uc5ec\uc131 > \ub0a8\uc131 (3\ubc30), 40\ub300~70\ub300 \uc720\ubcd1\ub960 : 0.3~1%, \ud55c\uad6d\uc778\uc740 1.4% \ubc1c\ubcd1\ub960 : \ud55c\uad6d\uc778\uc740 10\ub9cc\uba85 \ub2f9 42\uba85 1-2. \uc704\ud5d8 \uc694\uc778 \uc720\uc804\uc801 \uc694\uc778\uacfc \ud658\uacbd\uc801 \uc694\uc778\uc774 \uc0c1\ud638\uc791\uc6a9\ud55c\ub2e4. \uc720\uc804\uc801 \uc694\uc778 HLA-related : HLA-DRB1\uc774 \uac00\uc7a5 \uc704\ud5d8\ud55c \uc778\uc790 (11% \uc815\ub3c4\uc758 \uc720\uc804\uc801 \uae30\uc5ec) \u2192 *04:05 (\ub3d9\uc591), *04:01 (\uc11c\uc591), *09:01 (\ud55c\uad6d, \uc77c\ubcf8 \ub4f1 \uc544\uc2dc\uc544) \u2192 \ud55c\uad6d\uc778\uc740 *04:05\uc640 *09:01\uc758 \uac15\ub825\ud55c \uc5f0\uad00\uad00\uacc4\uac00 \uc788\uc74c. Non-HLA : PADI4, STAT4, PTPN22, TRAF1-C5 \ub4f1 \ud658\uacbd\uc801 \uc694\uc778 \ud761\uc5f0, \uce58\uc8fc\uc5fc, \uc7a5\ub0b4\uc138\uade0, \uac10\uc5fc (EBV, Parvovirus B19), \uc5ec\uc131\ud638\ub974\ubaac, \ud558\ub8e8 10\uc794 \uc774\uc0c1\uc758 \ucee4\ud53c\uc18c\ubaa8, \uacbd\uad6c\ud53c\uc784\uc57d \uc0ac\uc6a9, \ube44\ub9cc, Low socioeconomical state 2. \ubcd1\uc778\uae30\uc804 \uac00\ub3d9\uad00\uc808 (Diarthrodial joint)\uc758 \ud65c\ub9c9\uc870\uc9c1\uc5d0 \uc77c\ucc28\uc801\uc73c\ub85c \uc5fc\uc99d \ubc1c\uc0dd \u2192 \ud65c\ub9c9 \uc99d\uc2dd \u2192 \uc5f0\uace8 \ubc0f \ubf08 \uc190\uc0c1 \u2192 \uc778\ub300, \ud798\uc904, \uad00\uc808\ub0ad, \uadfc\uc721\uc758 \uc190\uc0c1, \uc57d\ud654, \ubd88\uade0\ud615 3. \uc784\uc0c1\uc99d\uc0c1 3-1. \uc870\uae30 \uad00\uc808 \uc99d\uc0c1 \uc218\uc8fc ~ \uc218\uac1c\uc6d4\uc5d0 \uac78\uccd0 \uc11c\uc11c\ud788 \ub098\ud0c0\ub098\ub294 \uc5ec\ub7ec \uad00\uc808\uc758 tenderness, stiffness, swelling \ub2e8\uad00\uc808\uc758 \ubc18\ubcf5\uc801 or \uc774\ub3d9\uc131 \uad00\uc808\uce68\ubc94 (Recurrent & migratory) : \uc218\uc2dc\uac04~\uc218\uc77c \ub3d9\uc548 \uc99d\uc0c1\uc774 \uc788\ub2e4\uac00 \uc18c\uc2e4 \ud6c4 \uc218\uac1c\uc6d4 \ud6c4 \ube44\uc2b7\ud55c \uc99d\uc0c1\uc774 \uc7ac\ubc1c\ud558\ub294 \uc7ac\ubc1c\ub958\ub9c8\ud2f0\uc998 (palindromic rheumatism)\ub3c4 \ubc1c\uc0dd 1\uc2dc\uac04 \uc774\uc0c1\uc758 \uc870\uc870\uac15\uc9c1 (Morning stiffness) 3-2. \uc870\uae30 \uad00\uc808 \uc678 \uc99d\uc0c1 General ache, stiffness, CTS, BW loss, depression, fatigue, etc. 3-3. \uad00\uc808\uc99d\uc0c1 Wrist, MCP, MTP, PIP\ub97c \uc8fc\ub85c \uce68\ubc94, C1~2\ub97c \uc81c\uc678\ud55c C-spine involve\ub294 \uc5c6\ub2e4. \ucd08\uae30\uc758 \uc911\uc694\ud55c \uc18c\uacac\uc740 involved joint\uc758 tenderness & sweling Atlantoaxial joint, AC joint, SC joint, TMJ, Cricoarytenoid joint\ub3c4 involve Hand grip strength\uc758 \uac10\uc18c, Trigger finger, CTS \uc99d\uc0c1\ub3c4 \ubc1c\uc0dd \uac00\ub2a5 Ulnar drift, swan neck, Boutonniere deformities, Digital infarction (d/t vasculitis), radial drift \uc190\ubaa9, \ud314\uafc8\uce58, \uc5b4\uae68 \uad00\uc808, \ubc1c/\ubc1c\ubaa9 \uad00\uc808, \ubb34\ub98e\uad00\uc808, \uace0\uad00\uc808\ub3c4 \uce68\ubc94 3-4. \uad00\uc808 \uc678 \uc99d\uc0c1 \uc804\uc2e0\uc99d\uc0c1 : \uc804\uc2e0\ud1b5\uc99d, \ubee3\ubee3\ud568, \ubbf8\uc5f4, \uccb4\uc911\uac10\uc18c, \ud53c\ub85c\uac10, \uc6b0\uc6b8\uac10 \uace8\uac10\uc18c\uc99d : osteoporotic fracture & hip fracture \uadfc\uc721\uce68\ubc94 : synovitis, myositis, vasculitis, drug-induced myopathy \ud53c\ubd80\uce68\ubc94 : rheumatoid nodule (elbow), skin ulcer \uc548\uad6c\uce68\ubc94 : \uc0c1\uacf5\ub9c9\uc5fc, \uacf5\ub9c9\uc5fc, ulcerative keratitis, keratoconjunctivitis sicca (10~20%) \ud638\ud761\uae30\uacc4 : Interstitial pneumonitis (UIP, NIP), organizing pneumonia (OP, BOOP, COP), Caplan's syndrome (pneumoconiosis + multiple peripheral basilar nodule), pleuritis (RA or MTX or Leflunomide) \uc21c\ud658\uae30\uacc4 : myocarditis, myositis, CAD \ub4f1 \ud608\uad00\uc9c8\ud658 : \uc8fc\ub85c small ~ medium sized vessel : PAN\uacfc \uc720\uc0ac\ud55c \uc591\uc0c1 \uc2e0\uc7a5\uc9c8\ud658 : Focal GN, MN \uc2e0\uacbd\uacc4 : compressive myelopathy, mononeuritis multiplex \ud608\uc561\uacc4 : Felty's syndrome (neutropenia, thrombocytopenia, splenomegaly), ACD, DLBCL 4. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8 4-1. \ud608\uc561\uac80\uc0ac RF : \uc815\uc0c1\uc778\uc758 5%\uc5d0\uc11c \uc591\uc131, 65\uc138 \uc774\uc0c1\uc77c \ub54c 10~15%\uc5d0\uc11c \uc591\uc131, \uace0\uc5ed\uac00\uc77c \ub54c extra-articular manifestation \ub9ce\uc544 \uc608\ud6c4 \uc608\uce21\uc5d0 \ub3c4\uc6c0\uc774 \ub41c\ub2e4. Anti-CCP : RA\uc5d0 \ud2b9\uc774\uc801, \uc9c8\ud658 \ubc1c\ubcd1 \uc218\ub144 \uc804\ubd80\ud130 \uc591\uc131\uc73c\ub85c \ub098\uc634, \uc591\uc131\uc77c \ub54c \uad00\uc808 \ud30c\uad34\uac00 \ub354 \ub9ce\uc774 \uc9c4\ud589, \ud761\uc5f0\uacfc \uace0\uc5ed\uac00\uac00 \uc5f0\uad00\uc774 \uc788\uc74c. CRP, ESR : \uc608\ud6c4\uc640 \uc5f0\uad00, \uc9c0\uc18d\uc801 \uc0c1\uc2b9\uc740 \uc9c8\ubcd1\uc758 \uc9c0\uc18d\uc801\uc778 \uc9c4\ud589\uc73c\ub85c \uc778\ud55c \ubc29\uc0ac\uc120\uc801 \uc9c4\ud589\uacfc \uc0c1\uad00\uad00\uacc4 \uc788\uc74c. 4-2. \ubc29\uc0ac\uc120\uac80\uc0ac X-ray : \ub300\uce6d\uc801\uc778 \uad00\uc808 \uce68\ubc94 \ubc0f \ubbf8\ub780 (Hand \u2192 foot \u2192 knee \u2192 hip \u2192 neck \u2192 shoulder \u2192 elbow), \uc8fc\ub85c MCP, PIP\uc5d0\uc11c \uc798 \ubcf4\uc784. MSUS : \ucd08\uae30\uc5d0 2nd MCP, 5th MTP\uc5d0\uc11c erosion\uc774 \uc798 \ubc1c\uacac\ub428 MRI \ub3c4 \uc788\uc9c0\ub9cc \uc798 \uc548\ucc0d\ub294\ub2e4. 4-3. \ubd84\ub958\uae30\uc900 1987 ACR RA classification criteria \u2192 \ub2e4\uc18c \uc9c4\ud589\ub41c \ud615\ud0dc\uc758 RA\ub97c \uc9c4\ub2e8\ud560 \ub54c \uc720\uc6a9\ud568. Note ENG \uad6d\ubb38 Sed sagittis eleifend rutrum Donec vitae suscipit est Nulla tempor lobortis orci Sed sagittis eleifend rutrum Donec vitae suscipit est Nulla tempor lobortis orci 2010 ACR/EULAR RA classification criteria \u2192 DIPs, CMCs, 1st MTP\ub294 \ud3c9\uac00\uc5d0\uc11c \uc81c\uc678\ud55c\ub2e4. \u2192 \uc870\uae30\uc5d0 \ubd84\ub958(\uc9c4\ub2e8)\ud574\uc11c \uad00\uc808\ud30c\uad34\uac00 \uc77c\uc5b4\ub098\uae30 \uc804\uc5d0 \uc801\uc808\ud788 \uce58\ub8cc\ud574\uc11c \uce58\ub8cc \uc131\uacfc\ub97c \ub192\uc774\ub824\ub294 \ubaa9\uc801\uc784 Note ENG \uad6d\ubb38 Sed sagittis eleifend rutrum Donec vitae suscipit est Nulla tempor lobortis orci Sed sagittis eleifend rutrum Donec vitae suscipit est Nulla tempor lobortis orci 4-4. \uac10\ubcc4\uc9c4\ub2e8 OA : DIP \uce68\ubc94, Heberden nodule, morning stiffness < 30min, X-ray\uc0c1 JSN Palindromic rheumatism : migratory arthralgia (Behcet's ds.\uc640\ub3c4 \uac10\ubcc4\ud558\uc790) FMS, Hypermobility syndrome : no arthritis/synovitis, no APR elevation, Tender point \uc720\ubb34 Seronegative RA : \ud5a5\ud6c4 RA\ub85c \uc9c4\ud589\ud558\ub294\uc9c0 \uc798 \ucc59\uaca8\ubcf4\uc790. Reactive arhritis : \uc120\ud589\ud558\ub294 urogenital/enteric invection + Sacroilitis + HLA-B27 (+) \uc720\ubb34, Dactylitis \ub4f1 Psoriatic arthritis : \ud53c\ubd80\ubcd1\ubcc0, \uc190\ud1b1\ubcc0\ud654, \uc18c\uc2dc\uc9c0\uc190\uac00\ub77d (dactylitis), \ucc99\ucd94\uce68\ubc94, \uc808\ub2e8\uad00\uc808\uc5fc (arthritis mutilans) Crystalopathies : uric acid level, medication, attack \uc591\uc0c1 \ub4f1 Infection-associated : Parvovirus, HBV, HCV, Mumps, EBV\ub4f1 5. \uce58\ub8cc\uc6d0\uce59 MTX\uc758 \uae08\uae30\uac00 \uc5c6\ub2e4\uba74 MTX\ub97c \uc6b0\uc120 \ucc98\ubc29\ud55c\ub2e4. MTX \uae08\uae30\uac00 \uc788\ub2e4\uba74 leflunomide\ub098 SSZ\ub97c \ucc98\ubc29\ud55c\ub2e4. short term GC\ub97c \ucd94\uac00\ud574 \ubcfc \uc218\ub3c4 \uc788\ub2e4. DAS28-CRP\ub97c \ud3c9\uac00\ud574\uc11c 3\uac1c\uc6d4 \ud6c4\uc5d0 \ud638\uc804\ub418\uace0 6\uac1c\uc6d4\uc9f8\uc5d0 Remission\uc5d0 \ub3c4\ub2ec\ud558\ub294\uc9c0 \ud655\uc778\ud55c\ub2e4. Prognostic factor (Ab\uac00 high titer\uc774\uac70\ub098, high ds. activity\uc774\uac70\ub098, early joint damage\uac00 \uc788\uac70\ub098, csDMARDs 2\uac1c\uc5d0 fail\ud588\ub294\uc9c0)\ub97c \ud3c9\uac00\ud55c\ub2e4. Prognostic factor\uac00 \uc788\ub2e4\uba74 bDMARD \ub610\ub294 JAK-I\ub97c \ucd94\uac00\ud558\uace0 3~6\uac1c\uc6d4\uc9f8\uc5d0 \ud3c9\uac00\ud55c \ud6c4, \ud6a8\uacfc \uc5c6\uc73c\uba74 \ubc14\uafd4\ubcf8\ub2e4. \ud6a8\uacfc\uac00 \uc788\ub2e4\uba74 \uc57d\uc81c\ub97c \uc720\uc9c0\ud558\uac70\ub098 \uc6a9\ub7c9\uc744 \uac10\ub7c9\ud55c\ub2e4. 6. \uacbd\uacfc\uc640 \uc608\ud6c4","title":"Rheumatoid Arthritis"},{"location":"ra/ra/#1","text":"","title":"1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790"},{"location":"ra/ra/#1-1","text":"\uc804 \uc138\uacc4\uc801\uc73c\ub85c\ub294 0.3~1%, 10\ub9cc\uba85 \ub2f9 5~50\uba85, \uc5ec\uc131 > \ub0a8\uc131 (3\ubc30), 40\ub300~70\ub300 \uc720\ubcd1\ub960 : 0.3~1%, \ud55c\uad6d\uc778\uc740 1.4% \ubc1c\ubcd1\ub960 : \ud55c\uad6d\uc778\uc740 10\ub9cc\uba85 \ub2f9 42\uba85","title":"1-1. \uc5ed\ud559"},{"location":"ra/ra/#1-2","text":"\uc720\uc804\uc801 \uc694\uc778\uacfc \ud658\uacbd\uc801 \uc694\uc778\uc774 \uc0c1\ud638\uc791\uc6a9\ud55c\ub2e4. \uc720\uc804\uc801 \uc694\uc778 HLA-related : HLA-DRB1\uc774 \uac00\uc7a5 \uc704\ud5d8\ud55c \uc778\uc790 (11% \uc815\ub3c4\uc758 \uc720\uc804\uc801 \uae30\uc5ec) \u2192 *04:05 (\ub3d9\uc591), *04:01 (\uc11c\uc591), *09:01 (\ud55c\uad6d, \uc77c\ubcf8 \ub4f1 \uc544\uc2dc\uc544) \u2192 \ud55c\uad6d\uc778\uc740 *04:05\uc640 *09:01\uc758 \uac15\ub825\ud55c \uc5f0\uad00\uad00\uacc4\uac00 \uc788\uc74c. Non-HLA : PADI4, STAT4, PTPN22, TRAF1-C5 \ub4f1 \ud658\uacbd\uc801 \uc694\uc778 \ud761\uc5f0, \uce58\uc8fc\uc5fc, \uc7a5\ub0b4\uc138\uade0, \uac10\uc5fc (EBV, Parvovirus B19), \uc5ec\uc131\ud638\ub974\ubaac, \ud558\ub8e8 10\uc794 \uc774\uc0c1\uc758 \ucee4\ud53c\uc18c\ubaa8, \uacbd\uad6c\ud53c\uc784\uc57d \uc0ac\uc6a9, \ube44\ub9cc, Low socioeconomical state","title":"1-2. \uc704\ud5d8 \uc694\uc778"},{"location":"ra/ra/#2","text":"\uac00\ub3d9\uad00\uc808 (Diarthrodial joint)\uc758 \ud65c\ub9c9\uc870\uc9c1\uc5d0 \uc77c\ucc28\uc801\uc73c\ub85c \uc5fc\uc99d \ubc1c\uc0dd \u2192 \ud65c\ub9c9 \uc99d\uc2dd \u2192 \uc5f0\uace8 \ubc0f \ubf08 \uc190\uc0c1 \u2192 \uc778\ub300, \ud798\uc904, \uad00\uc808\ub0ad, \uadfc\uc721\uc758 \uc190\uc0c1, \uc57d\ud654, \ubd88\uade0\ud615","title":"2. \ubcd1\uc778\uae30\uc804"},{"location":"ra/ra/#3","text":"","title":"3. \uc784\uc0c1\uc99d\uc0c1"},{"location":"ra/ra/#3-1","text":"\uc218\uc8fc ~ \uc218\uac1c\uc6d4\uc5d0 \uac78\uccd0 \uc11c\uc11c\ud788 \ub098\ud0c0\ub098\ub294 \uc5ec\ub7ec \uad00\uc808\uc758 tenderness, stiffness, swelling \ub2e8\uad00\uc808\uc758 \ubc18\ubcf5\uc801 or \uc774\ub3d9\uc131 \uad00\uc808\uce68\ubc94 (Recurrent & migratory) : \uc218\uc2dc\uac04~\uc218\uc77c \ub3d9\uc548 \uc99d\uc0c1\uc774 \uc788\ub2e4\uac00 \uc18c\uc2e4 \ud6c4 \uc218\uac1c\uc6d4 \ud6c4 \ube44\uc2b7\ud55c \uc99d\uc0c1\uc774 \uc7ac\ubc1c\ud558\ub294 \uc7ac\ubc1c\ub958\ub9c8\ud2f0\uc998 (palindromic rheumatism)\ub3c4 \ubc1c\uc0dd 1\uc2dc\uac04 \uc774\uc0c1\uc758 \uc870\uc870\uac15\uc9c1 (Morning stiffness)","title":"3-1. \uc870\uae30 \uad00\uc808 \uc99d\uc0c1"},{"location":"ra/ra/#3-2","text":"General ache, stiffness, CTS, BW loss, depression, fatigue, etc.","title":"3-2. \uc870\uae30 \uad00\uc808 \uc678 \uc99d\uc0c1"},{"location":"ra/ra/#3-3","text":"Wrist, MCP, MTP, PIP\ub97c \uc8fc\ub85c \uce68\ubc94, C1~2\ub97c \uc81c\uc678\ud55c C-spine involve\ub294 \uc5c6\ub2e4. \ucd08\uae30\uc758 \uc911\uc694\ud55c \uc18c\uacac\uc740 involved joint\uc758 tenderness & sweling Atlantoaxial joint, AC joint, SC joint, TMJ, Cricoarytenoid joint\ub3c4 involve Hand grip strength\uc758 \uac10\uc18c, Trigger finger, CTS \uc99d\uc0c1\ub3c4 \ubc1c\uc0dd \uac00\ub2a5 Ulnar drift, swan neck, Boutonniere deformities, Digital infarction (d/t vasculitis), radial drift \uc190\ubaa9, \ud314\uafc8\uce58, \uc5b4\uae68 \uad00\uc808, \ubc1c/\ubc1c\ubaa9 \uad00\uc808, \ubb34\ub98e\uad00\uc808, \uace0\uad00\uc808\ub3c4 \uce68\ubc94","title":"3-3. \uad00\uc808\uc99d\uc0c1"},{"location":"ra/ra/#3-4","text":"\uc804\uc2e0\uc99d\uc0c1 : \uc804\uc2e0\ud1b5\uc99d, \ubee3\ubee3\ud568, \ubbf8\uc5f4, \uccb4\uc911\uac10\uc18c, \ud53c\ub85c\uac10, \uc6b0\uc6b8\uac10 \uace8\uac10\uc18c\uc99d : osteoporotic fracture & hip fracture \uadfc\uc721\uce68\ubc94 : synovitis, myositis, vasculitis, drug-induced myopathy \ud53c\ubd80\uce68\ubc94 : rheumatoid nodule (elbow), skin ulcer \uc548\uad6c\uce68\ubc94 : \uc0c1\uacf5\ub9c9\uc5fc, \uacf5\ub9c9\uc5fc, ulcerative keratitis, keratoconjunctivitis sicca (10~20%) \ud638\ud761\uae30\uacc4 : Interstitial pneumonitis (UIP, NIP), organizing pneumonia (OP, BOOP, COP), Caplan's syndrome (pneumoconiosis + multiple peripheral basilar nodule), pleuritis (RA or MTX or Leflunomide) \uc21c\ud658\uae30\uacc4 : myocarditis, myositis, CAD \ub4f1 \ud608\uad00\uc9c8\ud658 : \uc8fc\ub85c small ~ medium sized vessel : PAN\uacfc \uc720\uc0ac\ud55c \uc591\uc0c1 \uc2e0\uc7a5\uc9c8\ud658 : Focal GN, MN \uc2e0\uacbd\uacc4 : compressive myelopathy, mononeuritis multiplex \ud608\uc561\uacc4 : Felty's syndrome (neutropenia, thrombocytopenia, splenomegaly), ACD, DLBCL","title":"3-4. \uad00\uc808 \uc678 \uc99d\uc0c1"},{"location":"ra/ra/#4","text":"","title":"4. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8"},{"location":"ra/ra/#4-1","text":"RF : \uc815\uc0c1\uc778\uc758 5%\uc5d0\uc11c \uc591\uc131, 65\uc138 \uc774\uc0c1\uc77c \ub54c 10~15%\uc5d0\uc11c \uc591\uc131, \uace0\uc5ed\uac00\uc77c \ub54c extra-articular manifestation \ub9ce\uc544 \uc608\ud6c4 \uc608\uce21\uc5d0 \ub3c4\uc6c0\uc774 \ub41c\ub2e4. Anti-CCP : RA\uc5d0 \ud2b9\uc774\uc801, \uc9c8\ud658 \ubc1c\ubcd1 \uc218\ub144 \uc804\ubd80\ud130 \uc591\uc131\uc73c\ub85c \ub098\uc634, \uc591\uc131\uc77c \ub54c \uad00\uc808 \ud30c\uad34\uac00 \ub354 \ub9ce\uc774 \uc9c4\ud589, \ud761\uc5f0\uacfc \uace0\uc5ed\uac00\uac00 \uc5f0\uad00\uc774 \uc788\uc74c. CRP, ESR : \uc608\ud6c4\uc640 \uc5f0\uad00, \uc9c0\uc18d\uc801 \uc0c1\uc2b9\uc740 \uc9c8\ubcd1\uc758 \uc9c0\uc18d\uc801\uc778 \uc9c4\ud589\uc73c\ub85c \uc778\ud55c \ubc29\uc0ac\uc120\uc801 \uc9c4\ud589\uacfc \uc0c1\uad00\uad00\uacc4 \uc788\uc74c.","title":"4-1. \ud608\uc561\uac80\uc0ac"},{"location":"ra/ra/#4-2","text":"X-ray : \ub300\uce6d\uc801\uc778 \uad00\uc808 \uce68\ubc94 \ubc0f \ubbf8\ub780 (Hand \u2192 foot \u2192 knee \u2192 hip \u2192 neck \u2192 shoulder \u2192 elbow), \uc8fc\ub85c MCP, PIP\uc5d0\uc11c \uc798 \ubcf4\uc784. MSUS : \ucd08\uae30\uc5d0 2nd MCP, 5th MTP\uc5d0\uc11c erosion\uc774 \uc798 \ubc1c\uacac\ub428 MRI \ub3c4 \uc788\uc9c0\ub9cc \uc798 \uc548\ucc0d\ub294\ub2e4.","title":"4-2. \ubc29\uc0ac\uc120\uac80\uc0ac"},{"location":"ra/ra/#4-3","text":"","title":"4-3. \ubd84\ub958\uae30\uc900"},{"location":"ra/ra/#1987-acr-ra-classification-criteria","text":"\u2192 \ub2e4\uc18c \uc9c4\ud589\ub41c \ud615\ud0dc\uc758 RA\ub97c \uc9c4\ub2e8\ud560 \ub54c \uc720\uc6a9\ud568. Note ENG \uad6d\ubb38 Sed sagittis eleifend rutrum Donec vitae suscipit est Nulla tempor lobortis orci Sed sagittis eleifend rutrum Donec vitae suscipit est Nulla tempor lobortis orci","title":"1987 ACR RA classification criteria"},{"location":"ra/ra/#2010-acreular-ra-classification-criteria","text":"\u2192 DIPs, CMCs, 1st MTP\ub294 \ud3c9\uac00\uc5d0\uc11c \uc81c\uc678\ud55c\ub2e4. \u2192 \uc870\uae30\uc5d0 \ubd84\ub958(\uc9c4\ub2e8)\ud574\uc11c \uad00\uc808\ud30c\uad34\uac00 \uc77c\uc5b4\ub098\uae30 \uc804\uc5d0 \uc801\uc808\ud788 \uce58\ub8cc\ud574\uc11c \uce58\ub8cc \uc131\uacfc\ub97c \ub192\uc774\ub824\ub294 \ubaa9\uc801\uc784 Note ENG \uad6d\ubb38 Sed sagittis eleifend rutrum Donec vitae suscipit est Nulla tempor lobortis orci Sed sagittis eleifend rutrum Donec vitae suscipit est Nulla tempor lobortis orci","title":"2010 ACR/EULAR RA classification criteria"},{"location":"ra/ra/#4-4","text":"OA : DIP \uce68\ubc94, Heberden nodule, morning stiffness < 30min, X-ray\uc0c1 JSN Palindromic rheumatism : migratory arthralgia (Behcet's ds.\uc640\ub3c4 \uac10\ubcc4\ud558\uc790) FMS, Hypermobility syndrome : no arthritis/synovitis, no APR elevation, Tender point \uc720\ubb34 Seronegative RA : \ud5a5\ud6c4 RA\ub85c \uc9c4\ud589\ud558\ub294\uc9c0 \uc798 \ucc59\uaca8\ubcf4\uc790. Reactive arhritis : \uc120\ud589\ud558\ub294 urogenital/enteric invection + Sacroilitis + HLA-B27 (+) \uc720\ubb34, Dactylitis \ub4f1 Psoriatic arthritis : \ud53c\ubd80\ubcd1\ubcc0, \uc190\ud1b1\ubcc0\ud654, \uc18c\uc2dc\uc9c0\uc190\uac00\ub77d (dactylitis), \ucc99\ucd94\uce68\ubc94, \uc808\ub2e8\uad00\uc808\uc5fc (arthritis mutilans) Crystalopathies : uric acid level, medication, attack \uc591\uc0c1 \ub4f1 Infection-associated : Parvovirus, HBV, HCV, Mumps, EBV\ub4f1","title":"4-4. \uac10\ubcc4\uc9c4\ub2e8"},{"location":"ra/ra/#5","text":"MTX\uc758 \uae08\uae30\uac00 \uc5c6\ub2e4\uba74 MTX\ub97c \uc6b0\uc120 \ucc98\ubc29\ud55c\ub2e4. MTX \uae08\uae30\uac00 \uc788\ub2e4\uba74 leflunomide\ub098 SSZ\ub97c \ucc98\ubc29\ud55c\ub2e4. short term GC\ub97c \ucd94\uac00\ud574 \ubcfc \uc218\ub3c4 \uc788\ub2e4. DAS28-CRP\ub97c \ud3c9\uac00\ud574\uc11c 3\uac1c\uc6d4 \ud6c4\uc5d0 \ud638\uc804\ub418\uace0 6\uac1c\uc6d4\uc9f8\uc5d0 Remission\uc5d0 \ub3c4\ub2ec\ud558\ub294\uc9c0 \ud655\uc778\ud55c\ub2e4. Prognostic factor (Ab\uac00 high titer\uc774\uac70\ub098, high ds. activity\uc774\uac70\ub098, early joint damage\uac00 \uc788\uac70\ub098, csDMARDs 2\uac1c\uc5d0 fail\ud588\ub294\uc9c0)\ub97c \ud3c9\uac00\ud55c\ub2e4. Prognostic factor\uac00 \uc788\ub2e4\uba74 bDMARD \ub610\ub294 JAK-I\ub97c \ucd94\uac00\ud558\uace0 3~6\uac1c\uc6d4\uc9f8\uc5d0 \ud3c9\uac00\ud55c \ud6c4, \ud6a8\uacfc \uc5c6\uc73c\uba74 \ubc14\uafd4\ubcf8\ub2e4. \ud6a8\uacfc\uac00 \uc788\ub2e4\uba74 \uc57d\uc81c\ub97c \uc720\uc9c0\ud558\uac70\ub098 \uc6a9\ub7c9\uc744 \uac10\ub7c9\ud55c\ub2e4.","title":"5. \uce58\ub8cc\uc6d0\uce59"},{"location":"ra/ra/#6","text":"","title":"6. \uacbd\uacfc\uc640 \uc608\ud6c4"},{"location":"sjogren/ss/","text":"\ub208\ub9c8\ub984\uacfc \uc785\ub9c8\ub984 \uc99d\uc0c1\uc744 \ud638\uc18c\ud558\uba70, \ubcd1\ub9ac\uc801\uc73c\ub85c\ub294 \uc678\ubd84\ube44\uc0d8\uc758 \ub9bc\ud504\uad6c\uce68\uc724 \ubc0f \ud30c\uad34\ub85c \uc778\ud55c \uae30\ub2a5 \uc800\ud558\ub97c \ud2b9\uc9d5\uc73c\ub85c \ud558\ub294 \uc790\uac00\uba74\uc5ed\uc9c8\ud658 1. Historical Perspective (1888) Johann von Mikulicz-Radecki : \ub208\ubb3c\uc0d8, \uc774\ud558\uc120, \ud131\ubc11\uc0d8\uc758 \uc591\uce21\uc131, \ubb34\ud1b5\uc131 \uc885\ucc3d \ubc1c\ud45c (1925) Henri Gourgerot : \ud0c0\uc561\uc120 \uc704\ucd95 \ubc0f \ub208, \uc785, \uc9c8\uc758 \uac74\uc870\ub97c \ub3d9\ubc18\ud55c \ucf00\uc774\uc2a4 \ubc1c\ud45c (1933) Henrik Sjogren : 19\uac1c\uc758 Keratoconjunctivitis sicca \ucf00\uc774\uc2a4 (2\uac74\uc740 \uce68\uc0d8 \ubd80\uc885 \ud3ec\ud568) (1953) Morgan & Castleman : 18\uac1c\uc758 \ub208\ubb3c\uc0d8/\uce68\uc0d8 \ube44\ub300 Bx. \uacb0\uacfc \ubc1c\ud45c (1960) Joseph J. Bunim et al. : 40\uba85\uc758 Sjogren syndrome case \ubc1c\ud45c (1965) NIH : \ub2e4\ub978 CTS\uac00 \uc5c6\ub294 Sicca syndrome \ud658\uc790\uc758 75%\uc5d0\uc11c ANA (+), Anti-Ro/La (+/+) (1970) minor labial biopsy & focus score 2. \uc815\uc758 \ubc0f \ubd84\ub958 Sjogren's syndrome = Keratoconjunctivitis sicca + Xerostomia Keratoconjunctivitis sicca = dryness of the cornea and conjunctiva Xerostomia = subjective symptoms of dry mouth \ubd84\ub958 Primary : KCS or Xerostomia without other CTD + Serologic and/or histopathologic criteria Secondary : KCS or Xerostomia with Other CTD (RA, SLE, SSc, PM/DM, Vasculitis, etc.) 3. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790 40~50\ub300, M:F = 14.5:1 \uc720\ubcd1\ub960 : 0.1~4.6% Secondary SS : RA\uc5d0\uc11c\ub294 4~31%, SLE\uc5d0\uc11c\ub294 6~19%, SSc\uc5d0\uc11c\ub294 14~21% 4. \ubcd1\uc778\uae30\uc804 \ubcd1\ub9ac \uc18c\uacac : \uce68\uc0d8\uc758 \ub9bc\ud504\uad6c \uce68\uc724 (\uc8fc\ub85c T cell or B cell, DC/Plasma cell/macrophages) \uc720\uc804\uc801 \uc694\uc778 + \ud658\uacbd\uc801 \uc694\uc778 + \uba74\uc5ed\ud559\uc801 \uc694\uc778 5. \uc784\uc0c1\uc99d\uc0c1 5-1. \uc8fc\uc694 \uc99d\uc0c1 (Glandular manifestation) : \uac74\uc870\uc99d\uc0c1 : \ub300\ubd80\ubd84 8~10\ub144 \ub3d9\uc548 \ub290\ub9ac\uac8c \uc9c4\ud589 \ub208 : \uac74\uc131\uac01\ub9c9\uacb0\ub9c9\uc5fc (keratoconjunctivitis sicca) - lacrimal gland\uc758 \ub9cc\uc131 \uc5fc\uc99d\ub54c\ubb38\uc5d0 \ub208\ubb3c\ubd84\ube44\uac00 \uac10\uc18c\ud558\uc5ec conjunctival & bulbar epithelium\uc744 \ud30c\uad34\ud568. \uc785 : \uce68\ubd84\ube44 \uac10\uc18c\ub85c \uc778\ud55c \uad6c\uac15\uac74\uc870\uc99d - \uc539\uace0 \uc0bc\ud0a4\ub294\ub370 \uc5b4\ub824\uc6c0, \ub9db\uc758 \ubcc0\ud654, \uc7a5\uc2dc\uac04 \ub9d0\ud558\uae30\uc758 \uc5b4\ub824\uc6c0, \ucda9\uce58, \uac08\ub77c\uc9c4 \uce58\uc544, \uad6c\uac15 \uce78\ub514\ub2e4\uc99d \uadc0\ubc11\uc0d8/\ud070\uce68\uc0d8\uc758 \ube44\ub300 : \uc804\uccb4 primary SS \ud658\uc790\uc758 \uc57d 1/4 \uc815\ub3c4. \uac74\uc870\ub41c \uc810\uc561\uc774 \uc77c\uc2dc\uc801\uc73c\ub85c \uc8fc\uc694 \uad00\uc744 \ub9c9\uc544\uc11c \ube44\ub300\ud574\uc9d0. 5-2. \uae30\ud0c0 \uc99d\uc0c1 (Extraglandular manifestation) Fatigue (70%) : SS \uc790\uccb4 \uc99d\uc0c1 \ub610\ub294 Depression, anxiety, FMS, sleep deficit \ub54c\ubb38\uc77c \uc218\ub3c4 \uc788\ub2e4. RP (13~33%) : Sicca symptom \uc2dc\uc791 \uba87 \ub144 \uc804\ubd80\ud130 \uc120\ud589\ud568. Digital ulcer\ub294 \ub4dc\ubb3c\ub2e4. Skin : \uac74\uc131 \ud53c\ubd80, \ub208\uaebc\ud480 \ud53c\ubd80\uc5fc, \uac01\uc9c8\uc5fc, \ud658\ud615 \ud64d\ubc18, \uc790\ubc18\ubcd1, Cutaneous vasculitis, Livedo reticularis - \ub300\uac1c \ub2e4\ub978 extraglandular manifestation\uc5d0 \ub3d9\ubc18\ub41c\ub2e4. Vasculitis \uc591\uc0c1\uc740 medium/small vessel vasculitis \uc591\uc0c1\uacfc \uc720\uc0ac\ud568. (Deep perivascular lymphocytic infiltrate without epidermal changes) Joint (45%) : 1/3 \uc5d0\uc11c\ub294 \uad00\uc808\uc99d\uc0c1\uc774 SS \uc99d\uc0c1\ubcf4\ub2e4 \uba3c\uc800 \ubc1c\uc0dd\ud55c\ub2e4. Lung (11.4%) \uc8fc\ub85c ILD (NSIP, UIP pattern) Kidney (5%) : TIN, Type 1 RTA, GN (\uc8fc\ub85c lymphoma\uc640 \uad00\ub828), NDI GI : Dysphagia, dyspepsia, Esophageal achalasia, PBC NR : depression, mild cognitive disorder, peripheral neuropathy CV : \ub1cc\ud608\uad00/\uc2ec\uadfc\uacbd\uc0c9 \uc704\ud5d8 \uc99d\uac00 Thyroid : Anti-Thyroglobin Ab (+), TSH elevation Lymphoma : NHL (\uc9c0\uc18d\uc801\uc778 \uce68\uc0d8\ube44\ub300, \uc790\uc0c9\ubc18, \ubc31\ud608\uad6c\uac10\uc18c\uc99d, ectopic germinal center) - MALT, DLBCL \ub4f1 6. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8 6-1. \uae30\ubcf8 \uac1c\ub150 \uc8fc\uad00\uc801\uc778 \uc99d\uc0c1\uc774 \uc788\ub294\uac00? \u2192 \uac74\uc131\uc548 / \uad6c\uac15\uac74\uc870\uc99d \uc790\uac00\uba74\uc5ed\uc131\uc774 \uc788\ub294\uac00? (=\uc790\uac00\ud56d\uccb4\uac00 \ub098\uc624\ub294\uac00?) \u2192 Anti-Ro/SSa \uadf8 \uc99d\uc0c1\uc744 \uac80\uc0ac\ub85c \uc99d\uba85\ud560 \uc218 \uc788\ub294\uac00? \u2192 Shirmer test, OSS / Sialometry, Sialography, Scintigraphy, \uae30\ud0c0 \uac80\uc0ac \u2192 US / MRI Minor labial salivary gland biopsy : focus score \u22651 Focus = 50\uac1c \uc774\uc0c1\uc758 lymphocyte cluster greater than or equal to 1 per 4 mm 2 of tissue \uc77c \ub54c \uc591\uc131 focus score > 3\uc774\uba74 lymphoma risk\uac00 \uc62c\ub77c\uac04\ub2e4. SS \uc9c4\ub2e8 \ubfd0\ub9cc \uc544\ub2c8\ub77c MALToma, sarcoidosis, IgG4-related ds. \uac10\ubcc4\uc5d0\ub3c4 \uc720\uc6a9\ud558\ub2e4. ** \uc784\uc0c1\uc801/Lab finding \uc774 \uba85\ud655\ud558\ub2e4\uba74 \uad73\uc774 biopsy\ub97c \ud558\uc9c0 \uc54a\uc544\ub3c4 \ub41c\ub2e4. ** \uc99d\uc0c1\uc740 \uc788\ub294\ub370 Anti-Ro (-) or low titer\uba74 biopsy\ub97c \ud574\uc57c \ud55c\ub2e4. ** \uac74\uc131\uc548\uc774 \uc788\ub294 \ud658\uc790\uc758 \ub300\ubd80\ubd84\uc740 \uc1fc\uadf8\ub80c\uc774 \uc544\ub2c8\ub2e4. ** \uc77c\ubc18 \uc778\uad6c\uc758 \uc57d 25%\uac00 \uad6c\uac15 \uac74\uc870 \uc99d\uc0c1\uc744 \uac00\uc9c0\uace0 \uc788\uace0, \ub300\ubd80\ubd84\uc740 \uc1fc\uadf8\ub80c\uc774 \uc544\ub2c8\ub2e4. 6-2. \ud608\uc561\uac80\uc0ac anemia, leukopenia ESR elevation Hypergammmaglobulinemia : 80% Low C3, C4 : 5~10% Anti-Ro/La Ab., RF, ANA, Tg, TPO, Anti-mitochondrial ab., Anti-Muscarin3 Rc Ab. ** Anti-La Ab.\ub294 \uc774\uc81c \ub354 \uc774\uc0c1 \uc784\uc0c1\uc801\uc73c\ub85c \uc9c4\ub2e8\uc5d0 \uc720\uc6a9\ud558\uc9c0 \uc54a\uc74c. ** Anti-Ro Ab.\ub294 \ucda9\ubd84\ud55c \uc5ed\uac00\ub77c\uc57c \ud55c\ub2e4. 6-3. \uae30\ud0c0\uac80\uc0ac \ub208\uac80\uc0ac schirmer test < 5mm Rose bengal stain : keratoconjunctivitis sicca > 3 (\uc544\ud30c\uc11c \uc774\uc81c \uc548\uc4f4\ub2e4) OSS : lissamine greein or fluorescein stain >= 3 Tear film break-up test : \uce68\uc0d8\uac80\uc0ac Sialometry Sialography Scintigraphy minor labial salivary gland biopsy : gold standard 6-4. \ubd84\ub958\uae30\uc900 2002 AECG (IV or VI \ub9cc\uc871\ud560 \ub54c 4\uac1c \uc774\uc0c1) I. ocular symptoms; II. oral symptoms; III. ocular signs (Schirmer-I test \u22645 mm/5 min or Rose Bengal score \u22654 by the van Bijsterveld scoring system); IV. histopathologic features (focus score \u22651 on labial salivary gland biopsy); V. objective evidence of salivary gland involvement by at least one abnormal test (salivary scintigraphy, parotid sialography, or unstimulated salivary flow rate \u22641.5 mL/15 min); VI. positive test for anti-Ro/SS-A or anti-La/SS-B antibodies. 2012 SICCAC & ACR : \uc624\ub85c\uc9c0 \uac1d\uad00\uc801\uc778 \uac80\uc0ac\uc5d0 \uadfc\uac70\ud568 (3 \uc911 2\uac1c \uc774\uc0c1) - too invasive! I. a positive test for serum anti-Ro/SS-A and/or anti-La/SS-B antibodies or a positive test for rheumatoid factor and an ANA titer of greater than or equal to 1:320; II. a labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus greater than or equal to 1 per 4 mm 2 ; III. keratoconjunctivitis sicca with an ocular staining score greater than or equal to 3. 2016 ACR/EULAR : \uac74\uc870\uc99d\uc0c1 + \uae30\uc900 (9\uc810 \uc911 4\uc810 \uc774\uc0c1) I. histopathology showing focal lymphocytic sialadenitis with a focus score greater than or equal to 1 per 4 mm 2 ; II. the presence of anti-Ro/SS-A antibodies; III. a SICCA ocular staining score of greater than or equal to 5 using lissamine green or fluorescein dye (or Rose Bengal score \u22654 by the van Bijsterveld scoring system); IV. a Schirmer test of less than or equal to 5 mm per 5 minutes; V. Unstimulated whole salivary flow of less than or equal to 0.1 mL per minute. ** 2016 ACR/EULAR\ub294 Anti-La Ab.\ub97c \ubd84\ub958\uae30\uc900\uc5d0\uc11c \uc81c\uc678\ud558\uace0, OSS\ub97c \ud3ec\ud568\uc2dc\ud0b4. ** Rose bengal dye\ub294 \uc544\ud504\uace0 \uac01\ub9c9\uc5d0 \ud1b5\uc99d\uc744 \uc720\ubc1c\ud558\uae30 \ub54c\ubb38\uc5d0 \uc81c\uc678\ud568 6-5. \uac10\ubcc4\uc9c4\ub2e8 (\ubc30\uc81c) \ub450\uacbd\ubd80 \ubc29\uc0ac\uc120\uce58\ub8cc \uacfc\uac70\ub825, HCV, HIV, Sarcoidosis, amyloidosis, GVHD, IgG4-related ds. \uc57d\ubb3c (\ud56d\ucf5c\ub9b0\uc791\uc6a9), \uc9c1\uc5c5 \ud658\uacbd, \ud3d0\uacbd \uc5ec\ubd80 \ub4f1 7. \uce58\ub8cc\uc6d0\uce59 7-1. \uc694\uc57d \uac74\uc870 \uc99d\uc0c1\uc5d0 \ub300\ud574\uc11c\ub294 pilocarpine\uc774\ub098 \ubb34\uac00\ub2f9 \uc0ac\ud0d5, \uc778\uacf5 \ub208\ubb3c \ub4f1\uc758 \ubcf4\uc870\uc81c\ub97c \uc4f4\ub2e4. \uc804\uc2e0 \uc99d\uc0c1\uc5d0 \ub300\ud574\uc11c\ub294 RA\ub098 SLE\uc5d0\uc11c \uc4f0\ub294 \uc57d\uc81c\uc640 \uc720\uc0ac\ud55c \uc57d\uc81c\ub97c \uc0ac\uc6a9\ud55c\ub2e4. MS : NSAIDs, HCQ, MTX, GC Skin : Topical steroid, HCQ -> MTX Lung : ILD\uac00 \uc2ec\ud558\uba74 High dose GC, MMF, AZA 7-2. Disease activity & severity ESSDAI, ESSPRI 8. \uacbd\uacfc\uc640 \uc608\ud6c4 low complement, cryoglobulinemia, vasculitis, lymphoma \ub4f1\uc774 \ud569\ubcd1\uc99d\uc73c\ub85c \ub098\ud0c0\ub098\uba74 \uc0ac\ub9dd\ub960\uc774 \uc99d\uac00\ud560 \uc218 \uc788\ub2e4.","title":"Sj\u00f6gren's syndrome"},{"location":"sjogren/ss/#1-historical-perspective","text":"(1888) Johann von Mikulicz-Radecki : \ub208\ubb3c\uc0d8, \uc774\ud558\uc120, \ud131\ubc11\uc0d8\uc758 \uc591\uce21\uc131, \ubb34\ud1b5\uc131 \uc885\ucc3d \ubc1c\ud45c (1925) Henri Gourgerot : \ud0c0\uc561\uc120 \uc704\ucd95 \ubc0f \ub208, \uc785, \uc9c8\uc758 \uac74\uc870\ub97c \ub3d9\ubc18\ud55c \ucf00\uc774\uc2a4 \ubc1c\ud45c (1933) Henrik Sjogren : 19\uac1c\uc758 Keratoconjunctivitis sicca \ucf00\uc774\uc2a4 (2\uac74\uc740 \uce68\uc0d8 \ubd80\uc885 \ud3ec\ud568) (1953) Morgan & Castleman : 18\uac1c\uc758 \ub208\ubb3c\uc0d8/\uce68\uc0d8 \ube44\ub300 Bx. \uacb0\uacfc \ubc1c\ud45c (1960) Joseph J. Bunim et al. : 40\uba85\uc758 Sjogren syndrome case \ubc1c\ud45c (1965) NIH : \ub2e4\ub978 CTS\uac00 \uc5c6\ub294 Sicca syndrome \ud658\uc790\uc758 75%\uc5d0\uc11c ANA (+), Anti-Ro/La (+/+) (1970) minor labial biopsy & focus score","title":"1. Historical Perspective"},{"location":"sjogren/ss/#2","text":"Sjogren's syndrome = Keratoconjunctivitis sicca + Xerostomia Keratoconjunctivitis sicca = dryness of the cornea and conjunctiva Xerostomia = subjective symptoms of dry mouth \ubd84\ub958 Primary : KCS or Xerostomia without other CTD + Serologic and/or histopathologic criteria Secondary : KCS or Xerostomia with Other CTD (RA, SLE, SSc, PM/DM, Vasculitis, etc.)","title":"2. \uc815\uc758 \ubc0f \ubd84\ub958"},{"location":"sjogren/ss/#3","text":"40~50\ub300, M:F = 14.5:1 \uc720\ubcd1\ub960 : 0.1~4.6% Secondary SS : RA\uc5d0\uc11c\ub294 4~31%, SLE\uc5d0\uc11c\ub294 6~19%, SSc\uc5d0\uc11c\ub294 14~21%","title":"3. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790"},{"location":"sjogren/ss/#4","text":"\ubcd1\ub9ac \uc18c\uacac : \uce68\uc0d8\uc758 \ub9bc\ud504\uad6c \uce68\uc724 (\uc8fc\ub85c T cell or B cell, DC/Plasma cell/macrophages) \uc720\uc804\uc801 \uc694\uc778 + \ud658\uacbd\uc801 \uc694\uc778 + \uba74\uc5ed\ud559\uc801 \uc694\uc778","title":"4. \ubcd1\uc778\uae30\uc804"},{"location":"sjogren/ss/#5","text":"","title":"5. \uc784\uc0c1\uc99d\uc0c1"},{"location":"sjogren/ss/#5-1-glandular-manifestation","text":"\uac74\uc870\uc99d\uc0c1 : \ub300\ubd80\ubd84 8~10\ub144 \ub3d9\uc548 \ub290\ub9ac\uac8c \uc9c4\ud589 \ub208 : \uac74\uc131\uac01\ub9c9\uacb0\ub9c9\uc5fc (keratoconjunctivitis sicca) - lacrimal gland\uc758 \ub9cc\uc131 \uc5fc\uc99d\ub54c\ubb38\uc5d0 \ub208\ubb3c\ubd84\ube44\uac00 \uac10\uc18c\ud558\uc5ec conjunctival & bulbar epithelium\uc744 \ud30c\uad34\ud568. \uc785 : \uce68\ubd84\ube44 \uac10\uc18c\ub85c \uc778\ud55c \uad6c\uac15\uac74\uc870\uc99d - \uc539\uace0 \uc0bc\ud0a4\ub294\ub370 \uc5b4\ub824\uc6c0, \ub9db\uc758 \ubcc0\ud654, \uc7a5\uc2dc\uac04 \ub9d0\ud558\uae30\uc758 \uc5b4\ub824\uc6c0, \ucda9\uce58, \uac08\ub77c\uc9c4 \uce58\uc544, \uad6c\uac15 \uce78\ub514\ub2e4\uc99d \uadc0\ubc11\uc0d8/\ud070\uce68\uc0d8\uc758 \ube44\ub300 : \uc804\uccb4 primary SS \ud658\uc790\uc758 \uc57d 1/4 \uc815\ub3c4. \uac74\uc870\ub41c \uc810\uc561\uc774 \uc77c\uc2dc\uc801\uc73c\ub85c \uc8fc\uc694 \uad00\uc744 \ub9c9\uc544\uc11c \ube44\ub300\ud574\uc9d0.","title":"5-1. \uc8fc\uc694 \uc99d\uc0c1 (Glandular manifestation) :"},{"location":"sjogren/ss/#5-2-extraglandular-manifestation","text":"Fatigue (70%) : SS \uc790\uccb4 \uc99d\uc0c1 \ub610\ub294 Depression, anxiety, FMS, sleep deficit \ub54c\ubb38\uc77c \uc218\ub3c4 \uc788\ub2e4. RP (13~33%) : Sicca symptom \uc2dc\uc791 \uba87 \ub144 \uc804\ubd80\ud130 \uc120\ud589\ud568. Digital ulcer\ub294 \ub4dc\ubb3c\ub2e4. Skin : \uac74\uc131 \ud53c\ubd80, \ub208\uaebc\ud480 \ud53c\ubd80\uc5fc, \uac01\uc9c8\uc5fc, \ud658\ud615 \ud64d\ubc18, \uc790\ubc18\ubcd1, Cutaneous vasculitis, Livedo reticularis - \ub300\uac1c \ub2e4\ub978 extraglandular manifestation\uc5d0 \ub3d9\ubc18\ub41c\ub2e4. Vasculitis \uc591\uc0c1\uc740 medium/small vessel vasculitis \uc591\uc0c1\uacfc \uc720\uc0ac\ud568. (Deep perivascular lymphocytic infiltrate without epidermal changes) Joint (45%) : 1/3 \uc5d0\uc11c\ub294 \uad00\uc808\uc99d\uc0c1\uc774 SS \uc99d\uc0c1\ubcf4\ub2e4 \uba3c\uc800 \ubc1c\uc0dd\ud55c\ub2e4. Lung (11.4%) \uc8fc\ub85c ILD (NSIP, UIP pattern) Kidney (5%) : TIN, Type 1 RTA, GN (\uc8fc\ub85c lymphoma\uc640 \uad00\ub828), NDI GI : Dysphagia, dyspepsia, Esophageal achalasia, PBC NR : depression, mild cognitive disorder, peripheral neuropathy CV : \ub1cc\ud608\uad00/\uc2ec\uadfc\uacbd\uc0c9 \uc704\ud5d8 \uc99d\uac00 Thyroid : Anti-Thyroglobin Ab (+), TSH elevation Lymphoma : NHL (\uc9c0\uc18d\uc801\uc778 \uce68\uc0d8\ube44\ub300, \uc790\uc0c9\ubc18, \ubc31\ud608\uad6c\uac10\uc18c\uc99d, ectopic germinal center) - MALT, DLBCL \ub4f1","title":"5-2. \uae30\ud0c0 \uc99d\uc0c1 (Extraglandular manifestation)"},{"location":"sjogren/ss/#6","text":"","title":"6. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8"},{"location":"sjogren/ss/#6-1","text":"\uc8fc\uad00\uc801\uc778 \uc99d\uc0c1\uc774 \uc788\ub294\uac00? \u2192 \uac74\uc131\uc548 / \uad6c\uac15\uac74\uc870\uc99d \uc790\uac00\uba74\uc5ed\uc131\uc774 \uc788\ub294\uac00? (=\uc790\uac00\ud56d\uccb4\uac00 \ub098\uc624\ub294\uac00?) \u2192 Anti-Ro/SSa \uadf8 \uc99d\uc0c1\uc744 \uac80\uc0ac\ub85c \uc99d\uba85\ud560 \uc218 \uc788\ub294\uac00? \u2192 Shirmer test, OSS / Sialometry, Sialography, Scintigraphy, \uae30\ud0c0 \uac80\uc0ac \u2192 US / MRI Minor labial salivary gland biopsy : focus score \u22651 Focus = 50\uac1c \uc774\uc0c1\uc758 lymphocyte cluster greater than or equal to 1 per 4 mm 2 of tissue \uc77c \ub54c \uc591\uc131 focus score > 3\uc774\uba74 lymphoma risk\uac00 \uc62c\ub77c\uac04\ub2e4. SS \uc9c4\ub2e8 \ubfd0\ub9cc \uc544\ub2c8\ub77c MALToma, sarcoidosis, IgG4-related ds. \uac10\ubcc4\uc5d0\ub3c4 \uc720\uc6a9\ud558\ub2e4. ** \uc784\uc0c1\uc801/Lab finding \uc774 \uba85\ud655\ud558\ub2e4\uba74 \uad73\uc774 biopsy\ub97c \ud558\uc9c0 \uc54a\uc544\ub3c4 \ub41c\ub2e4. ** \uc99d\uc0c1\uc740 \uc788\ub294\ub370 Anti-Ro (-) or low titer\uba74 biopsy\ub97c \ud574\uc57c \ud55c\ub2e4. ** \uac74\uc131\uc548\uc774 \uc788\ub294 \ud658\uc790\uc758 \ub300\ubd80\ubd84\uc740 \uc1fc\uadf8\ub80c\uc774 \uc544\ub2c8\ub2e4. ** \uc77c\ubc18 \uc778\uad6c\uc758 \uc57d 25%\uac00 \uad6c\uac15 \uac74\uc870 \uc99d\uc0c1\uc744 \uac00\uc9c0\uace0 \uc788\uace0, \ub300\ubd80\ubd84\uc740 \uc1fc\uadf8\ub80c\uc774 \uc544\ub2c8\ub2e4.","title":"6-1. \uae30\ubcf8 \uac1c\ub150"},{"location":"sjogren/ss/#6-2","text":"anemia, leukopenia ESR elevation Hypergammmaglobulinemia : 80% Low C3, C4 : 5~10% Anti-Ro/La Ab., RF, ANA, Tg, TPO, Anti-mitochondrial ab., Anti-Muscarin3 Rc Ab. ** Anti-La Ab.\ub294 \uc774\uc81c \ub354 \uc774\uc0c1 \uc784\uc0c1\uc801\uc73c\ub85c \uc9c4\ub2e8\uc5d0 \uc720\uc6a9\ud558\uc9c0 \uc54a\uc74c. ** Anti-Ro Ab.\ub294 \ucda9\ubd84\ud55c \uc5ed\uac00\ub77c\uc57c \ud55c\ub2e4.","title":"6-2. \ud608\uc561\uac80\uc0ac"},{"location":"sjogren/ss/#6-3","text":"\ub208\uac80\uc0ac schirmer test < 5mm Rose bengal stain : keratoconjunctivitis sicca > 3 (\uc544\ud30c\uc11c \uc774\uc81c \uc548\uc4f4\ub2e4) OSS : lissamine greein or fluorescein stain >= 3 Tear film break-up test : \uce68\uc0d8\uac80\uc0ac Sialometry Sialography Scintigraphy minor labial salivary gland biopsy : gold standard","title":"6-3. \uae30\ud0c0\uac80\uc0ac"},{"location":"sjogren/ss/#6-4","text":"2002 AECG (IV or VI \ub9cc\uc871\ud560 \ub54c 4\uac1c \uc774\uc0c1) I. ocular symptoms; II. oral symptoms; III. ocular signs (Schirmer-I test \u22645 mm/5 min or Rose Bengal score \u22654 by the van Bijsterveld scoring system); IV. histopathologic features (focus score \u22651 on labial salivary gland biopsy); V. objective evidence of salivary gland involvement by at least one abnormal test (salivary scintigraphy, parotid sialography, or unstimulated salivary flow rate \u22641.5 mL/15 min); VI. positive test for anti-Ro/SS-A or anti-La/SS-B antibodies. 2012 SICCAC & ACR : \uc624\ub85c\uc9c0 \uac1d\uad00\uc801\uc778 \uac80\uc0ac\uc5d0 \uadfc\uac70\ud568 (3 \uc911 2\uac1c \uc774\uc0c1) - too invasive! I. a positive test for serum anti-Ro/SS-A and/or anti-La/SS-B antibodies or a positive test for rheumatoid factor and an ANA titer of greater than or equal to 1:320; II. a labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus greater than or equal to 1 per 4 mm 2 ; III. keratoconjunctivitis sicca with an ocular staining score greater than or equal to 3. 2016 ACR/EULAR : \uac74\uc870\uc99d\uc0c1 + \uae30\uc900 (9\uc810 \uc911 4\uc810 \uc774\uc0c1) I. histopathology showing focal lymphocytic sialadenitis with a focus score greater than or equal to 1 per 4 mm 2 ; II. the presence of anti-Ro/SS-A antibodies; III. a SICCA ocular staining score of greater than or equal to 5 using lissamine green or fluorescein dye (or Rose Bengal score \u22654 by the van Bijsterveld scoring system); IV. a Schirmer test of less than or equal to 5 mm per 5 minutes; V. Unstimulated whole salivary flow of less than or equal to 0.1 mL per minute. ** 2016 ACR/EULAR\ub294 Anti-La Ab.\ub97c \ubd84\ub958\uae30\uc900\uc5d0\uc11c \uc81c\uc678\ud558\uace0, OSS\ub97c \ud3ec\ud568\uc2dc\ud0b4. ** Rose bengal dye\ub294 \uc544\ud504\uace0 \uac01\ub9c9\uc5d0 \ud1b5\uc99d\uc744 \uc720\ubc1c\ud558\uae30 \ub54c\ubb38\uc5d0 \uc81c\uc678\ud568","title":"6-4. \ubd84\ub958\uae30\uc900"},{"location":"sjogren/ss/#6-5","text":"\ub450\uacbd\ubd80 \ubc29\uc0ac\uc120\uce58\ub8cc \uacfc\uac70\ub825, HCV, HIV, Sarcoidosis, amyloidosis, GVHD, IgG4-related ds. \uc57d\ubb3c (\ud56d\ucf5c\ub9b0\uc791\uc6a9), \uc9c1\uc5c5 \ud658\uacbd, \ud3d0\uacbd \uc5ec\ubd80 \ub4f1","title":"6-5. \uac10\ubcc4\uc9c4\ub2e8 (\ubc30\uc81c)"},{"location":"sjogren/ss/#7","text":"","title":"7. \uce58\ub8cc\uc6d0\uce59"},{"location":"sjogren/ss/#7-1","text":"\uac74\uc870 \uc99d\uc0c1\uc5d0 \ub300\ud574\uc11c\ub294 pilocarpine\uc774\ub098 \ubb34\uac00\ub2f9 \uc0ac\ud0d5, \uc778\uacf5 \ub208\ubb3c \ub4f1\uc758 \ubcf4\uc870\uc81c\ub97c \uc4f4\ub2e4. \uc804\uc2e0 \uc99d\uc0c1\uc5d0 \ub300\ud574\uc11c\ub294 RA\ub098 SLE\uc5d0\uc11c \uc4f0\ub294 \uc57d\uc81c\uc640 \uc720\uc0ac\ud55c \uc57d\uc81c\ub97c \uc0ac\uc6a9\ud55c\ub2e4. MS : NSAIDs, HCQ, MTX, GC Skin : Topical steroid, HCQ -> MTX Lung : ILD\uac00 \uc2ec\ud558\uba74 High dose GC, MMF, AZA","title":"7-1. \uc694\uc57d"},{"location":"sjogren/ss/#7-2-disease-activity-severity","text":"ESSDAI, ESSPRI","title":"7-2. Disease activity &amp; severity"},{"location":"sjogren/ss/#8","text":"low complement, cryoglobulinemia, vasculitis, lymphoma \ub4f1\uc774 \ud569\ubcd1\uc99d\uc73c\ub85c \ub098\ud0c0\ub098\uba74 \uc0ac\ub9dd\ub960\uc774 \uc99d\uac00\ud560 \uc218 \uc788\ub2e4.","title":"8. \uacbd\uacfc\uc640 \uc608\ud6c4"},{"location":"sle%26aps/aps/","text":"APS\ub294 \ud56d\uc778\uc9c0\uc9c8\ud56d\uccb4\uc640 \uad00\ub828\ud558\uc5ec \ud608\uc804 \ud615\uc131\uacfc \uc784\uc2e0 \uc774\ud658\uc744 \ud2b9\uc9d5\uc73c\ub85c \ud558\ub294 \uc9c8\ud658\uc774\ub2e4. \ub2e8\ub3c5\uc73c\ub85c \ubc1c\uc0dd\ud558\uac70\ub098 (\uc77c\ucc28 \ud56d\uc778\uc9c0\uc9c8\ud56d\uccb4\uc99d\ud6c4\uad70) \ub610\ub294 SLE\uc640 \uac19\uc740 \ub2e4\ub978 \uc790\uac00\uba74\uc5ed\uc9c8\ud658\uc5d0 \ub3d9\ubc18\ub418\uc5b4 (\uc774\ucc28 \ud56d\uc778\uc9c0\uc9c8\ud56d\uccb4\uc99d\ud6c4\uad70) \ubc1c\uc0dd\ud55c\ub2e4. 1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790 1-1. \uc5ed\ud559 \ubb34\uc99d\uc0c1 \ubcf4\uc720\uc790 / \uc804\ud615\uc801 APS / \uc784\uc2e0 \uc774\ud658\uc5d0 \uad6d\ud55c\ub41c APS / \ud608\uc804\uc774\ub098 \uc784\uc2e0 \uc774\ud658 \uc774\uc640\uc758 \uc99d\uc0c1\uc744 \ubcf4\uc774\ub294 APS\ub85c \uad6c\ubd84 \uac00\ub2a5 \uc815\uc0c1\uc778\uc5d0\uc11c APS \uc591\uc131\ub960\uc740 1~5% \ubc1c\uc0dd\ub960 : 10\ub9cc\uba85 \ub2f9 5\uba85, \uc720\ubcd1\ub960 : 10\ub9cc\uba85 \ub2f9 20~50\uba85 \ub0a8\uc131 < \uc5ec\uc131 2. \ubcd1\uc778\uae30\uc804 Two hit hypothesis : aPL\uc5d0 \uc758\ud574 \ud608\uc804\uc774 \uc798 \uc0dd\uae38 \uc218 \uc788\ub294 \uc0c1\ud0dc (1st hit)\uc5d0\uc11c \ucd94\uac00\uc801\uc778 \uc720\ubc1c\uc778\uc790 (2nd hit)\uac00 \uc788\uc5b4\uc57c \ud608\uc804\uc774 \ubc1c\uc0dd\ud568. \ud608\uc804 \ubc1c\uc0dd \ud0dc\uc544 \uc190\uc2e4 : Anti-b2GP1 Ab\uc5d0 \uc758\ud574 \uc0dd\uc131\ub41c \ud608\uc804 or inflammation or hormone \ubd84\ube44 \uc5b5\uc81c \ub4f1\uc758 \uae30\uc804\uc5d0 \uc758\ud574 \ubc1c\uc0dd 3. \uc784\uc0c1\uc99d\uc0c1 3-1. \uc8fc\uc99d\uc0c1 \ud608\uad00 \ud608\uc804 \ubc0f \uc784\uc2e0 \uc774\ud658 \ud608\uc804 : artery & vein \uc784\uc2e0 \uc774\ud658 : \uc784\uc2e0 10\uc8fc \uc774\uc804\uc758 3\ud68c \uc774\uc0c1\uc758 \uc5f0\uc18d\uc801\uc778 \uc784\uc2e0 \uc190\uc2e4, \ub2e4\ub978 \uc774\uc720\ub85c\ub294 \uc124\uba85\ub418\uc9c0 \uc54a\ub294 \uc784\uc2e0 10\uc8fc \uc774\uc0c1\uc758 \ud0dc\uc544\uc0ac\ub9dd\uacfc \uc790\uad81\ub0b4 \uc131\uc7a5\uc9c0\ud604, \uc784\uc2e0\uad00\ub828 \uc0b0\ubaa8\ud608\uc804\uc99d, \ud0dc\ubc18\ubd80\uc804\uc73c\ub85c \uc778\ud55c 34\uc8fc \uc774\uc804\uc758 \uc870\uc0b0, \uc790\uac04\uc99d, \uc790\uac04\uc804\uc99d 3-2. \uae30\ud0c0\uc99d\uc0c1 HD : Thrombocytopenia (30~40%) : \ub300\uac1c 50,000 \uc774\uc0c1\uc73c\ub85c \uacbd\ubbf8\ud568, Hemolytic anemia (6~10%) Skin : livedo reticularis, pseudovasculiticlesion, acrocyanosis, anetoderma, necrotic skin ulcer, superficial phlebitis CAPS : 1\uc8fc \uc774\ub0b4\uc5d0 \ubc1c\uc0dd\ud55c 3\uac1c \uc774\uc0c1\uc758 \uc7a5\uae30\ub97c \uce68\ubc94\ud558\ub294 \uc791\uc740 \ud608\uad00 \ud3d0\uc0c9 + aPL \uc591\uc131 : \uc8fc\ub85c \uac10\uc5fc, \uc218\uc220, \uc678\uc0c1, \uc885\uc591, SLE \uc545\ud654\uc5d0 \uc758\ud568 4. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8 4-1. \ud608\uc561\uac80\uc0ac LAC : aPTT\ub97c \uc5f0\uc7a5\uc2dc\ud0a4\uc9c0\ub9cc \uc2e4\uc81c\ub85c\ub294 \ud608\uc804\uc99d\uc744 \uc77c\uc73c\ud0b4. \uac00\uc7a5 \uac15\ub825\ud55c \ud608\uc804\uc99d\uc758 \uc608\uce21\uc778\uc790 aCL : IgG aCL\uc774 \ud608\uc804\uc99d\uacfc \uac00\uc7a5 \uad00\ub828 \uc788\ub2e4\uace0 \uc54c\ub824\uc9d0. 20 GPL or MPL \uc774\uc0c1\uc758 titer\uac00 6\uc8fc \uac04\uaca9\uc73c\ub85c 1\ud68c \uc774\uc0c1 \ub098\uc624\uba74 \uc9c4\ub2e8\uc801 \ud2b9\uc774\ub3c4\uac00 \ub192\uc74c. Anti-b2GPI ab : aCL\ubcf4\ub2e4 \uc9c4\ub2e8\uc801 \ud2b9\uc774\ub3c4\uac00 \ub354 \ub192\uc740\ub370, VDRL\uc5d0 \uc704\uc591\uc131\uc744 \ubcf4\uc774\uae30\ub3c4 \ud568. 4-2. \ubd84\ub958\uae30\uc900 Sapporo classification criteria (1998) : \ud55c \uac00\uc9c0 \uc774\uc0c1\uc758 \uac80\uc0ac\uc18c\uacac + APS lab\uc774 6\uc8fc \uac04\uaca9\uc73c\ub85c 2\ubc88 \uc774\uc0c1 \uac80\ucd9c (LAC, aCL) Sydney classification criteria (2006) : \ud55c \uac00\uc9c0 \uc774\uc0c1\uc758 \uac80\uc0ac\uc18c\uacac + APS lab\uc774 12\uc8fc \uac04\uaca9\uc73c\ub85c 2\uc8fc \uc774\uc0c1 \uac80\ucd9c (LAC, aCL, Anti-b2GPI Ab) \uad00\ub828\ub41c \uc784\uc0c1\uc18c\uacac : thrombocytopenia, \uc778\uc9c0\uae30\ub2a5\uc7a5\uc560, livedo reticularis, APS related renal disease, valve involvement 4-3. \uac10\ubcc4\uc9c4\ub2e8 \uc720\uc804\uc801 \uacfc\uc751\uace0\uc131 \uc870\uac74 : Factor V leiden, Prothrombin \ubcc0\uc774, Protein C/S, Antithrombin III deficiency \ud6c4\ucc9c\uc801 \uacfc\uc751\uace0\uc131 \uc870\uac74 : Pregnancy, Oral contraceptives, HRT, Nephrotic syndrome, DM, Obesity, surgery, vasculitis, malignancy 5.\uce58\ub8cc\uc6d0\uce59 5-1. \uc694\uc57d \uce58\ub8cc\uc758 \uc8fc\uc694 \ubaa9\ud45c : \uc774\ubbf8 \ud608\uc804\uc99d\uc774 \ubc1c\uc0dd\ud588\ub2e4\uba74 \uc7ac\ubc1c \ubc29\uc9c0, \uc99d\uc0c1\uc774 \uc544\uc9c1 \uc5c6\uc5c8\ub2e4\uba74 \uc608\ubc29 \uc7ac\ubc1c \ubc29\uc9c0 : Warfarinization (PT INR 2~3) \uc608\ubc29 : HCQ +- low dose aspirin (75~100mg) : aspirin\uc758 \ud6a8\uacfc\ub294 \uc544\uc9c1 \ub17c\ub780\uc774 \uc788\uc74c. \uc784\uc2e0\uad00\ub9ac : APS lab\uc744 \ubc18\ubcf5 \uac80\uc0ac. (\uc784\uc2e0 \uc911\uae30 \uc774\uc804\uae4c\uc9c0\ub294 2~4\uc8fc \uac04\uaca9, \uc774\ud6c4\ub85c\ub294 1~2\uc8fc \uac04\uaca9) -> heparin + low dose aspirin CAPS : anticoagulation + GC, Plasmaphresis, IVIG 5-2.\uac00\uc774\ub4dc\ub77c\uc778 6. \uacbd\uacfc\uc640 \uc608\ud6c4 \uc804\uccb4 \ud658\uc790\uc758 1/4 : \ubc1c\ubcd1\uc5d0\uc11c \uc7a5\uae30 \uc190\uc0c1\uae4c\uc9c0 \uc57d 10\ub144 \uc18c\uc694. 10\ub144 \uc0dd\uc874\uac00\ub2a5\uc131 90.7% \uc8fc\uc694 \uc0ac\ub9dd \uc6d0\uc778\uc740 \uc2ec\ud55c \ud608\uc804\uc99d\uacfc \uac10\uc5fc.","title":"APS"},{"location":"sle%26aps/aps/#1","text":"","title":"1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790"},{"location":"sle%26aps/aps/#1-1","text":"\ubb34\uc99d\uc0c1 \ubcf4\uc720\uc790 / \uc804\ud615\uc801 APS / \uc784\uc2e0 \uc774\ud658\uc5d0 \uad6d\ud55c\ub41c APS / \ud608\uc804\uc774\ub098 \uc784\uc2e0 \uc774\ud658 \uc774\uc640\uc758 \uc99d\uc0c1\uc744 \ubcf4\uc774\ub294 APS\ub85c \uad6c\ubd84 \uac00\ub2a5 \uc815\uc0c1\uc778\uc5d0\uc11c APS \uc591\uc131\ub960\uc740 1~5% \ubc1c\uc0dd\ub960 : 10\ub9cc\uba85 \ub2f9 5\uba85, \uc720\ubcd1\ub960 : 10\ub9cc\uba85 \ub2f9 20~50\uba85 \ub0a8\uc131 < \uc5ec\uc131","title":"1-1. \uc5ed\ud559"},{"location":"sle%26aps/aps/#2","text":"Two hit hypothesis : aPL\uc5d0 \uc758\ud574 \ud608\uc804\uc774 \uc798 \uc0dd\uae38 \uc218 \uc788\ub294 \uc0c1\ud0dc (1st hit)\uc5d0\uc11c \ucd94\uac00\uc801\uc778 \uc720\ubc1c\uc778\uc790 (2nd hit)\uac00 \uc788\uc5b4\uc57c \ud608\uc804\uc774 \ubc1c\uc0dd\ud568. \ud608\uc804 \ubc1c\uc0dd \ud0dc\uc544 \uc190\uc2e4 : Anti-b2GP1 Ab\uc5d0 \uc758\ud574 \uc0dd\uc131\ub41c \ud608\uc804 or inflammation or hormone \ubd84\ube44 \uc5b5\uc81c \ub4f1\uc758 \uae30\uc804\uc5d0 \uc758\ud574 \ubc1c\uc0dd","title":"2. \ubcd1\uc778\uae30\uc804"},{"location":"sle%26aps/aps/#3","text":"","title":"3. \uc784\uc0c1\uc99d\uc0c1"},{"location":"sle%26aps/aps/#3-1","text":"\ud608\uad00 \ud608\uc804 \ubc0f \uc784\uc2e0 \uc774\ud658 \ud608\uc804 : artery & vein \uc784\uc2e0 \uc774\ud658 : \uc784\uc2e0 10\uc8fc \uc774\uc804\uc758 3\ud68c \uc774\uc0c1\uc758 \uc5f0\uc18d\uc801\uc778 \uc784\uc2e0 \uc190\uc2e4, \ub2e4\ub978 \uc774\uc720\ub85c\ub294 \uc124\uba85\ub418\uc9c0 \uc54a\ub294 \uc784\uc2e0 10\uc8fc \uc774\uc0c1\uc758 \ud0dc\uc544\uc0ac\ub9dd\uacfc \uc790\uad81\ub0b4 \uc131\uc7a5\uc9c0\ud604, \uc784\uc2e0\uad00\ub828 \uc0b0\ubaa8\ud608\uc804\uc99d, \ud0dc\ubc18\ubd80\uc804\uc73c\ub85c \uc778\ud55c 34\uc8fc \uc774\uc804\uc758 \uc870\uc0b0, \uc790\uac04\uc99d, \uc790\uac04\uc804\uc99d","title":"3-1. \uc8fc\uc99d\uc0c1"},{"location":"sle%26aps/aps/#3-2","text":"HD : Thrombocytopenia (30~40%) : \ub300\uac1c 50,000 \uc774\uc0c1\uc73c\ub85c \uacbd\ubbf8\ud568, Hemolytic anemia (6~10%) Skin : livedo reticularis, pseudovasculiticlesion, acrocyanosis, anetoderma, necrotic skin ulcer, superficial phlebitis CAPS : 1\uc8fc \uc774\ub0b4\uc5d0 \ubc1c\uc0dd\ud55c 3\uac1c \uc774\uc0c1\uc758 \uc7a5\uae30\ub97c \uce68\ubc94\ud558\ub294 \uc791\uc740 \ud608\uad00 \ud3d0\uc0c9 + aPL \uc591\uc131 : \uc8fc\ub85c \uac10\uc5fc, \uc218\uc220, \uc678\uc0c1, \uc885\uc591, SLE \uc545\ud654\uc5d0 \uc758\ud568","title":"3-2. \uae30\ud0c0\uc99d\uc0c1"},{"location":"sle%26aps/aps/#4","text":"","title":"4. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8"},{"location":"sle%26aps/aps/#4-1","text":"LAC : aPTT\ub97c \uc5f0\uc7a5\uc2dc\ud0a4\uc9c0\ub9cc \uc2e4\uc81c\ub85c\ub294 \ud608\uc804\uc99d\uc744 \uc77c\uc73c\ud0b4. \uac00\uc7a5 \uac15\ub825\ud55c \ud608\uc804\uc99d\uc758 \uc608\uce21\uc778\uc790 aCL : IgG aCL\uc774 \ud608\uc804\uc99d\uacfc \uac00\uc7a5 \uad00\ub828 \uc788\ub2e4\uace0 \uc54c\ub824\uc9d0. 20 GPL or MPL \uc774\uc0c1\uc758 titer\uac00 6\uc8fc \uac04\uaca9\uc73c\ub85c 1\ud68c \uc774\uc0c1 \ub098\uc624\uba74 \uc9c4\ub2e8\uc801 \ud2b9\uc774\ub3c4\uac00 \ub192\uc74c. Anti-b2GPI ab : aCL\ubcf4\ub2e4 \uc9c4\ub2e8\uc801 \ud2b9\uc774\ub3c4\uac00 \ub354 \ub192\uc740\ub370, VDRL\uc5d0 \uc704\uc591\uc131\uc744 \ubcf4\uc774\uae30\ub3c4 \ud568.","title":"4-1. \ud608\uc561\uac80\uc0ac"},{"location":"sle%26aps/aps/#4-2","text":"Sapporo classification criteria (1998) : \ud55c \uac00\uc9c0 \uc774\uc0c1\uc758 \uac80\uc0ac\uc18c\uacac + APS lab\uc774 6\uc8fc \uac04\uaca9\uc73c\ub85c 2\ubc88 \uc774\uc0c1 \uac80\ucd9c (LAC, aCL) Sydney classification criteria (2006) : \ud55c \uac00\uc9c0 \uc774\uc0c1\uc758 \uac80\uc0ac\uc18c\uacac + APS lab\uc774 12\uc8fc \uac04\uaca9\uc73c\ub85c 2\uc8fc \uc774\uc0c1 \uac80\ucd9c (LAC, aCL, Anti-b2GPI Ab) \uad00\ub828\ub41c \uc784\uc0c1\uc18c\uacac : thrombocytopenia, \uc778\uc9c0\uae30\ub2a5\uc7a5\uc560, livedo reticularis, APS related renal disease, valve involvement","title":"4-2. \ubd84\ub958\uae30\uc900"},{"location":"sle%26aps/aps/#4-3","text":"\uc720\uc804\uc801 \uacfc\uc751\uace0\uc131 \uc870\uac74 : Factor V leiden, Prothrombin \ubcc0\uc774, Protein C/S, Antithrombin III deficiency \ud6c4\ucc9c\uc801 \uacfc\uc751\uace0\uc131 \uc870\uac74 : Pregnancy, Oral contraceptives, HRT, Nephrotic syndrome, DM, Obesity, surgery, vasculitis, malignancy","title":"4-3. \uac10\ubcc4\uc9c4\ub2e8"},{"location":"sle%26aps/aps/#5","text":"","title":"5.\uce58\ub8cc\uc6d0\uce59"},{"location":"sle%26aps/aps/#5-1","text":"\uce58\ub8cc\uc758 \uc8fc\uc694 \ubaa9\ud45c : \uc774\ubbf8 \ud608\uc804\uc99d\uc774 \ubc1c\uc0dd\ud588\ub2e4\uba74 \uc7ac\ubc1c \ubc29\uc9c0, \uc99d\uc0c1\uc774 \uc544\uc9c1 \uc5c6\uc5c8\ub2e4\uba74 \uc608\ubc29 \uc7ac\ubc1c \ubc29\uc9c0 : Warfarinization (PT INR 2~3) \uc608\ubc29 : HCQ +- low dose aspirin (75~100mg) : aspirin\uc758 \ud6a8\uacfc\ub294 \uc544\uc9c1 \ub17c\ub780\uc774 \uc788\uc74c. \uc784\uc2e0\uad00\ub9ac : APS lab\uc744 \ubc18\ubcf5 \uac80\uc0ac. (\uc784\uc2e0 \uc911\uae30 \uc774\uc804\uae4c\uc9c0\ub294 2~4\uc8fc \uac04\uaca9, \uc774\ud6c4\ub85c\ub294 1~2\uc8fc \uac04\uaca9) -> heparin + low dose aspirin CAPS : anticoagulation + GC, Plasmaphresis, IVIG","title":"5-1. \uc694\uc57d"},{"location":"sle%26aps/aps/#5-2","text":"","title":"5-2.\uac00\uc774\ub4dc\ub77c\uc778"},{"location":"sle%26aps/aps/#6","text":"\uc804\uccb4 \ud658\uc790\uc758 1/4 : \ubc1c\ubcd1\uc5d0\uc11c \uc7a5\uae30 \uc190\uc0c1\uae4c\uc9c0 \uc57d 10\ub144 \uc18c\uc694. 10\ub144 \uc0dd\uc874\uac00\ub2a5\uc131 90.7% \uc8fc\uc694 \uc0ac\ub9dd \uc6d0\uc778\uc740 \uc2ec\ud55c \ud608\uc804\uc99d\uacfc \uac10\uc5fc.","title":"6. \uacbd\uacfc\uc640 \uc608\ud6c4"},{"location":"sle%26aps/sle/","text":"\uc804\uc2e0\ud64d\ubc18\ub8e8\ud478\uc2a4\ub294 \ub2e4\uc591\ud55c \uc7a5\uae30\uce68\ubc94\uacfc \uc774\uc5d0 \ub530\ub978 \uc784\uc0c1\uc99d\uc0c1\uc744 \ub098\ud0c0\ub0b4\uba70, \ubc1c\ubcd1\ucd08\uae30\uc5d0 \ud558\ub098 \ub610\ub294 \uc5ec\ub7ec \uc7a5\uae30\ub97c \uce68\ubc94\ud560 \uc218\ub3c4 \uc788\uace0 \uc9c8\ubcd1\uc758 \uacbd\uacfc\uc5d0 \ub530\ub77c \uc0c8\ub85c\uc6b4 \uc784\uc0c1\uc99d\uc0c1\uc774 \ub098\ud0c0\ub098\uae30\ub3c4 \ud55c\ub2e4. 1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790 1-1. \uc5ed\ud559 \uac00\uc784\uae30\ub97c \ud3ec\ud568\ud55c \uc80a\uc740 (16~55\uc138) \uc5ec\uc131\uc5d0\uac8c \uc8fc\ub85c \ubc1c\ubcd1 (F:M = 9:1). \ub178\uc778 \ub8e8\ud478\uc2a4\ub294 \uc99d\uc0c1\uc774 \uac00\ubcbc\uc6b4 \uacbd\ud5a5. \uc720\ubcd1\ub960 : 10\ub9cc\uba85 \ub2f9 100\uba85 (\ud55c\uad6d\uc778\uc740 26.5\uba85) \ubc1c\ubcd1\ub960 : 10\ub9cc\uba85 \ub2f9 4~7\uba85 (\ud55c\uad6d\uc778\uc740 2.5\uba85) 1-2. \uc608\ud6c4 \uace0\uc5f0\ub839, \ub0a8\uc131, \ubbf8\uad6d \ud751\uc778, \ub192\uc740 SLEDAI, GC \uc0ac\uc6a9, HTN \uc788\uc744 \ub54c \uae30\uad00 \uc190\uc0c1\uc774 \ub9ce\uc774 \ubc1c\uc0dd \uae30\uad00\uc190\uc0c1\uc774 \uc788\uc73c\uba74 \uc0ac\ub9dd\ub960\uc740 1.46\ubc30 \uc99d\uac00 SLE \ud658\uc790\ub294 \uc77c\ubc18\uc778\uc5d0 \ube44\ud574 \uc0ac\ub9dd\ub960 3~5\ubc30 \uc99d\uac00, \uc8fc\uc694 \uc0ac\ub9dd \uc6d0\uc778\uc740 LN, \ub192\uc740 SLEDAI, \uac10\uc5fc, \uc2ec\ud608\uad00\uacc4 \uc9c8\ud658 \ub4f1 2. \ubcd1\uc778\uae30\uc804 \uc720\uc804\uc801 \uc694\uc778 \ubcf4\uccb4\uc720\uc804\uc790 C1q, C4, C2, HLA-DR2 & DR3 Fcr \uc218\uc6a9\uccb4 \uc774\uc0c1 \ud658\uacbd\uc801 \uc694\uc778 \uc131\ud638\ub974\ubaac\uc758 \uc5ed\ud560 : estradiol\uc740 \uc9c0\uc18d\uc801\uc778 \uba74\uc5ed\ubc18\uc751 \uc720\ubc1c, \ub0a8\uc131\ud638\ub974\ubaac\uc740 \uba74\uc5b5\uc5b5\uc81c\ud6a8\uacfc \uac10\uc5fc : Parvo B19, CMV, EBV \uc790\uc678\uc120, Silica dust, \ud761\uc5f0, \uc57d\ubb3c (hydralazine, procainamide, quinidine, INH, diltiazem, minocycline \ub4f1) \uba74\uc5ed\ud559\uc801 \uc694\uc778 \uc138\ud3ec\uc790\uba78\uc0ac\uc758 \uc774\uc0c1 NETs\uc758 \uc774\uc0c1 TLR\uc758 \uc774\uc0c1 T/B cell\uc758 \uc774\uc0c1 3. \uc784\uc0c1\uc99d\uc0c1 3-1. \uad00\uc808\uc99d\uc0c1 76~100%\uc5d0\uc11c \ubc1c\ud604 (\uac00\uc7a5 \ud754\ud55c \uc99d\uc0c1) 2\uac1c \uc774\uc0c1\uc758 \uad00\uc808\uc5d0 swelling\uc744 \ub3d9\ubc18\ud55c synovitis, 30\ubd84 \uc774\uc0c1\uc758 \uc870\uc870\uac15\uc9c1. \uace8\ubcc0\ud615\uc740 \ub4dc\ubb3c\ub2e4. \uacfc\ub3c4\ud55c \uc6b4\ub3d9\uc131 \ubcd1\ubcc0 -> Jaccoud\u2019s arthropathy AVN (+) : \uace0\uad00\uc808\uc5d0 \uad6d\ud55c\ub41c \ud1b5\uc99d, 5~10%, \uc8fc\ub85c GC \uc0ac\uc6a9\uacfc \uad00\ub828 Myositis : SLE itself or Drug (HCQ, GC) 3-2. \uad00\uc808 \uc678 \uc99d\uc0c1 \ud53c\ubd80\uc99d\uc0c1 : ACLE (malar rash, photosensitivity), SCLE, CCLE (discoid rash, alopecia) \uc810\ub9c9\uc99d\uc0c1 : \uad6c\uac15, \ucf54, \ud56d\ubb38, \uc0dd\uc2dd\uae30, \ud608\uad00\uc5fc (\ub450\ub4dc\ub7ec\uae30, \uc790\ubc18, \uc190\uac00\ub77d\uada4\uc591, \ud64d\ubc18\uc131 \uad6c\uc9c4) \ub1cc\uc2e0\uacbd\uc99d\uc0c1 : 2/3\uc5d0\uc11c \ubc1c\uc0dd. neuro + psychiatric sx. \uc8fc\ub85c seizure, headache \ud615\ud0dc\ub85c \ubc1c\uc0dd. Transverse myelitis \ud608\uc561\ud559\uc801\uc99d\uc0c1 : ACD, Lymphopenia, leukopenia, thrombocytopenia. \uc5f0\uad00\ub41c TTP/HUS, hemolytic anemia \uc2ec\ud3d0\uc99d\uc0c1 : pericarditis, myocarditis, Libman-Sacks endocarditis, CAD, Diffuse alveolar hemorrhage, shrinking lung syndrome, PAH \uc2e0\uc7a5\uc99d\uc0c1 : Urine protein 500mg/d or dipstick 3+ or RBC casts \uc704\uc7a5\uad00\uc99d\uc0c1 : \uc5f0\ud558\uace4\ub780, ascites, pancreatitis, serositis, protein-losing enteropathy \uac04\uc99d\uc0c1 : Budd-Chiari syndrome \uc548\uacfc \uc99d\uc0c1 : sicca syndrome, \uacf5\ub9c9\uc5fc, \uc2dc\uc2e0\uacbd\uc5fc, retinal toxicity (HCQ) \uc7a5\ub9c9\uc5fc : \ud749\ub9c9\uc5fc, \uc2ec\uc7a5\ub9c9\uc5fc, \ubcf5\ub9c9\uc5fc \ub4f1 4. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8 4-1. \ud608\uc561\uac80\uc0ac CBC : ACD, Hemolytic anemia (direct Coomb\u2019s test), leukopenia (lymphopenia), thrombocytopenia, HUS/TTP Chemistry : routine + CRP (<4~5mg/dl) U/A : Urine protein 500mg/d or dipstick 3+ or RBC cast Autoimmune markers : ANA 1:80, Anti-dsDNA, Anti-Sm, APS, etc. Complement : C3, C4, CH50 Ds. activity\ub97c \ubc18\uc601\ud558\ub294 \uac80\uc0ac : Anti-dsDNA\uc640 Complement titer -> \ud638\uc804 \uc774\ud6c4\ub85c\ub3c4 dsDNA\ub294 \uace0\uc5ed\uac00\ub85c \ubcf4\uc77c \uc218\ub3c4 \uc788\ub2e4. 4-2. \uc870\uc9c1\uac80\uc0ac Skin : Immunoglobulin\uacfc complement \uad6c\uc131\uc694\uc18c\ub4e4\uc774 dermoepidermal junction\uc744 \ub530\ub77c \uce68\ucc29 Kidney : LN \ubd84\ub958, \ub2e4\ub978 \uc9c8\ud658 \uac10\ubcc4, \uce58\ub8cc, \uc608\ud6c4\uc640 \uad00\ub828 4-3. \ubd84\ub958\uae30\uc900 1997 revised ACR classification criteria 2012 SLICC classification criteria 2019 ACR/EULAR classification criteria 4-4. \uac10\ubcc4\uc9c4\ub2e8 5. \uce58\ub8cc\uc6d0\uce59 5-1. \uac1c\ub150 \uc694\uc57d \uad00\ud574 \ub3c4\ub2ec or \ub0ae\uc740 \uc9c8\ubcd1\ud65c\uc131\ub3c4 \uc720\uc9c0\uac00 \ubaa9\ud45c \uc9c8\ubcd1\ud65c\uc131\ub3c4 \ud3c9\uac00\uac00 \uc911\uc694 : \uc99d\uc0c1, P/E, Lab, Anti-dsDNA, Complement, SLEDAI \ube44\uc57d\ubb3c\uc694\ubc95 : \uc77c\uad11\ucc28\ub2e8, \uae08\uc5f0, \uc801\uc808\ud55c \uc601\uc591\uacf5\uae09, \uc6b4\ub3d9, \uc608\ubc29\uc811\uc885 \uc57d\ubb3c\uc694\ubc95 : HCQ, Low dose GC, Immunosuppressant \uae30\ud0c0 \uc99d\uc0c1\uc5d0 \ub9de\ub294 \uce58\ub8cc Dyslipidemia, DM, HTN, Osteoporosis \uad00\ub9ac, Cancer screening \uc784\uc2e0 \uc804 Ro/La \ud3c9\uac00, 6\uac1c\uc6d4 \uc774\uc0c1 remission state\uc5ec\uc57c \ud55c\ub2e4. PRD, AZA, HCQ, ASA\ub294 \uc0ac\uc6a9 \uac00\ub2a5, Congenital heart block \uace0\ub824 5-2. \uac00\uc774\ub4dc\ub77c\uc778 5-3. Disease activity assessment \uae30\ubcf8 \uac1c\ub150 single summary score system : SLEDAI, SLAM \ub4f1 Organ-specific score system : BILAG SLEDAI \ucd5c\uadfc 10\uc77c \ub3d9\uc548\uc758 \uc9c8\ubcd1\ud65c\uc131\ub3c4 \ud3c9\uac00 (6\uc810 \uc774\uc0c1\uc774\uba74 \uc911\ub4f1\ub3c4, 20\uc810 \uc774\uc0c1\uc774\uba74 \uace0\uc911\uc99d) SLEDAI-2K, SELENA-SLEDAI \uac00\uc7a5 \uac04\ub2e8\ud558\uace0 \uc27d\uc9c0\ub9cc \uae30\uc874 \uc99d\uc0c1\uc758 \uc545\ud654\ub098 \uc77c\ubd80 \ud638\uc804\uc744 \ubbfc\uac10\ud558\uac8c \ud3c9\uac00\ud558\uae30 \uc5b4\ub835\uace0 \uc99d\uc0c1 \uc911\uc99d\ub3c4\uc5d0 \ub530\ub978 \uac00\uc911\uce58\uac00 \uc5c6\ub2e4. BILAG 9\uac1c organ system\uc5d0 \ub300\ud55c \uc9c0\ud45c (2004), \ucd5c\uadfc 4\uc8fc\uac04\uc758 \uc9c8\ubcd1\ud65c\uc131\ub3c4\ub97c \uc9c0\ub09c 4\uc8fc\uac04\uc758 \ud65c\uc131\ub3c4\uc640 \ube44\uad50 \uac01 organ system \ud65c\uc131\ub3c4\ub97c A ~ E\ub85c \ud3c9\uac00 (A\uac00 \uc81c\uc77c \ub192\uc740 \ud65c\uc131\ub3c4) Severe : A\ub85c \ubc14\ub014 \ub54c. Moderate : B\ub85c \ubc14\ub014 \ub54c. Effect : A & B\uac00 \uc5c6\uc744 \ub584 \uac00\uc7a5 \ud3ec\uad04\uc801\uc774\uace0 \uc9c8\ubcd1\ud65c\uc131\ub3c4/\uc911\uc99d\ub3c4\ub97c \uac10\ubcc4\ud560 \uc218 \uc788\uc73c\uba70 \ubbfc\uac10\ub3c4\uac00 \ub192\uc73c\ub098, \uc2e4\uc81c \uc784\uc0c1\uc5d0\uc11c \uc4f0\uae30\uc5d0\ub294 \ud3c9\uac00 \ud56d\ubaa9\uc774 \ub9ce\uace0 \ubcf5\uc7a1\ud558\ub2e4. \uae30\ud0c0 \uc9c0\ud45c SLAM-R (2001) : \ucd5c\uadfc 4\uc8fc\uac04\uc758 \uc9c8\ubcd1\ud65c\uc131\ub3c4 \uce21\uc815 ECLAM, LAI, SLAQ \ub4f1\ub3c4 \uc788\ub2e4. 5-4. Damage assessment SLICC/ACR-DI \uc190\uc0c1 : 6\uac1c\uc6d4 \uc774\uc0c1 \uc9c0\uc18d\ub418\uac70\ub098 \ubcd1\ub9ac\ud559\uc801 \ubc18\ud754\uc774 \ub3d9\ubc18\ub41c \ube44\uac00\uc5ed\uc801 \uc99d\uc0c1 12\uac1c \uc7a5\uae30 \uc2dc\uc2a4\ud15c\uc5d0 \ub300\ud55c 41\uac1c \ud3c9\uac00\ud56d\ubaa9, 0~46\uc810 \uc0ac\ub9dd\ub960 \uc608\uce21\uacfc \uc608\ud6c4 \ud310\uc815\uc5d0 \ub3c4\uc6c0 LDIQ (\uc124\ubb38\uc9c0) BILD (\uc124\ubb38\uc9c0) 6. \uacbd\uacfc\uc640 \uc608\ud6c4","title":"SLE"},{"location":"sle%26aps/sle/#1","text":"","title":"1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790"},{"location":"sle%26aps/sle/#1-1","text":"\uac00\uc784\uae30\ub97c \ud3ec\ud568\ud55c \uc80a\uc740 (16~55\uc138) \uc5ec\uc131\uc5d0\uac8c \uc8fc\ub85c \ubc1c\ubcd1 (F:M = 9:1). \ub178\uc778 \ub8e8\ud478\uc2a4\ub294 \uc99d\uc0c1\uc774 \uac00\ubcbc\uc6b4 \uacbd\ud5a5. \uc720\ubcd1\ub960 : 10\ub9cc\uba85 \ub2f9 100\uba85 (\ud55c\uad6d\uc778\uc740 26.5\uba85) \ubc1c\ubcd1\ub960 : 10\ub9cc\uba85 \ub2f9 4~7\uba85 (\ud55c\uad6d\uc778\uc740 2.5\uba85)","title":"1-1. \uc5ed\ud559"},{"location":"sle%26aps/sle/#1-2","text":"\uace0\uc5f0\ub839, \ub0a8\uc131, \ubbf8\uad6d \ud751\uc778, \ub192\uc740 SLEDAI, GC \uc0ac\uc6a9, HTN \uc788\uc744 \ub54c \uae30\uad00 \uc190\uc0c1\uc774 \ub9ce\uc774 \ubc1c\uc0dd \uae30\uad00\uc190\uc0c1\uc774 \uc788\uc73c\uba74 \uc0ac\ub9dd\ub960\uc740 1.46\ubc30 \uc99d\uac00 SLE \ud658\uc790\ub294 \uc77c\ubc18\uc778\uc5d0 \ube44\ud574 \uc0ac\ub9dd\ub960 3~5\ubc30 \uc99d\uac00, \uc8fc\uc694 \uc0ac\ub9dd \uc6d0\uc778\uc740 LN, \ub192\uc740 SLEDAI, \uac10\uc5fc, \uc2ec\ud608\uad00\uacc4 \uc9c8\ud658 \ub4f1","title":"1-2. \uc608\ud6c4"},{"location":"sle%26aps/sle/#2","text":"\uc720\uc804\uc801 \uc694\uc778 \ubcf4\uccb4\uc720\uc804\uc790 C1q, C4, C2, HLA-DR2 & DR3 Fcr \uc218\uc6a9\uccb4 \uc774\uc0c1 \ud658\uacbd\uc801 \uc694\uc778 \uc131\ud638\ub974\ubaac\uc758 \uc5ed\ud560 : estradiol\uc740 \uc9c0\uc18d\uc801\uc778 \uba74\uc5ed\ubc18\uc751 \uc720\ubc1c, \ub0a8\uc131\ud638\ub974\ubaac\uc740 \uba74\uc5b5\uc5b5\uc81c\ud6a8\uacfc \uac10\uc5fc : Parvo B19, CMV, EBV \uc790\uc678\uc120, Silica dust, \ud761\uc5f0, \uc57d\ubb3c (hydralazine, procainamide, quinidine, INH, diltiazem, minocycline \ub4f1) \uba74\uc5ed\ud559\uc801 \uc694\uc778 \uc138\ud3ec\uc790\uba78\uc0ac\uc758 \uc774\uc0c1 NETs\uc758 \uc774\uc0c1 TLR\uc758 \uc774\uc0c1 T/B cell\uc758 \uc774\uc0c1","title":"2. \ubcd1\uc778\uae30\uc804"},{"location":"sle%26aps/sle/#3","text":"","title":"3. \uc784\uc0c1\uc99d\uc0c1"},{"location":"sle%26aps/sle/#3-1","text":"76~100%\uc5d0\uc11c \ubc1c\ud604 (\uac00\uc7a5 \ud754\ud55c \uc99d\uc0c1) 2\uac1c \uc774\uc0c1\uc758 \uad00\uc808\uc5d0 swelling\uc744 \ub3d9\ubc18\ud55c synovitis, 30\ubd84 \uc774\uc0c1\uc758 \uc870\uc870\uac15\uc9c1. \uace8\ubcc0\ud615\uc740 \ub4dc\ubb3c\ub2e4. \uacfc\ub3c4\ud55c \uc6b4\ub3d9\uc131 \ubcd1\ubcc0 -> Jaccoud\u2019s arthropathy AVN (+) : \uace0\uad00\uc808\uc5d0 \uad6d\ud55c\ub41c \ud1b5\uc99d, 5~10%, \uc8fc\ub85c GC \uc0ac\uc6a9\uacfc \uad00\ub828 Myositis : SLE itself or Drug (HCQ, GC)","title":"3-1. \uad00\uc808\uc99d\uc0c1"},{"location":"sle%26aps/sle/#3-2","text":"\ud53c\ubd80\uc99d\uc0c1 : ACLE (malar rash, photosensitivity), SCLE, CCLE (discoid rash, alopecia) \uc810\ub9c9\uc99d\uc0c1 : \uad6c\uac15, \ucf54, \ud56d\ubb38, \uc0dd\uc2dd\uae30, \ud608\uad00\uc5fc (\ub450\ub4dc\ub7ec\uae30, \uc790\ubc18, \uc190\uac00\ub77d\uada4\uc591, \ud64d\ubc18\uc131 \uad6c\uc9c4) \ub1cc\uc2e0\uacbd\uc99d\uc0c1 : 2/3\uc5d0\uc11c \ubc1c\uc0dd. neuro + psychiatric sx. \uc8fc\ub85c seizure, headache \ud615\ud0dc\ub85c \ubc1c\uc0dd. Transverse myelitis \ud608\uc561\ud559\uc801\uc99d\uc0c1 : ACD, Lymphopenia, leukopenia, thrombocytopenia. \uc5f0\uad00\ub41c TTP/HUS, hemolytic anemia \uc2ec\ud3d0\uc99d\uc0c1 : pericarditis, myocarditis, Libman-Sacks endocarditis, CAD, Diffuse alveolar hemorrhage, shrinking lung syndrome, PAH \uc2e0\uc7a5\uc99d\uc0c1 : Urine protein 500mg/d or dipstick 3+ or RBC casts \uc704\uc7a5\uad00\uc99d\uc0c1 : \uc5f0\ud558\uace4\ub780, ascites, pancreatitis, serositis, protein-losing enteropathy \uac04\uc99d\uc0c1 : Budd-Chiari syndrome \uc548\uacfc \uc99d\uc0c1 : sicca syndrome, \uacf5\ub9c9\uc5fc, \uc2dc\uc2e0\uacbd\uc5fc, retinal toxicity (HCQ) \uc7a5\ub9c9\uc5fc : \ud749\ub9c9\uc5fc, \uc2ec\uc7a5\ub9c9\uc5fc, \ubcf5\ub9c9\uc5fc \ub4f1","title":"3-2. \uad00\uc808 \uc678 \uc99d\uc0c1"},{"location":"sle%26aps/sle/#4","text":"","title":"4. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8"},{"location":"sle%26aps/sle/#4-1","text":"CBC : ACD, Hemolytic anemia (direct Coomb\u2019s test), leukopenia (lymphopenia), thrombocytopenia, HUS/TTP Chemistry : routine + CRP (<4~5mg/dl) U/A : Urine protein 500mg/d or dipstick 3+ or RBC cast Autoimmune markers : ANA 1:80, Anti-dsDNA, Anti-Sm, APS, etc. Complement : C3, C4, CH50 Ds. activity\ub97c \ubc18\uc601\ud558\ub294 \uac80\uc0ac : Anti-dsDNA\uc640 Complement titer -> \ud638\uc804 \uc774\ud6c4\ub85c\ub3c4 dsDNA\ub294 \uace0\uc5ed\uac00\ub85c \ubcf4\uc77c \uc218\ub3c4 \uc788\ub2e4.","title":"4-1. \ud608\uc561\uac80\uc0ac"},{"location":"sle%26aps/sle/#4-2","text":"Skin : Immunoglobulin\uacfc complement \uad6c\uc131\uc694\uc18c\ub4e4\uc774 dermoepidermal junction\uc744 \ub530\ub77c \uce68\ucc29 Kidney : LN \ubd84\ub958, \ub2e4\ub978 \uc9c8\ud658 \uac10\ubcc4, \uce58\ub8cc, \uc608\ud6c4\uc640 \uad00\ub828","title":"4-2. \uc870\uc9c1\uac80\uc0ac"},{"location":"sle%26aps/sle/#4-3","text":"1997 revised ACR classification criteria 2012 SLICC classification criteria 2019 ACR/EULAR classification criteria","title":"4-3. \ubd84\ub958\uae30\uc900"},{"location":"sle%26aps/sle/#4-4","text":"","title":"4-4. \uac10\ubcc4\uc9c4\ub2e8"},{"location":"sle%26aps/sle/#5","text":"","title":"5. \uce58\ub8cc\uc6d0\uce59"},{"location":"sle%26aps/sle/#5-1","text":"\uad00\ud574 \ub3c4\ub2ec or \ub0ae\uc740 \uc9c8\ubcd1\ud65c\uc131\ub3c4 \uc720\uc9c0\uac00 \ubaa9\ud45c \uc9c8\ubcd1\ud65c\uc131\ub3c4 \ud3c9\uac00\uac00 \uc911\uc694 : \uc99d\uc0c1, P/E, Lab, Anti-dsDNA, Complement, SLEDAI \ube44\uc57d\ubb3c\uc694\ubc95 : \uc77c\uad11\ucc28\ub2e8, \uae08\uc5f0, \uc801\uc808\ud55c \uc601\uc591\uacf5\uae09, \uc6b4\ub3d9, \uc608\ubc29\uc811\uc885 \uc57d\ubb3c\uc694\ubc95 : HCQ, Low dose GC, Immunosuppressant \uae30\ud0c0 \uc99d\uc0c1\uc5d0 \ub9de\ub294 \uce58\ub8cc Dyslipidemia, DM, HTN, Osteoporosis \uad00\ub9ac, Cancer screening \uc784\uc2e0 \uc804 Ro/La \ud3c9\uac00, 6\uac1c\uc6d4 \uc774\uc0c1 remission state\uc5ec\uc57c \ud55c\ub2e4. PRD, AZA, HCQ, ASA\ub294 \uc0ac\uc6a9 \uac00\ub2a5, Congenital heart block \uace0\ub824","title":"5-1. \uac1c\ub150 \uc694\uc57d"},{"location":"sle%26aps/sle/#5-2","text":"","title":"5-2. \uac00\uc774\ub4dc\ub77c\uc778"},{"location":"sle%26aps/sle/#5-3-disease-activity-assessment","text":"\uae30\ubcf8 \uac1c\ub150 single summary score system : SLEDAI, SLAM \ub4f1 Organ-specific score system : BILAG SLEDAI \ucd5c\uadfc 10\uc77c \ub3d9\uc548\uc758 \uc9c8\ubcd1\ud65c\uc131\ub3c4 \ud3c9\uac00 (6\uc810 \uc774\uc0c1\uc774\uba74 \uc911\ub4f1\ub3c4, 20\uc810 \uc774\uc0c1\uc774\uba74 \uace0\uc911\uc99d) SLEDAI-2K, SELENA-SLEDAI \uac00\uc7a5 \uac04\ub2e8\ud558\uace0 \uc27d\uc9c0\ub9cc \uae30\uc874 \uc99d\uc0c1\uc758 \uc545\ud654\ub098 \uc77c\ubd80 \ud638\uc804\uc744 \ubbfc\uac10\ud558\uac8c \ud3c9\uac00\ud558\uae30 \uc5b4\ub835\uace0 \uc99d\uc0c1 \uc911\uc99d\ub3c4\uc5d0 \ub530\ub978 \uac00\uc911\uce58\uac00 \uc5c6\ub2e4. BILAG 9\uac1c organ system\uc5d0 \ub300\ud55c \uc9c0\ud45c (2004), \ucd5c\uadfc 4\uc8fc\uac04\uc758 \uc9c8\ubcd1\ud65c\uc131\ub3c4\ub97c \uc9c0\ub09c 4\uc8fc\uac04\uc758 \ud65c\uc131\ub3c4\uc640 \ube44\uad50 \uac01 organ system \ud65c\uc131\ub3c4\ub97c A ~ E\ub85c \ud3c9\uac00 (A\uac00 \uc81c\uc77c \ub192\uc740 \ud65c\uc131\ub3c4) Severe : A\ub85c \ubc14\ub014 \ub54c. Moderate : B\ub85c \ubc14\ub014 \ub54c. Effect : A & B\uac00 \uc5c6\uc744 \ub584 \uac00\uc7a5 \ud3ec\uad04\uc801\uc774\uace0 \uc9c8\ubcd1\ud65c\uc131\ub3c4/\uc911\uc99d\ub3c4\ub97c \uac10\ubcc4\ud560 \uc218 \uc788\uc73c\uba70 \ubbfc\uac10\ub3c4\uac00 \ub192\uc73c\ub098, \uc2e4\uc81c \uc784\uc0c1\uc5d0\uc11c \uc4f0\uae30\uc5d0\ub294 \ud3c9\uac00 \ud56d\ubaa9\uc774 \ub9ce\uace0 \ubcf5\uc7a1\ud558\ub2e4. \uae30\ud0c0 \uc9c0\ud45c SLAM-R (2001) : \ucd5c\uadfc 4\uc8fc\uac04\uc758 \uc9c8\ubcd1\ud65c\uc131\ub3c4 \uce21\uc815 ECLAM, LAI, SLAQ \ub4f1\ub3c4 \uc788\ub2e4.","title":"5-3. Disease activity assessment"},{"location":"sle%26aps/sle/#5-4-damage-assessment","text":"SLICC/ACR-DI \uc190\uc0c1 : 6\uac1c\uc6d4 \uc774\uc0c1 \uc9c0\uc18d\ub418\uac70\ub098 \ubcd1\ub9ac\ud559\uc801 \ubc18\ud754\uc774 \ub3d9\ubc18\ub41c \ube44\uac00\uc5ed\uc801 \uc99d\uc0c1 12\uac1c \uc7a5\uae30 \uc2dc\uc2a4\ud15c\uc5d0 \ub300\ud55c 41\uac1c \ud3c9\uac00\ud56d\ubaa9, 0~46\uc810 \uc0ac\ub9dd\ub960 \uc608\uce21\uacfc \uc608\ud6c4 \ud310\uc815\uc5d0 \ub3c4\uc6c0 LDIQ (\uc124\ubb38\uc9c0) BILD (\uc124\ubb38\uc9c0)","title":"5-4. Damage assessment"},{"location":"sle%26aps/sle/#6","text":"","title":"6. \uacbd\uacfc\uc640 \uc608\ud6c4"},{"location":"spondyloarthropathy/spa/","text":"HLA-B27 \uc720\uc804\uc790\uc640\uc758 \uc5f0\uad00\uc131\uc744 \uacf5\ud1b5\uc801\uc73c\ub85c \uac16\uace0 \uc788\ub294 \uc9c8\ud658 Sacroilitis, spondylitis, \ud558\uc9c0\uc758 \ube44\ub300\uce6d\uc801\uc778 oligoarthritis or enthesitis, uveitis, psoriasis, IBD 1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790 1-1. \uc5ed\ud559 \uc720\ubcd1\ub960 : HLA-B27\uc758 \uc720\ubcd1\ub960\uacfc \uc5f0\uad00\ub41c \uac83\uc73c\ub85c \ubcf4\uc784. RA\ubcf4\ub2e4\ub294 \uc720\ubcd1\ub960\uc774 \ub192\ub2e4. AS : \ub0a8\uc131 > \uc5ec\uc131 (2~3\ubc30), \ud55c\uad6d\uc778\uc758 4% 1-2. \ubcd1\uc778\uae30\uc804 \ubd80\ucc29\ubd80\uc5fc + \uace8\ud30c\uad34 \ubc0f \uc0dd\uc131 \ubd80\ucc29\ubd80\uc5fc : inflammatory cells + HLA-B27 + Bacteria + mechanical stress + cytokines (\uc720\uc804\uc694\uc778 + \ud658\uacbd\uc694\uc778 + \uba74\uc5ed) \uace8\ud30c\uad34 \ubc0f \uc0dd\uc131 : BMP, Wnt pathway 2. \uc784\uc0c1\uc99d\uc0c1 \uc5fc\uc99d\uc131 \ub4f1\ud1b5\uc99d : 70%. inflammatory back pain (IPAIN - Insidious onset, Pain at night, Age < 40, Improvement with exercise, No improvement with rest) \ub9d0\ucd08\uad00\uc808\uc5fc : \uc8fc\ub85c \ubb34\ub98e\uacfc \ubc1c\ubaa9, enthesitis, dactylitis \uad00\uc808\uc678\uc99d\uc0c1 : conjunctivitis, ant. uveitis, psoriasis, IBD (SPINEACHE - Sausage digit, Psoriasis, IBD, NSAIDs, Enthesitis, Arthritis, Crohn's/UC, HLA-B27, Eye (uveitis)) 3. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8 3-1. \ud608\uc561\uac80\uc0ac HLA-B27 : SpA\uc758 70%, AS\uc758 90% CRP/ESR \uc0c1\uc2b9 3-2. \uc601\uc0c1\uac80\uc0ac SI joint X-ray : mNY criteria\uc5d0 \ub530\ub978, 2~4\ub4f1\uae09\uc758 \uc591\uce21 \ucc9c\uc7a5\uad00\uc808\uc5fc \ub610\ub294 3~4\ub4f1\uae09\uc758 \ud3b8\uce21 \ucc9c\uc7a5\uad00\uc808\uc5fc MRI : nrAxSpA \uc9c4\ub2e8\uc5d0 \uc720\uc6a9. 3-3. \ubd84\ub958\uae30\uc900 4. \uac10\ubcc4\uc9c4\ub2e8 Lumbar sprain : acute onset, \ud2b9\uc815 \ub3d9\uc791\uc5d0 \uc758\ud574 \uc545\ud654, \ud734\uc2dd\ud558\uba74 \uacbd\uac10, 2\uac1c\uc6d4 \uc774\ub0b4 \uc790\uc5f0 \ud638\uc804 HNP : sciatica\uac00 \ud5c8\ubc85\uc9c0\ub97c \uac70\uccd0 \ubb34\ub98e \ubc11\uae4c\uc9c0 \ub0b4\ub824\uac08 \uc218\ub3c4 \uc788\uc73c\ub098, SpA\ub294 \ubb34\ub98e \ubc11\uae4c\uc9c0\ub294 \ud1b5\uc99d\uc774 \uc5c6\ub2e4. Epicondylitis : enthesitis\uc640 \ud63c\ub3d9\ub41c\ub2e4. FMS DISH, OCI, Bertolotti's syndrome \ub4f1 5. \uce58\ub8cc\uc6d0\uce59 6. \uacbd\uacfc\uc640 \uc608\ud6c4","title":"Spondylooarthropathy"},{"location":"spondyloarthropathy/spa/#1","text":"","title":"1. \uc5ed\ud559 \ubc0f \ubc1c\ubcd1 \uc778\uc790"},{"location":"spondyloarthropathy/spa/#1-1","text":"\uc720\ubcd1\ub960 : HLA-B27\uc758 \uc720\ubcd1\ub960\uacfc \uc5f0\uad00\ub41c \uac83\uc73c\ub85c \ubcf4\uc784. RA\ubcf4\ub2e4\ub294 \uc720\ubcd1\ub960\uc774 \ub192\ub2e4. AS : \ub0a8\uc131 > \uc5ec\uc131 (2~3\ubc30), \ud55c\uad6d\uc778\uc758 4%","title":"1-1. \uc5ed\ud559"},{"location":"spondyloarthropathy/spa/#1-2","text":"\ubd80\ucc29\ubd80\uc5fc + \uace8\ud30c\uad34 \ubc0f \uc0dd\uc131 \ubd80\ucc29\ubd80\uc5fc : inflammatory cells + HLA-B27 + Bacteria + mechanical stress + cytokines (\uc720\uc804\uc694\uc778 + \ud658\uacbd\uc694\uc778 + \uba74\uc5ed) \uace8\ud30c\uad34 \ubc0f \uc0dd\uc131 : BMP, Wnt pathway","title":"1-2. \ubcd1\uc778\uae30\uc804"},{"location":"spondyloarthropathy/spa/#2","text":"\uc5fc\uc99d\uc131 \ub4f1\ud1b5\uc99d : 70%. inflammatory back pain (IPAIN - Insidious onset, Pain at night, Age < 40, Improvement with exercise, No improvement with rest) \ub9d0\ucd08\uad00\uc808\uc5fc : \uc8fc\ub85c \ubb34\ub98e\uacfc \ubc1c\ubaa9, enthesitis, dactylitis \uad00\uc808\uc678\uc99d\uc0c1 : conjunctivitis, ant. uveitis, psoriasis, IBD (SPINEACHE - Sausage digit, Psoriasis, IBD, NSAIDs, Enthesitis, Arthritis, Crohn's/UC, HLA-B27, Eye (uveitis))","title":"2. \uc784\uc0c1\uc99d\uc0c1"},{"location":"spondyloarthropathy/spa/#3","text":"","title":"3. \uac80\uc0ac\uc18c\uacac\uacfc \uc9c4\ub2e8"},{"location":"spondyloarthropathy/spa/#3-1","text":"HLA-B27 : SpA\uc758 70%, AS\uc758 90% CRP/ESR \uc0c1\uc2b9","title":"3-1. \ud608\uc561\uac80\uc0ac"},{"location":"spondyloarthropathy/spa/#3-2","text":"SI joint X-ray : mNY criteria\uc5d0 \ub530\ub978, 2~4\ub4f1\uae09\uc758 \uc591\uce21 \ucc9c\uc7a5\uad00\uc808\uc5fc \ub610\ub294 3~4\ub4f1\uae09\uc758 \ud3b8\uce21 \ucc9c\uc7a5\uad00\uc808\uc5fc MRI : nrAxSpA \uc9c4\ub2e8\uc5d0 \uc720\uc6a9.","title":"3-2. \uc601\uc0c1\uac80\uc0ac"},{"location":"spondyloarthropathy/spa/#3-3","text":"","title":"3-3. \ubd84\ub958\uae30\uc900"},{"location":"spondyloarthropathy/spa/#4","text":"Lumbar sprain : acute onset, \ud2b9\uc815 \ub3d9\uc791\uc5d0 \uc758\ud574 \uc545\ud654, \ud734\uc2dd\ud558\uba74 \uacbd\uac10, 2\uac1c\uc6d4 \uc774\ub0b4 \uc790\uc5f0 \ud638\uc804 HNP : sciatica\uac00 \ud5c8\ubc85\uc9c0\ub97c \uac70\uccd0 \ubb34\ub98e \ubc11\uae4c\uc9c0 \ub0b4\ub824\uac08 \uc218\ub3c4 \uc788\uc73c\ub098, SpA\ub294 \ubb34\ub98e \ubc11\uae4c\uc9c0\ub294 \ud1b5\uc99d\uc774 \uc5c6\ub2e4. Epicondylitis : enthesitis\uc640 \ud63c\ub3d9\ub41c\ub2e4. FMS DISH, OCI, Bertolotti's syndrome \ub4f1","title":"4. \uac10\ubcc4\uc9c4\ub2e8"},{"location":"spondyloarthropathy/spa/#5","text":"","title":"5. \uce58\ub8cc\uc6d0\uce59"},{"location":"spondyloarthropathy/spa/#6","text":"","title":"6. \uacbd\uacfc\uc640 \uc608\ud6c4"},{"location":"vasculitis/vasculitis/","text":"Note: This is the demo content for demonstration purpose only. The primary function of this content is to show you what this theme can do. There is a more detailed explanation in the Getting Started section. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec ut nulla laoreet, finibus purus sit amet, ullamcorper felis. Aliquam sagittis consectetur ullamcorper. Ut dapibus ex a nibh euismod tincidunt. Vestibulum quam velit, placerat vel ipsum eget, vulputate aliquet nibh. Cras hendrerit, justo a sagittis pharetra, ante elit imperdiet quam, eget euismod mauris lacus at eros. Sed et est interdum leo ultricies feugiat non non est. Aenean sit amet sollicitudin tellus, at pellentesque massa. Vestibulum dapibus magna quis dui ultrices vestibulum. Stack Overflow Suspendisse hendrerit maximus metus in placerat. In ligula magna, efficitur sed ultrices non, iaculis ut ligula. Sed finibus efficitur cursus. Proin quis molestie purus. Vestibulum ut magna eget tortor tempor egestas eget eu orci. Integer porta cursus rutrum. Quisque porta suscipit sem, et tincidunt felis malesuada vel. Popular Discussion Forums Donec eget tellus magna. Duis eu metus sem. Donec nec ullamcorper dui. Phasellus turpis mauris, lacinia ac imperdiet eu, dapibus eu metus. Vestibulum porta lectus vel dui eleifend pretium. Nulla facilisi. Nam luctus quam at velit congue tincidunt. Ut tempus justo at urna varius commodo. Twitter Vestibulum maximus volutpat eros a lobortis. Duis cursus neque id sollicitudin vehicula. Morbi varius dapibus est, sed bibendum diam aliquam eu. Morbi maximus consequat sem id vestibulum. Nam semper, augue pharetra commodo commodo, magna augue ornare ligula, ut gravida nisi nulla vel velit. Quisque tincidunt posuere ex eget luctus. Sed a dui in turpis porttitor hendrerit quis id odio.","title":"Vasculitis"},{"location":"vasculitis/vasculitis/#stack-overflow","text":"Suspendisse hendrerit maximus metus in placerat. In ligula magna, efficitur sed ultrices non, iaculis ut ligula. Sed finibus efficitur cursus. Proin quis molestie purus. Vestibulum ut magna eget tortor tempor egestas eget eu orci. Integer porta cursus rutrum. Quisque porta suscipit sem, et tincidunt felis malesuada vel.","title":"Stack Overflow"},{"location":"vasculitis/vasculitis/#popular-discussion-forums","text":"Donec eget tellus magna. Duis eu metus sem. Donec nec ullamcorper dui. Phasellus turpis mauris, lacinia ac imperdiet eu, dapibus eu metus. Vestibulum porta lectus vel dui eleifend pretium. Nulla facilisi. Nam luctus quam at velit congue tincidunt. Ut tempus justo at urna varius commodo.","title":"Popular Discussion Forums"},{"location":"vasculitis/vasculitis/#twitter","text":"Vestibulum maximus volutpat eros a lobortis. Duis cursus neque id sollicitudin vehicula. Morbi varius dapibus est, sed bibendum diam aliquam eu. Morbi maximus consequat sem id vestibulum. Nam semper, augue pharetra commodo commodo, magna augue ornare ligula, ut gravida nisi nulla vel velit. Quisque tincidunt posuere ex eget luctus. Sed a dui in turpis porttitor hendrerit quis id odio.","title":"Twitter"}]}